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General introduction
Cancer and type 2 diabetes are common diseases with a considerable impact on 
public health. Both diseases are complex and have multiple subtypes, while the 
underlying pathophysiology is not well understood. Individually, these diseases 
are the subject of study of many research groups worldwide.
Cancer is typically classified by its anatomic origin (of which there are hundreds) 
and within which there are multiple subtypes. In 2013, the most prevalent cancers 
in the Netherlands were prostate (21%), skin (basal cell carcinoma excluded; 14%) 
and colorectal cancer (CRC; 14%) among males and breast (30%), skin (basal cell 
carcinoma excluded; 14%) and CRC (12%) among females1. The various forms 
can behave very differently from one another, they can spread to different parts 
of the body through the bloodstream or lymphatic system (this is called metastasis), 
but the original site of the cancer cells determines the cancer type. Traditionally 
cancer is treated using surgery, radiotherapy and/or chemotherapy, but nowadays 
targeted therapies make personalised medicine a reality and will continue to help 
doctors tailor cancer treatment based on the characteristics of a tumour within an 
individual.
For adults with diabetes, type 2 diabetes is by far the most common type of 
diabetes (>90%) and is characterized by hyperglycaemia and variable degrees of 
insulin deficiency and resistance2. The majority of patients with type 2 diabetes, 
from now on referred to as diabetes, are asymptomatic and hyperglycaemia is 
noted on routine laboratory evaluation. Classic symptoms of hyperglycaemia, 
often noted only in retrospect, include polyuria, polydipsia, nocturia, blurred vision, 
and infrequently, weight loss3. The diagnosis is based on one of four abnormalities: 
a glycated haemoglobin ≥ 6.5% (HbA1c; 48 mmol/mol), a fasting plasma glucose 
≥ 7.0 mmol/L, a random elevated glucose with symptoms, or an abnormal oral 
glucose tolerance test (OGTT)2,4. After the diagnosis of diabetes, the glycaemic 
control is checked every three to six months by using the HbA1c measurement 
and physicians try to achieve normal or near normal glycaemia with an HbA1c goal 
of <7% (53 mmol/mol)2,4. Currently the Dutch guideline for the treatment of 
diabetes advises metformin, a biguanide, as first line treatment beside lifestyle 
advice as dietary modification, exercise and weight reduction4,5. However, when 
metformin fails to maintain normoglycaemia, additional agents are either added 
or substituted. Subsequent therapy can involve the use of up to 10 different drug 
families alone or in combination.
Morbidity from diabetes is a consequence of both macrovascular disease (coronary 
artery disease, peripheral arterial disease and stroke) and microvascular disease 
(retinopathy, nephropathy, and neuropathy)2. Once present, the progression of 
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these complications can be slowed with blood pressure lowering drugs, lipid-
modifying agents (statins), laser therapy for advanced retinopathy and angiotensin-
converting enzyme (ACE) inhibitors for nephropathy, beside the aggressive 
management of glycaemia with glucose lowering drugs (GLDs)2.
Combined occurrence of diabetes and cancer 
Diabetes and cancer are diagnosed within the same individual more frequently 
than would be expected by chance6-8. In 2009, the results of several studies were 
combined in a meta-analysis revealing that some cancers develop more commonly 
in patients with diabetes, while prostate cancer occurs less often in individuals 
with diabetes8. The highest cancer incidences in individuals with diabetes were 
found for cancers of the liver, pancreas and endometrium, while high incidences 
were seen for cancers of the colorectum, breast and bladder8. Consequently, a 
large proportion of cancer patients has diabetes, but this varies according to the 
type of cancer9 (Table 1). This thesis mainly focussed on the association between 
diabetes and CRC, since CRC is one of the most prevalent cancer types and occurs 
in both male and female. Among female patients the prevalence of diabetes was 
also high for endometrial cancer patients. Research on the association between 
diabetes and endometrial cancer was subject of this thesis as well. 
Burden of diabetes and cancer 
With the ageing of the population, the more or less constant risk of developing 
cancer and the declining risk of dying from cancer, the number of cancer survivors 
has substantially increased. According to the presented numbers in the report 
‘Cancer in the Netherlands till 2020’ the absolute 10-year prevalence will increase 
from 420,000 patients with cancer in 2009 till 660,000 patients with cancer in 
202010. In concordance with the prevalence of cancer, the prevalence of diabetes 
is increasing tremendously and strongly influenced by the ageing of population 
as well, since diabetes is mostly a disease of the elderly11,12. In addition, the 
increase in obesity and physical inactivity have an important role in the present 
rise of cancer and diabetes cases13. In the Netherlands in 2007 the number of 
individuals with diabetes was estimated to be 740,000 and in 2025 this is expected 
to increase to 1.3 million11. As a result of the dramatic increase in the number of 
patients with cancer or diabetes and the association between the diseases, in the 
Netherlands the number of newly diagnosed cancer patients who also have 
diabetes is expected to increase from about 5,500 per year in 2000 to 10,000 per 
year in 201510. In 2010-2011 16% of the males and 13% of the females with cancer 
had diabetes at the time of cancer diagnosis in the area of the Eindhoven Cancer 
Registry (Table 1). An increasing number of medical specialists will be confronted 
with individuals suffering from both diseases.
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Potential mechanisms linking diabetes and cancer
The transformation towards a malignancy can be divided into different steps: the 
initiation, promotion (stimulation of cell growth) and progression of a tumour 
(invasion and metastasis). Diabetes has been hypothesised to be associated with 
cancer incidence and outcomes by affecting one or more steps of this pathway. 
It remains however unclear whether the association between diabetes and cancer 
is largely explained by shared risk factors (obesity, poor diet, physical inactivity, 
and aging), or whether diabetes itself, and the specific metabolic derangements 
typical of diabetes (i.e. hyperglycaemia, insulin resistance, and hyperinsulinaemia), 
increase the incidence and mortality risk of some types of cancer. Evidence is 
accumulating that hyperinsulinaemia promotes tumour cell growth directly via 
the insulin receptor or indirectly via the insulin-like growth factor I (IGF-1) receptor, 
which are expressed on many cancer cells14. The IGF-I receptor seems necessary 
for the transforming ability of several oncogenes15, while insulin or the IGF-I can 
Table 1.  Prevalence of diabetes (%) among cancer patients at diagnosis.
Cancer type Males Females
1998-1999 2005-2006 2011-2012 1998-1999 2005-2006 2011-2012
Dutch population 12% 15% 10% 12%
All types of cancer a 9% 13% 16% ** 11% 13% 13% *
Pancreatic 18% 26% 26% 26% 28% 28%
Stomach 13% 13% 13% 14% 18% 20%
Liver 28% 39% 32% 18% 44% 14%
Oesophageal 11% 18% 17% * 15% 13% 12%
Colon 12% 15% 18% * 13% 16% 17% *
Rectal 8% 13% 16% * 13% 12% 15%
Lung 8% 14% 18% ** 9% 13% 13% *
Kidney 6% 19% 19% * 16% 19% 16%
Breast 8% 9% 10% *
Cervical 9% 11% 7%
Endometrial 14% 18% 18%
Ovarian 9% 14% 12%
Prostate 8% 10% 13% **
Testicular 0% 2% 3%
Bladder 9% 14% 17% ** 17% 13% 15%
Hodgkin lymphoma 4% 4% 8% 7% 5% 0%
Non-Hodgkin lymphoma 7% 11% 14% * 8% 14% 10%
a Except basal cell carcinoma; *P-trend<0.05; **P-trend<0.0001; Source: Eindhoven Cancer Registry and www.nivel.nl/
incidentie-en-prevalentiecijfers-in-de-huisartsenpraktijk. 
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stimulate the proliferation of tumour cells in vitro16. Moreover, mouse models 
showed that genetic manipulations that reduced IGF-1 signalling can lead to 
decreased tumour growth17. As a result, currently more than 100 clinical trials 
have examined the hypothesis that targeting the insulin and IGF-I receptor will 
be useful in cancer treatment.
Effect of diabetes on mortality among cancer patients
Uncertainty is great with respect to the association between diabetes and mortality 
among cancer patients. In 2010, as a result of these uncertainties, the American 
Diabetes Association and American Cancer Society reviewed the state of science 
concerning diabetes and cancer6. One of the key issues was a better understanding 
of whether diabetes influences cancer prognosis above and beyond the prognosis 
conferred by each disease state independently. Although several studies revealed 
that cancer patients with pre-existing diabetes had significantly worse overall 
mortality compared to patients without diabetes9,18-25, the question remains if the 
combined effect of cancer and diabetes results in an even worse mortality than 
the sum of the individual effects of cancer and diabetes. As a result, there is a need 
for studies who address this question, dealing with differences in cancer treatment 
between patients with and without diabetes, adjusting for potential differences 
in patient and tumour characteristics and focussing on cancer outcomes, such as 
recurrence rates and cancer specific mortality. All of these factors might play a 
role in the association between diabetes and mortality in cancer patients and 
studies taking all, or at least most of them, into account are desired. 
Since the pattern of cause of death is changing for diabetes patients – the risk of 
cardiovascular death in this group is declining – these patients might die of other 
causes, such as cancer. Thus in the near future, cancer might be the leading cause 
of death in individuals with diabetes. Therefore it is of utmost importance to further 
study the association between diabetes, cancer and mortality.  
Current potential ‘wonderdrugs’ and their effect on mortality 
among cancer patients
In the past years, the number of papers on the association between diabetes and 
cancer increased tremendously9,18,21,26 (Figure 1a). Furthermore, it was observed 
that the association between diabetes and mortality among cancer patients varied 
with GLDs, those treated with metformin appear to have decreased overall 
mortality26-32 (Figure 1b). Most studies that investigated this association had 
incredibly low hazard ratios in favour of metformin, suggesting strong protective 
effects. However, they had important methodological limitations, since some 
analyses introduced immortal time bias and most analyses did not take into account 
the duration of drug use27-32. As a consequence of these limitations and the 
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potential of the used methods to induce or exaggerate protective effects, the 
debate on whether metformin might be a candidate drug as anti-tumour agent is 
ongoing33. 
Besides metformin, there are other current potential ‘wonderdrugs’, which seem 
to have an effect on mortality among cancer patients34-41. Two of these drug types, 
addressed in several groups of cancer patients are: statins, which are lipid 
modifying agents, and aspirin, which is an antithrombotic agent. They are 
frequently prescribed to individuals with diabetes, i.e. around 50% of the diabetes 
population use statins and 40% use aspirin according to the current international 
literature42-44. The high use of these drugs indicate that the use of metformin, 
statins and aspirin are strongly related and that their effect should be studied 
together while taking into account the use of each other drug. The current literature 
does not answer the justified question whether there is still an effect of metformin, 
statin and aspirin use on overall mortality if adjusted for one another. 
The other perspective – the impact of cancer on diabetes control 
and drug use  
The development of a tumour, the diagnosis of cancer and the treatment of cancer 
may all influence diabetes. The presence of cancer might result in worse glycaemic 
control and medication adherence, potentially resulting in more diabetes 
complications in individuals with diabetes and indirectly higher mortality. However, 
to our knowledge, till now these hypotheses are only speculations and not 
investigated properly. 
HbA1c, as a marker of glycaemic control, represents the average blood glucose 
level over the life span of a red blood cell, which is approximately three months3. 
Figure 1. a) Number of publications on Pubmed with search  “Diabetes AND 
Cancer” per year;  b) Number of publications on Pubmed with 
search “Metformin AND Cancer” per year.
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The HbA1c-value might be influenced directly by the tumour, the weight loss in 
cancer patients and/or the treatment of cancer, leading to (required or 
inappropriate) changes in medication. Moreover, according to a study on HbA1c 
and mortality, individuals with diabetes and recent HbA1c values < 6.5% (OR 1.3; 
95% CI 1.2-1.4) and those with recent HbA1c values > 9.0% (OR 1.5; 95% CI 1.3-1.7) 
had higher mortality compared to those with recent ‘normal’ HbA1c values between 
6.5% and 9%45. If the presence of cancer results in HbA1c-values of < 6.5% or 
>9.0%, this will strengthen the hypothesis that the overall worse mortality seen in 
patients with diabetes and cancer might also be related to changes in glycaemic 
control due to cancer.
Good adherence to GLDs is crucial for achieving normal or near normal glycaemia 
(HbA1c goal of <7%; 53 mmol/mol2) and prolonging survival time46,47. Overall, 
only 65%-85% of the users of GLDs is regarded as adherent48,49; this might 
decrease even more due to cancer. If the presence of a cancer diagnosis can 
influence medication adherence among users of GLDs, this could also affect HbA1c 
levels leading to poor glycaemic control, higher risk of diabetes complications 
and worse overall mortality.
Outline
The research underlying this thesis aimed to understand how the combined effect 
of cancer and diabetes results in a worse mortality than the sum of the individual 
effects of cancer and diabetes. 
The main objectives of the studies described in this thesis were (Figure 2):
• To assess the impact of diabetes on cancer treatment, cancer recurrence, 
cancer-specific and overall mortality in cancer patients.
• To assess whether, and to which extent, metformin, statin and aspirin use is 
associated with overall mortality in CRC patients with diabetes.
• To explore changes in glycaemic control and medication adherence among 
individuals with diabetes at the time of cancer diagnosis.
As an introduction to this thesis we evaluated and summarised the epidemiological 
evidence available on the magnitude of the deteriorated outcomes among patients 
who have both diabetes and CRC and reviewed potential variables and pathways 
associated with worse outcome (Part I; Chapter 2).
In Part II of this thesis the impact of diabetes on the administration of cancer 
treatment, cancer recurrence and cancer-specific and overall mortality was 
evaluated. To assess the reciprocal impact of diabetes and cancer on mortality 
extensively, a study among endometrial cancer (EC) patients was performed. The 
influence of diabetes on cancer stage at diagnosis, cancer recurrence, and survival 
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was investigated, while the influence of the treatment of EC on glycaemic control, 
GLDs use, and complications of diabetes was investigated as well (Chapter 3). As 
CRC patients with diabetes have worse survival rates compared with those without 
diabetes, it is hypothesized to be at least partly explained by less aggressive cancer 
treatment for individuals with diabetes. In this thesis we described differences in 
patient, tumour, and treatment related variables between CRC patients with and 
without diabetes, thereby evaluating the implementation of national treatment 
guidelines (Chapter 4). The effect of diabetes on the administration of cancer 
treatment was assessed separately for colon and rectal cancer patients, because 
these types of cancer are treated differently. 
At the start of the research for this thesis numerous studies showed that the 
association between diabetes, cancer and mortality seemed to vary with GLDs, 
those treated with metformin appeared to have decreased overall mortality. These 
studies aroused our interest in metformin (Part III). The association between 
metformin use started after CRC diagnosis and mortality was explored using 
complex pharmaco-epidemiological analyses (Chapter 5). In the context of these 
complex analyses, this thesis includes a correspondence to the editor of the Journal 
of Clinical Oncology related to a study on metformin, mortality and prostate cancer 
(Chapter 6). Methodological considerations in the study of Margel et al. are
discussed that are relevant in part III of this thesis. 
Since the use of metformin, statin and aspirin, individually have been associated 
with decreased mortality in cancer patients and almost all individuals with diabetes 
receive statins and aspirins as co-medication, we assessed whether these drugs 
independently of one another influenced overall mortality in CRC patients
(Chapter 7).
Many studies provide insight into the influence of diabetes and GLDs on outcomes 
after cancer diagnosis. However, the worse mortality observed among patients 
with both diabetes and cancer can also be the result of the influence of cancer on 
diabetes parameters and GLDs. We aimed to reduce this gap in the literature by 
the addition of the studies in Part IV. 
Since no information is available about the impact of cancer on glycaemic control 
and physicians hypothesize that cancer deteriorates glycaemic control, which 
potentially influences mortality, we evaluated changes in HbA1c values around 
CRC diagnosis (Chapter 8). Furthermore, we were interested if the adherence to 
GLDs changes due to cancer diagnosis and treatment in individuals with diabetes, 
because worse medication adherence might lead to a higher risk of diabetes 
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complications and mortality (Chapter 9). 
In the general discussion the main findings and methodological considerations 
are discussed and implications for future research and clinical practice are outlined 
(Part V; Chapter 10).
Figure 2. Research questions investigated in this thesis.




The Eindhoven Cancer Registry (ECR) started in 1955 as part of a programme for 
nationwide cancer registration. Data on all newly diagnosed cancer patients were 
collected directly from pathology reports and medical records, sometimes through 
emerging hospital discharge registries. The registry started in three hospitals in 
Eindhoven and gradually expanded to include the southeastern part of the 
province of Noord-Brabant, the northern part of the province of Limburg (since 
1970) and the middle and southwestern part of Noord-Brabant since 1986 
(Figure 3).
Figure 3. The area of the Eindhoven Cancer Registry of the Netherlands 
Comprehensive Cancer Organisation. 
The area in the population-based ECR now hosts 2.4 million inhabitants and is 
served by 10 community hospitals, 6 regional pathology laboratories all 
participating in the nationwide network and registry of histo- and cytopathology 
(PALGA) and two large radiotherapy departments. The region is characterised by 
good access to medical care without financial obstacles. The distance to a hospital 
has always been less than 30 kilometres. 
Trained registration clerks actively collect data on diagnosis, patient characteristics, 
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staging, and detailed information about initial treatment (delivered within 6 months 
from diagnosis) from hospital medical records. The medical record is generally 
regarded as the most complete source of information on the patient’s past and 
current health status. Information on the vital status of the patients is obtained 
from the nationwide municipal personal records database. Since these registries 
do not provide information about the cause of death, additional data collection 
for information on cause of death was performed for one study in this thesis. 
Comorbidity at cancer diagnosis is obtained from the medical records by 
registration clerks and registered in the ECR according to an adapted version of 
the Charlson Comorbidity Index since 199350. Comorbidity was defined as 
life-shortening diseases that were present at the time of cancer diagnosis. The 
use of medication serves as an indicator for active disease, but comorbidity is only 
registered when it is described in the medical record. Diabetes includes both type 
1 and type 2 diseases and is registered as a dichotomous variable (yes/no), as are 
all other concomitant conditions.
PHARMO Database Network
The PHARmacoMOrbidity (PHARMO) Database Network is a population-based 
network of healthcare databases and combines data from different healthcare 
settings in the Netherlands. These different data sources are linked on a patient 
level through validated algorithms. Detailed information on the methodology and 
the validation of the used record linkage method can be found elsewhere51,52.
The longitudinal nature of the PHARMO Database Network system enables to 
follow-up more than 4 million (25%) residents of a well-defined population in the 
Netherlands for an average of ten years. Since the data collection period, 
catchment area and overlap between data sources differs, the final cohort size for 
any study will depend on the data sources included. As data sources are linked 
on an annual basis, the average lag time of the data is one year. All electronic 
patient records in the PHARMO Database Network include information on age, 
sex, socioeconomic status and mortality, while other information available is 
dependent on the data source. A detailed description of the different data sources 
is given below.
For this thesis the Out-patient Pharmacy Database comprises general practitioner 
or specialist prescribed healthcare products dispensed by the out-patient 
pharmacy. The dispensing records include information on type of product, date, 
strength, dosage regimen, and quantity, route of administration, prescriber 
specialty and costs. Drug dispensings are coded according to the WHO Anatomical 
Therapeutic Chemical (ATC) Classification System53. The out-patient pharmacy 
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data cover a catchment area representing 3.6 million residents.
 
The Clinical Laboratory Database comprises results of tests performed on clinical 
specimens. These laboratory tests are requested by general practitioners and 
medical specialists in order to get information concerning diagnosis, treatment, 
and prevention of disease. The electronic records include information on date 
and time of testing, test result, unit of measurement and type of clinical specimen. 
Laboratory tests are coded according to the Dutch WCIA coding system54. The 
clinical laboratory data cover a catchment area representing 1.2 million residents. 
Linkage of ECR with PHARMO
Both the ECR and the PHARMO Database Network are recognised as high quality 
sources for epidemiological research that collect information in overlapping 
regions in the Netherlands for a period of at least 10 years52. For this thesis data 
were obtained from the ECR and linked on a patient level to the PHARMO Database 
Network, covering a demographic region in the southeastern part of the 
Netherlands of approximately one million inhabitants. The construct and validity 
of the ECR-PHARMO cohort have been described in detail elsewhere52. 
The first cohort obtained after the linkage of the ECR and PHARMO databases 
consisted of 40,004 patients diagnosed with cancer between 1998 and 2006, 38% 
of the 104,562 cancer patients within the ECR were successfully linked (Figure 
4)52. After the inclusion of five more years of cancer patients (1998 – 2011), the 
size of the linked ECR-PHARMO cohort more than doubled to 91,540 patients. As 
a result of the expansion of the PHARMO Database Network within the ECR region, 
the percentage of cancer patients linked with PHARMO increased from 38% to 
46% (Figure 4). For this thesis specific groups of cancer patients from the linked 
ECR-PHARMO cohort were selected to answer the research questions, as can be 
seen in Figure 4. 
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Figure 4 Flowchart of the linkage process and cohort formation for this 
thesis.
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Abstract
Colorectal cancer (CRC) patients with pre-existing diabetes have significantly lower 
rates of overall survival compared with patients without diabetes. Against this 
backdrop, the American Diabetes Association and American Cancer Society in 
2010 reviewed the scientific literature concerning diabetes and cancer. One of 
the key issues identified for further investigation was the need for a better 
understanding of whether diabetes influences cancer prognosis above and beyond 
the prognosis conferred by each disease state independently. Whether the 
worsened survival of CRC patients with diabetes could be explained by less 
favourable patient-, tumour- and treatment related characteristics has also been 
elevated in numerous recent studies. However, as most studies did not account 
for all the various potential confounders, such as cancer stage, comorbidities and 
body mass index (BMI) in their analyses, the current evidence for the association 
between diabetes and survival in CRC patients remains inconclusive. Nevertheless, 
based on multiple examples in the literature, the present review demonstrates 
that diabetes affects the presentation of CRC as well as its treatment and outcome, 
which may then result in lower overall rates of survival in patients with, compared 
to those without, diabetes. 
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Introduction
Colorectal cancer (CRC) is more common in people with diabetes than in those 
without diabetes1-4, and patients with diabetes also have lower overall survival 
rates after CRC compared to those without diabetes, with 5-year survival of 35% 
and 48%, respectively5-13. In this context, the American Diabetes Association and 
American Cancer Society in 2010 reviewed the scientific literature concerning 
diabetes and cancer. One of the key issues identified for further investigation was 
the need for a better understanding of whether diabetes influences cancer 
prognosis above and beyond the prognosis conferred by each disease on its 
own14. This increased focus on diabetes, cancer and mortality has led to a rapid 
increase in reported observational studies using various data sources5-13 and the 
finding that the presence of diabetes can lead to lower overall survival in CRC 
patients by affecting the diagnosis, treatment and other outcomes of CRC. 
However, the association between diabetes and survival in CRC patients is highly 
complex, and many underlying factors, both known and unknown, could play a 
role. The aim of the present review was to evaluate and summarize the 
epidemiological evidence available on the magnitude of outcome worsening 
among patients who have both diseases, and to review the potential variables 
and pathways associated with those poorer outcomes.
To this end, a comprehensive literature review was used to examine the differences 
due to various factors associated with CRC in patients with and without diabetes 
that might be contributing to the higher mortality in those with diabetes. The 
associations explored are presented in Figure 1.  
Worsened outcomes among patients with colorectal 
cancer and diabetes
Overall survival
In several studies, cancer patients with pre-existing diabetes had significantly 
poorer overall survival compared to patients without diabetes5-13 (Table 1). When 
considering colon and rectal cancer separately, diabetes was significantly 
associated with lower overall survival in colon cancer patients, whereas this was 
less clear for rectal cancer patients7,9,12,15-17. One study showed that diabetes was 
associated with overall survival in patients with proximal colon cancer, but not in 
patients with distal colon cancer15. These cancer site-specific findings imply that 
diabetes not only influences the survival in CRC patients through shared risk 
factors, but may also influence the various subsites differently by affecting tumour 
and treatment characteristics (see below; Figure 1). 
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Cancer-specific survival
Although the attention on cancer-specific survival is increasing (Table 1), studies 
show mixed results and experts in cancer epidemiology recognize that the 
attribution of cause of death is often problematic18-20. Cause of death information 
taken from death certificates is frequently inaccurate and incomplete21. In addition, 
unreliable cause of death information can lead to misleading results22. This was 
well demonstrated by a previous study of CRC-specific survival in which 34% of 
rectal cancer patients were registered as having colon cancer as their underlying 
cause of death9. A few studies on CRC-specific survival found that diabetes was 
associated with lower rates of survival1,10,13, although others observed significantly 
worse CRC-specific survival only with rectal cancer9,13 (Table 1). More consistent 
was the finding that, when comparing CRC patients with and without diabetes, 
an increased risk of death due to other causes, especially cardiovascular disease, 
was evident9-11. However, in many of the above-mentioned studies, the analyses 
did not consider the presence of competing risks, i.e. the risk of death due to 
cancer competing with the risk of death due to other causes, especially 
cardiovascular disease18-20. As CRC patients with diabetes have a greater risk of 
dying from a cardiovascular event than cancer patients without diabetes, Cox 
regression analysis may have overestimated the actual risk of cancer death in 
diabetes patients19,20. To obtain a comprehensive picture of the impact of diabetes 
on survival, other causes of death must not be ignored, and overall survival analyses 
should be included as a point of reference. In addition, given the presence of 
competing risks, a cause-specific hazards model which combines proportional 
hazards models for the event of interest and the competing event may be more 
appropriate20. 
Cancer recurrence
One study evaluated the impact of diabetes on CRC recurrence and reported that 
patients with diabetes experienced a 5-year recurrence-free survival rate of 56% 
compared to 64% for those without diabetes7. Moreover, during the study 
follow-up, those with diabetes were more likely to die of recurrent disease7. 
Another study showed that the risk of recurrence was 32% higher in colon cancer 
patients with compared to those without diabetes, although this was not statistically 
significant15. One explanation for the apparently higher recurrence rates in CRC 
patients with compared to without diabetes could be increase tumour cell 
proliferation and metastases in the physiological environment of hyperinsulinaemia 
and hyperglycaemia23. As a consequence, the association between diabetes and 
cancer recurrence might be important in the overall relationship between diabetes 
and survival in CRC patients. In this case, additional studies focussing on cancer 
recurrence are needed. 
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Conclusions
There is extensive evidence that diabetes is associated with lower overall survival 
in CRC patients, although the data for cancer-specific survival and cancer 
recurrence are currently limited in the literature. Future studies need to bear in 
mind that the attribution of cause of death is often problematic and that the 
presence of competing risks should also be considered.   
Common risk factors 
The association between diabetes and prognosis in CRC patients is highly complex, 
as many underlying risk factors, such as age, lifestyle factors and comorbidities 
may be associated with the risk of diabetes and CRC as well as the prognosis after 
CRC14,24 (Figure 1). 
Age
A strong well-known prognostic factor in general is age, and the finding that CRC 
patients with diabetes are on average 3 to 5 years older than those without 
diabetes may have a major influence on the difference in mortality between the 
two groups6,9,15. Having a combination of both diseases is more common in the 
elderly, as the incidence of colon and/or rectal cancer is highest in those aged 
≥65 years, while the peak incidence of diabetes is at an even older age, around 
76 years in the Netherlands9,25-27. 
Lifestyle
Lifestyle factors, such as unhealthy diet, obesity and physical inactivity can influence 
the prognosis following CRC either directly or indirectly, as these factors may 
promote the development of other conditions, such as diabetes and cardiovascular 
disease28. Smoking is one such factor, as it may influence prognosis directly via 
the development of lung and cardiovascular disease, or indirectly in those with 
diabetes29. Among diabetes patients, smoking substantially raises the risk of 
neuropathy and nephropathy, resulting in a poorer prognosis for patients with 
both CRC and diabetes29. In addition, greater adherence to a typical Western diet 
(characterized by higher intakes of meat, sweets and refined grains) has been 
associated with significantly lower disease-free survival after a diagnosis of colon 
cancer30,31. 
Physical inactivity and obesity are potentially important confounding factors that 
should be considered, as both are hypothesized to influence insulin resistance 
and hyperinsulinaemia, thereby, indirectly affecting cancer outcomes32. Lack of 
exercise and being overweight are both strongly associated with the incidence 
of type 2 diabetes, with more severe obesity being linked directly to diabetes 
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onset at an earlier age33,34. In one study in CRC patients, those with obesity before 
cancer diagnosis had lower rates of survival compared to those of normal weight 
and the association appeared to be stronger for patients diagnosed with rectal, 
rather than colon, cancer35. Although this poorer survival in obese patients may 
be related to suboptimal surgical resection, one study of laparoscopic surgery for 
rectal cancer showed that body mass index (BMI) influenced the risk of conversion 
to an open procedure, but not surgical morbidity, quality of surgery or survival36. 
A meta-analysis of prospective cohort studies indicated that physical activity both 
before and after cancer diagnosis was associated with less CRC-specific mortality 
and overall mortality37,38. However, as BMI and physical activity can change over 
time, particularly during CRC therapy, repeated measurements of these lifestyle 
factors are likely to reduce misclassifications over time and so better reflect the 
effects of these factors on cancer survival39. Indeed, this was demonstrated by a 
longitudinal study in which BMI and physical activity in CRC patients were followed 
over time39. The CRC patients who were underweight at the time of diagnosis had 
worse cancer-specific survival, whereas patients who were either physically active 
or overweight had better cancer-specific survival. At 5 months post-diagnosis, 
CRC patients who had either lost or gained weight had lower overall survival, 
whereas those who increased their physical activity had higher survival rates39. 
Comorbidities
The association between various comorbidities and mortality was demonstrated 
decades ago40. Among CRC patients, those with diabetes have a significantly 
greater prevalence of cardiovascular disease, hypertension and cerebrovascular 
disease compared to those without diabetes, with prevalent rates of nearly 
50%9,12,27. In addition, diseases of the circulatory system are more often registered 
as the underlying cause of death in CRC patients with vs. those without diabetes, 
with rates of 18% vs. 12%, respectively9. Furthermore, besides vascular 
comorbidities, CRC patients with diabetes have more often been diagnosed with 
previous cancer and lung disease than those without diabetes9. However, although 
comorbidities appear to have led to the lower overall survival in patients with 
diabetes, the poorer cancer-specific survival found in some studies could not be 
explained by the high prevalence of comorbidities9,13,16.
Conclusions 
Age, smoking, dietary habits, BMI, physical activity and comorbidities are important 
potential confounding factors that should be considered when investigating the 
relationship between diabetes and overall mortality as well as cancer-specific 
mortality in CRC patients.
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Colorectal cancer development and diagnosis
Cancer stage
The most important prognostic factor in both colon and rectal cancer patients is 
the stage of the tumour at the time of diagnosis, with survival decreasing with 
increasing stage. Thus, if diabetes affects cancer stage at diagnosis, then, diabetes 
may have a major impact on survival among CRC patients. One study found that 
diabetes was associated with a trend towards diagnosis of early-stage (vs. late 
stage) CRC41, while another study found that poorly controlled diabetes, defined 
as an HbA1c value ≥7.5%, was particularly associated with a later stage of cancer 
at diagnosis42. It may be that, in such patients, medical care is focused on the 
management of diabetes and complications related to high blood glucose rather 
than on symptoms suggestive of cancer43. However, other studies support the 
theory (proposed by Feinstein) that earlier-stage disease is found in those with 
comorbidities because of increased contact with healthcare providers41,42,44,45. 
Indeed,  extensive investigation of a newly diagnosed patient with diabetes 
increases the chances of detecting early-stage cancer46. Recent observational 
studies addressing the time-varying risk of cancer incidence following diabetes 
onset have suggested that a substantial degree of detection bias in patients with 
diabetes is most likely due to increased ascertainment leading to earlier detection46 
(Figure 1). This detection bias in those with diabetes may indirectly influence the 
prognosis of patients with CRC, as those with early-stage CRC have better chances 
of curative treatment. 
Tumour subsite (colon vs. rectum)
Within the CRC patient population, differences in mortality are observed across 
various subsites. While the survival of patients with rectal cancer was worse than 
those with colon cancer in the years up to 2000, changes in the management of 
rectal cancer have since led to its survival rates levelling with those for colon 
cancer47. Although one study found that diabetes was associated with a risk of 
proximal colon cancer48 and not distal colon or rectal cancer, another study found 
that diabetes was associated with risk at all subsites49. In view of the difference in 
treatment regimens for colon and rectal cancer as well as the effect of diabetes 
on survival, colon and rectal cancer should be analyzed separately9,12,13,15. 
According to tumour subsites, the evidence for survival in CRC patients with 
diabetes is inconclusive; some studies have shown poorer CRC-specific survival 
for rectal cancer patients with diabetes, but not for colon cancer patients with 
diabetes9,13, while a study of colon cancer patients showed lower CRC-specific 
survival16. In addition, distal colon tumours have been associated with a decreased 
CRC-specific mortality compared to proximal colon tumours50. Thus, further studies 
of CRC-specific survival in these subgroups are needed, including a large-scale 
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population study taking into account the presence of competing risks, as discussed 
above.  
Conclusions
Evidence for the association between diabetes and stage of CRC at diagnosis is 
conflicting, with findings for both earlier as well as more advanced stages in 
patients with diabetes. Given the mixed results of previous research, the 
relationship between diabetes and survival in colon and rectal cancer patients 
should be addressed separately. 
Colorectal cancer treatment and response
Decision for treatment
The lower overall survival of CRC patients with diabetes compared to those without 
diabetes could be the result of differences in treatment regimens. Although no 
difference has been observed in surgical rates between CRC patients with and 
without diabetes, it has been found that patients with diabetes are less likely to 
receive chemotherapy12. The decision to give adjuvant treatment is based on 
weighing the relative benefits of a treatment in terms of reducing risk of recurrence 
and improving survival against its potential side effects and complications12. 
Treatment efficacy and the presence of complications may affect survival rates as 
well (Figure 1). 
A previous study of the Eindhoven Cancer Registry (ECR) revealed that CRC 
patients with diabetes are still receiving chemotherapy less often, although 
differences in treatment between CRC patients with and without diabetes are 
decreasing27. Furthermore, the proportion of stage II/III rectal cancer patients with 
and without diabetes who received radiotherapy was 58% and 75%, respectively, 
between 1999 and 2003, but this difference has more recently become smaller, 
with respective rates of 81% and 87%27. Chemotherapy is often not recommended 
for patients with significant comorbidities, such as diabetes, as such patients are 
likely to derive less benefit due to their limited life expectancy and higher risk of 
chemotherapy-induced toxicity12,27 (Figure 1). Ensuring that every high-risk CRC 
patient is referred to a medical oncologist is a crucial step in the administration 
of chemotherapy as well as quality of care51,52. Whereas especially in older patients 
such a visit is often replaced by a visit to another clinician and, thus, suboptimal 
information, as the sole advisor and prescriber of chemotherapy, a visit to the 
medical oncologist is the only way to receive chemotherapy. In addition, once 
referred, studies have shown that older oncologists may have an approach that 
may be more conservative because of less-recent training, more experience with 
chemotherapy toxicity and/or a lesser tendency to generalize the results of clinical 
trials53. 
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The patients themselves also play an important role in the decision to receive 
chemotherapy. It may be speculated that some patients, especially the elderly 
and those with diabetes, are less willing to accept the possible side effects of 
cancer treatment or have greater concerns about the negative effects that 
chemotherapy could have on their quality of life54. 
Although the beneficial effects of cancer treatment have been widely studied, the 
results in patients with comorbidities, such as diabetes have been rather less 
studied. Some studies of this patient population have found that CRC patients 
who received adjuvant cancer treatment had a better prognosis55-57. However, 
these studies are often prone to bias by selecting only the fittest patients and so 
may not be representative of all cancer patients with diabetes58. 
Cancer treatment response in diabetes patients
Diabetes may have a negative effect on cancer therapies. Cancer cells in patients 
with diabetes may be less sensitive to chemo/radiotherapy, resulting in higher 
rates of local tumour progression and lower rates of complete pathological 
response12,59. Also, the frequent presence of microvascular disease in patients 
with diabetes may reduce the release of radiosensitizing drugs in the hypoxic 
tumour environment59. Thus, research should focus on the effect of cancer 
treatment on the complete pathological response in patients with diabetes, taking 
into account detailed information on treatment dose, number and length of cycles, 
and possible dose adjustments.
Cancer treatment complications
Studies of complications in patients with diabetes after cancer treatment are limited 
and heterogeneous, and focus on various complications and 30-day mortality. 
Postoperative mortality or the 30-day mortality in most studies appeared to be 
higher in CRC patients with diabetes compared to those without diabetes, although 
the studies involved only small selected subgroups of patients6,60-62. Postoperative 
mortality in these patients could be higher due to infectious, cardiovascular and 
chemotherapy-related complications. Although the association between diabetes 
and infectious diseases was not confirmed in studies of complications after cancer 
treatment6,7,62, one study found that high postoperative glucose levels were 
associated with higher risk of surgical site infections63. The cellular effects of 
hyperglycaemia on wound healing during the postoperative period may have 
influenced the risk of infection. However, even though diabetes is a risk factor for 
atherosclerosis, resulting in higher risk of myocardial infarction and cardiovascular 
disease, studies investigating cardiovascular complications after surgery in CRC 
patients have shown mixed results6,7,61,62. Some could find no association between 
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diabetes and cardiovascular complications, while others found higher risks of 
hepatic decompensation after liver surgery, acute myocardial infarction and 
anastomotic complications in CRC patients with diabetes compared to those 
without diabetes6,7,61,62. Also, higher anastomotic leak rates were seen in CRC 
patients with diabetes that could have been related to microvascular disease in 
those with diabetes59,64.
Chemotherapy toxicity has been investigated to a lesser extent. One study reported 
a greater risk of severe treatment-related diarrhea after chemotherapy in colon 
cancer patients with compared to without diabetes, while the rates of other major 
toxicities were not significantly different7. Also, receiving adjuvant therapy was 
not associated with a greater probability of chemotherapy toxicity, defined as 
all-causes hospitalization rates after chemotherapy among colon cancer patients 
with diabetes58. Another study found that the dose of chemotherapy was reduced 
in 43% of colon cancer patients mostly because of gastrointestinal and neurological 
side effects, and was similar in those with and without diabetes17.
Conclusions   
Less administration of chemotherapy, more patient refusal of adjuvant treatment, 
lower rates of pathological response, higher postoperative mortality, and higher 
rates of infectious, cardiovascular and chemotherapy-related complications may 
be associated with lower overall survival rates in CRC patients with diabetes.
Diabetes treatment and control
Diabetes control
It may be hypothesized that some individuals perceive a diagnosis of CRC as more 
serious and life-threatening than diabetes, leading them to prioritize cancer 
treatment over appropriate diet, glucose monitoring and taking anti-diabetic 
medications as prescribed. The lack of attention to diabetes during cancer 
treatment may lie behind the variability of HbA1c values and development of 
hyperglycaemia, hypoglycaemia or other diabetes complications that, in turn, can 
increase the risk of infections, hospitalizations and even mortality. One small study 
of CRC patients with diabetes revealed that those with well-controlled diabetes 
(HbA1c <7.5%) had significantly better cancer-specific survival than those with 
poorly-controlled diabetes (HbA1c ≥7.5%)65.
Besides the lack of attention to diabetes treatment, the corticosteroids used in 
cancer treatment protocols can affect glucose levels directly and therefore 
influence the above-mentioned complications, as will hyperglycaemia 
indirectly66-69. 
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Glucose-lowering drugs
CRC patients with diabetes treated with metformin as part of their anti-diabetic 
therapy appear to have superior overall rates of survival70-74. However, whether 
the observed benefits of metformin can be attributed to its use before and/or 
after the diagnosis of cancer is not clear. A methodological limitation of many 
studies of metformin and CRC outcomes is that they include the use of metformin 
as a dichotomous variable in the analyses. However, as the medications used by 
diabetes patients can vary considerably over time, the inclusion of cumulative 
exposures in the analysis would have been a more accurate way to investigate the 
effect of metformin on mortality75. Given these suboptimal study designs, the 
debate as to whether and to what extent metformin might influence the prognosis 
for CRC patients and be a candidate drug as an additional therapy to adjuvant 
chemotherapy is still ongoing. 
In addition, the decision to use metformin to treat diabetes may have been 
influenced by clinical and metabolic factors that might have influenced the 
prognosis of CRC, leading to a situation in which metformin use may be associated 
with a better prognosis, but not responsible for it. While awaiting the results of 
randomized metformin trials76,77, observational studies using a time-varying 
approach of cumulative drug duration are suggested.
Conclusions 
The lack of attention to diabetes during cancer treatment may adversely affect 
diabetes control, resulting in lower overall survival, although the evidence is scanty. 
The debate as to whether or not the glucose-lowering drug metformin influences 
the prognosis of CRC is ongoing, as previous studies had many methodological 
complications. 
Discussion
This comprehensive review highlights the complexity of the association between 
diabetes, CRC and patient survival. Several potential explanations have been 
proposed for the observed association between overall and CRC-specific survival 
and diabetes in CRC patients. New studies should account for all aspects of this 
association, including consideration of common risk factors and cancer stage and 
treatment differences, while focusing on tumour-related outcomes, such as 
recurrence and cancer-specific survival, as well as considering the effects of 
competing risks.
Understanding the relationship between diabetes, cancer and its prognosis may 
be considered one of the next challenges in this field, and new studies need to 
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account for the abundance of factors associated with having both diseases and 
survival. Once an association between diabetes, recurrence and cancer-related 
survival is established, the underlying mechanism may then be studied in greater 
detail. 
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Abstract
Objective: The purpose of this study was to investigate the influence of diabetes 
mellitus (DM) on cancer stage at diagnosis, cancer recurrence, and survival of 
endometrial cancer (EC) patients and the influence of the treatment of EC on 
glycaemic control, treatment, and complications of DM.
Methods: In this retrospective cohort study all 1,644 patients with EC newly 
diagnosed in 2000-2008 and recorded in the population-based Eindhoven Cancer 
Registry (ECR) were included. In addition, from this total cohort a subcohort was 
selected for additional data collection and analyses, including 193 EC patients 
with DM and an age-matched sample of 195 EC patients without DM. Patients 
with FIGO stage IV as well as non-endometrioid histology were excluded. 
Results: In the total cohort EC patients with DM had a significantly higher age 
(69 years vs. 64 years), higher FIGO stages and more additional comorbidities 
compared to EC patients without DM. The 5-year overall survival rate for EC 
patients with DM was significantly lower than for EC patients without DM (68% vs. 
84%). After adjusting for age, stage, period of diagnosis, cardiovascular disease, 
and treatment, this significant effect of DM on overall mortality persisted (HR 1.4; 
95% CI 1.0−1.8). Subcohort analyses showed that EC patients with DM were 
diagnosed more often with a higher body mass index (BMI) (34 kg/m2 vs. 30 kg/
m2) and EC was not significantly associated with changes in DM characteristics 
over time. Although the 5-year overall survival rate for EC patients with DM was 
significantly lower in the subcohort, for EC-specific mortality (n=388) no statistically 
significant effect of DM was observed after adjustment for FIGO stage (HR 1.7; 
95% CI 0.7−3.9). 
Conclusions: EC patients with DM compared to those without had worse patient 
characteristics, a higher FIGO stage, similar recurrence rates and worse overall 
survival. 
Effect of diabetes on endometrial cancer recurrence and survival | 47
3
Introduction
Endometrial cancer (EC), the most common of gynaecological malignancies, is 
suggested to be biologically associated with diabetes mellitus (DM), since shared 
risk factors, such as physical inactivity, obesity as well as high-saturated diet, only 
partly explain the observed higher risk of EC in DM patients1-6. Although the effect 
of DM on cancer risk may be small, given the high incidence of both DM and EC7-9, 
even a modest association between DM and cancer means a considerable effect 
on public health. Furthermore, the number of newly diagnosed cancer patients 
with DM is expected to even double from 5500 in 2000 to 10,400 in 201510. 
In addition, many studies showed that EC patients with pre-existing DM had a 
significantly increased overall mortality, while only one study investigated the 
effect of DM on EC-specific mortality11-16.  This study found no effect of DM on 
EC-specific mortality, however, numbers of DM patients and deaths were small, 
and information about treatment of EC was missing12. The treatment of EC may 
affect glycaemic control, treatment, and complications of DM as well, whereas 
studies investigating this effect are lacking. 
The potential biological link between the two diseases is incompletely understood 
and the mediators for this association are not known, but are thought to be related 
to hyperinsulinaemia (either due to insulin resistance or due to administered 
insulin), hyperglycaemia, insulin-like growth factor, and adipocytokines3. Moreover, 
evidence from observational studies suggest that some oral glucose lowering 
medications used to treat hyperglycaemia are associated with either increased 
or reduced cancer risk and mortality17-18.
The purpose of the present study was to investigate whether EC patients with DM 
had a different stage at diagnosis, were treated differently, had different recurrence 
rates, and worse overall and EC-specific survival compared to EC patients without 
DM. In view of the association between EC and DM, the effect of treatment of EC 




The Eindhoven Cancer Registry (ECR), maintained by the Comprehensive Cancer 
Centre South (CCCS), records data on all patients newly diagnosed with cancer 
in the southern part of the Netherlands, an area with 2.4 million inhabitants. The 
registry is notified by six pathology departments, hospital medical records offices 
in 10 community hospitals, and two large radiotherapy institutes. 
Data on patient characteristics such as date of birth and postal code, as well as 
tumour characteristics such as date of diagnosis, tumour type, histology, stage, 
and initial treatment are routinely extracted from medical records by trained 
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registrars. The guideline for initial treatment of EC patients in the ECR region did 
change in our study period19-20. Between 1998 and 2004 five hospitals in the ECR 
region participated in a study about routine performance of pelvic 
lymphadenectomy for EC patients with FIGO stage I, these five were included in 
the total cohort and subcohort analysis19. For all EC patients with FIGO stage II 
radical hysterectomy with lymphadenectomy was advised in our region. Based 
on the results of the PORTEC I trial about radiotherapy, the EC guideline changed 
in 2000, only in the presence of two or three of the risk factors (>50% myometrial 
invasion, grade 3 histological type, age ≥60 years) adjuvant radiotherapy was 
advised21. 
Comorbidity is obtained from the medical records according to an adapted version 
of the Charlson Comorbidity Index22. Comorbidity was defined as life-shortening 
diseases that were present at the time of cancer diagnosis. Medication use served 
as indicator for active disease; comorbidity was registered when described in the 
medical record. DM included both type 1 and type 2 diseases and was registered 
as a dichotomous variable (yes/no), as were all other concomitant conditions. 
Tumour site and morphology were classified according to the International 
Classification of Diseases for Oncology, 3rd edition (ICD-O)23. Socioeconomic status 
(SES), based on individual fiscal data on the economic value of the home and 
household income, was provided at an aggregated level for each postal code24. 
Information about vital status was obtained from the municipal personal records 
database (GBA) for all EC patients included in this study.
Total cohort
For this retrospective cohort study we included all patients with EC, newly 
diagnosed between 2000 and 2008 from the ECR (Figure 1). Only patients with 
endometrioid EC were selected because this type of EC is oestrogen driven and 
related to risk factors like obesity, hyperinsulinaemia, and DM25. We selected all 
patients with FIGO stages I, II, and III, according to the International Federation 
of Gynaecology and Obstetrics (FIGO, 1988)26. FIGO stage IV (n=58) was excluded 
because treatment differed with other FIGO stages and no effect of DM on 
prognosis was seen for this subgroup in earlier studies15. After selection a total 
of 255 EC patients with DM and 1,389 EC patients without DM remained for the 
total cohort analyses, using data from the ECR and GBA (Figure 1). 
Subcohort
Out of the total cohort seven hospitals in the ECR region consented to provide 
additional in-depth data. This resulted in a selection of 193 EC patients with DM 
for the subcohort, they were matched on age, thereby selecting an age-matched 
group of 195 EC patients without DM for in-depth analyses. Matching for age was 
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randomly performed according to 5-year age groups. 
For the subcohort data collection analysis we went back to the medical records 
and collected information about BMI, smoking status, complications after 
radiotherapy, type of DM, date of onset, and the presence of complications due 
to DM. These complications were registered as microvascular (retinopathy, 
nephropathy, and neuropathy) and macrovascular complications (coronary disease 
and peripheral arterial disease). To study the effect of EC on the regulation of DM, 
HbA1C values, DM medication, and DM complications were registered in the year 
before diagnosis and the year after diagnosis of EC. Information about recurrence 
rate and cause of death was also collected from the medical records. Recurrence 
was defined as the existence of local (vaginal cuff) or regional recurrence (pelvis), 
or metastatic disease (lymph nodes and organs). Cause of death was obtained 
from the medical record when possible, otherwise it was determined by contacting 
the general practitioner. In addition, we also obtained information from the 
Registration System Oncological Gynaecology (ROGY), a web-based patient 
information system, maintained since 2006 by gynaecologists in the CCCS area27. 
Furthermore, we linked the patients of the subcohort with Pharmo RLS (Institute 
for Drug Outcomes Research) in order to obtain information about laboratory 
Figure 1. Flowchart of the selection of endometrial cancer patients for the 
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DM, diabetes mellitus; EC, endometrial cancer; ECR, Eindhoven Cancer Registry.
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tests, medication, and hospitalization28.
Statistical analysis
The SAS computer package (version 9.2) was used for all statistical analyses (SAS 
Institute, Cary, NC, 1999). A p-value <0.05 was regarded as statistically significant.
Differences between EC patients with and without DM in the total cohort and 
subcohort were analyzed using chi square and the t-test when applicable. 
Overall survival analysis of the total cohort and subcohort was analyzed using the 
life-table method to evaluate prognosis after diagnosis of EC for patients with or 
without DM. Survival time was defined as the time from diagnosis to death or 
January 1, 2010 for the patients who were still alive. In the total cohort, survival 
was also analyzed according to FIGO stage at diagnosis and DM status. 
The independent prognostic effect of DM on overall survival of EC patients was 
estimated using Cox proportional hazard analyses. The effect of DM over time 
satisfied the assumption of proportionality since the graphs of the log(log(survival)) 
versus log of survival time resulted in graphs with parallel lines. The hazard rates 
for death of EC patients with DM compared to EC patients without DM were further 
adjusted for age, stage, period of diagnosis, specific comorbidities, and treatment. 
In addition, in the subcohort EC-specific survival and recurrence free survival was 
analyzed. EC-specific survival was analyzed using the life-table method to evaluate 
prognosis after diagnosis of EC, with EC-specific death as event, while censoring 
other causes of death. The hazard rates for death due to EC, comparing EC patients 
with and without DM, were further adjusted for stage. Recurrence free survival of 
EC patients with DM compared to without DM was analyzed as well. This survival 




In the period 2000-2008, 1,644 women were diagnosed with EC, 255 (16%) of 
whom had DM at cancer diagnosis. EC patients with DM were on average 5 years 
older, diagnosed more often with a higher FIGO stage, and a lower SES (Table 
1). Cardiovascular disease, hypertension, cerebrovascular disease, and pulmonary 
disease were more often present in EC patients with DM compared to EC patients 
without DM.  Although EC patients with DM received surgery with lymphadenectomy 
less often, the number of positive lymph nodes did not differ between both groups 
(Table 1). EC patients with DM received radiotherapy more often compared to 
EC patients without DM. 
At the end of follow-up, out of the total cohort 82 (31%) EC patients with DM died 
compared to 228 (16%) without DM. The 5-year overall survival rate for EC patients 
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Table 1. Characteristics of patients with EC FIGO stage I-III according to 
DM status (n=1,644).









n (%) n (%) n (%) n (%)
Mean age (± SD) 64 (± 10.3) 69 (± 9.1)** 69 (± 8.5) 70 (± 9.0)
FIGO stage a
   I 1158 (83) 190 (75) 160 (82) 135 (70)
      IA 187 (16) 23 (12) 22 (14) 19 (14)
      IB 610 (53) 97 (51) 75 (47) 68 (50)
      IC 350 (31) 69 (37) 63 (39) 48 (36)
   II 103 (8) 28 (11) 11 (6) 24 (12)
   III 128 (9) 37 (14) * 24 (12) 34 (18) *
Grade EC a
   I 588 (44) 113 (45) 68 (37) 81 (43)
   II 546 (41) 96 (39) 80 (44) 71 (38)
   III 191 (15) 41 (16) 35 (19) 36 (19)
Socioeconomic status a
   Low 331 (24) 92 (37) 56 (29) 76 (41)
   Middle 532 (39) 91 (37) 74 (38) 66 (35)
   High 442 (33) 50 (20) 56 (29) 32 (17)
   Institutionalized 59 (4) 15 (6) ** 7 (4) 13 (7) *
Comorbidities a
   Cardiovascular disease 180 (15) 83 (33) ** 44 (23) 68 (35) *
   Hypertension 359 (30) 142 (56 ** 77 (40) 111 (57) *
   Cerebrovascular disease 32 (3) 17 (7) * 5 (3) 16 (8)*
   Pulmonary disease 54 (5) 21 (8) * 7 (4) 19 (10) *
   Previous cancer 159 (13) 35 (14) 28 (14) 28 (14)
Received surgery 1373 (99) 250 (98) 192 (98) 188 (97)
Type of surgery
   With lymphadenectomy 421 (30) 57 (22) 67 (34) 57 (30)
      Positive lymph nodes 34 (8) 5 (9) 5 (7) 5 (9)
   Without lymphadenectomy 968 (70) 198 (78) * 128 (66) 136 (70)
Received chemotherapy 27 (2) 2 (1) 2 (1) 1 (1)
Received radiotherapy 384 (28) 98 (38) * 62 (32) 73 (38)
Type of radiotherapy
   External beam radiotherapy 227 (16) 56 (22) 38 (19) 38 (20)
   Brachytherapy 70 (5) 24 (9) 9 (5) 18 (9)
   Combination 79 (6) 15 (6) 13 (7) 14 (7)
BMI (kg/m2, ± SD) a n.a. 30.1 (± 6.7) 33.7 (± 7.3) *
   <25 56 (50) 42 (33)
   30-35 30 (27) 36 (29)
   >35 26 (23) 47 (38) *
Smoking statusa n.a.
   Yes 11 (11) 14 (14)
   No 76 (75) 81 (79)
   Quit 14 (14) 8 (8)
DM, diabetes mellitus; EC, endometrial cancer; a Does not add up to total due to missings, percentages determined 
for available data; * p<0.05;  ** p<0.0001.
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with DM was significantly lower than for EC patients without DM (68% vs. 84%) 
(Figure 2). After adjusting for age, stage, period of diagnosis, specific comorbidities, 
and treatment, this significant effect of DM on overall survival persisted (HR 1.3; 
95% CI 1.0−1.8) (Table 3).
Subcohort
The patient characteristics of the subcohort of 388 EC patients were comparable 
to those in the total cohort. However, the percentage of EC patients who received 
lymphadenectomy and the proportion of additional comorbidities was higher 
compared to the percentage in the total cohort (Table 1). The in-depth data 
showed that EC patients with DM were diagnosed more often with a higher BMI 
compared to EC patients without DM, while smoking status did not differ between 
the two groups (Table 1).
The average duration of DM was nine years and nine patients were diagnosed 
with DM in the year before or at diagnosis of EC (Table 2). Mean HbA1c values, 
BMI, and number of patients using medication remained almost similar from the 
year before up to one year after diagnosis of EC. Fifty-nine patients (30%) had one 
or more DM-related complications at the time of EC diagnosis and after EC 
diagnosis, 16 patients, without complications before diagnosis, developed micro- 
or macrovascular complications (Table 2). 
In the survival analysis of the subcohort, the 5-year overall survival rate for EC 
patients with DM was significantly lower than for EC patients without DM (65% vs. 
85%). After adjusting for age, stage, period of diagnosis, specific comorbidities, 
and treatment, this significant effect of DM on overall survival persisted (HR 2.3; 
95% CI 1.4−3.7) (Table 3). In contrast, for EC-specific mortality (n=388) no 
statistically significant effect of DM was observed after adjustment for FIGO stage 
(HR 1.4; 95% CI 0.7−2.6) (Table 3 and Figure 3). Although not statistically significant, 
evaluation of the cause of death showed that EC patients with DM died of 
comorbidity most often (n=33, 54%), whereas EC patients without DM died of EC 
(n=16, 57%) most often. Comorbidity included all different types of comorbid 
diseases present in the Charlson Comorbidity Index. In the group of comorbidities, 
cardiovascular and cerebrovascular diseases were the most common causes of 
death in EC patients (23% in patients with DM and 25% in patients without DM).
In the selected subcohort recurrent disease was found in 26 (14%) EC patients 
with DM compared to 27 (14%) without DM. Metastasis was the most frequent 
type of recurrence and was observed in 9% of EC patients with DM and 8% of EC 
patients without DM. Recurrence free survival was significantly lower for EC patients 
with DM compared to those without (p=0.0001). However, the difference between 
overall survival and recurrence free survival, was approximately the same for 
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Figure 2. Overall survival of EC patients according to DM status and FIGO 
stage.
DM, diabetes mellitus; EC, endometrial cancer.
Figure 3. Overall and EC-specific survival of EC patients according to DM 
status.
DM, diabetes mellitus; EC, endometrial cancer.
54 | Chapter 3
3
patients with and without DM. The recurrence did not differ between EC patients 
with and without DM, while the overall survival did differ strongly between both 
groups. 
Discussion
In the present study, we found that EC patients with DM had a significantly higher 
overall mortality than those without DM. In addition, DM was not associated with 
higher recurrence rates, or a higher EC-specific mortality after adjustment for the 
observed higher FIGO stages found for patients with DM. DM treatment and DM 
complications did not change significantly when patients were compared before 
and after EC diagnosis and treatment.
Table 2. DM characteristics before and after diagnosis of EC for patients 
with DM at cancer diagnosis (n=388).
Before diagnosis a After diagnosis b
n=193 n=193
n (%) n (%)
DM type
   1 2 (1)
   2 191 (99)
DM length at diagnosis (years, ± SD) 8.7 (± 7.7)
   <1 9 (5)
   1 7 (4)
   2-5 41 (21)
   5-10 40 (21)
   >10 45 (23)
   Unknown 51 (26)
BMI mean (kg/m2, ± SD) 34.1 (± 6.9) 33.3 (± 6.7)
Hba1c mean (%,± SD) 7.6 (± 1.3) 7.5 (± 1.3)
Medication
   Oral glucose-lowering 105 (55) 99 (51)
   Insulin 22 (11) 24 (13)
   Diet 2 (1) 1 (1)
   Oral glucose-lowering and insulin 38 (20) 47 (24)
   No medication 3 (1) 2 (1)
   Unknown 23 (12) 20 (10)
Complications
   Microvascular 8 (4) 11 (6)
   Macrovascular 41 (21) 49 (25)
   Both 10 (5) 15 (8)
   No complications 92 (48) 76 (39)
   Unknown 42 (22) 42 (22)
DM, diabetes mellitus; EC, endometrial cancer; a In the year before diagnosis of EC, until diagnosis; b From diagnosis 
of EC, until 1 year after diagnosis. 
Effect of diabetes on endometrial cancer recurrence and survival | 55
3
Previous studies have already identified DM as a prognostic factor for EC in 
postmenopausal patients11-16. In one of these, a Dutch population-based study, 
the hazard ratio was 1.4 (95% CI 1.1−1.8 ), while in another study of 93 DM patients 
a HR of 1.7 (95% CI 1.1−2.5) was found when comparing EC patients with and 
without DM12,15. However, in these studies no association between EC-specific 
mortality and DM was found. Cause of death has never been properly investigated 
for patients with EC, making it difficult to understand whether the observed 
increased overall mortality can simply be explained by an effect of DM or is a true 
effect due to interaction between the two diseases.
While in our study EC patients with DM had a higher FIGO stage at diagnosis 
compared to patients without DM, in other studies baseline DM was not associated 
Table 3. Multivariate regression analysis of the effect of diabetes on 
all-cause mortality and EC-specific mortality.
Total cohort (n=1,644) Subcohort (n=388)
All-cause mortality a All-cause mortality a EC-specific mortality b
HR c (95% CI) HR c (95% CI) HR c (95% CI)
DM
   Yes 1.3 (1.0-1.8) * 2.3 (1.4-3.7) * 1.4 (0.7-2.6)
   No 1.0 1.0 1.0
Age 1.1 (1.1-1.1) ** 1.1 (1.0-1.1) **
FIGO
   Stage I 1.0 1.0
   Stage II 2.0 (1.4-2.9) * 2.0 (1.1-3.7) * 6.9 (3.1-15.4) **
   Stage III 3.7 (2.7-5.2) ** 3.8 (2.1-6.8) ** 8.7 (4.3-17.5) **
Period of diagnosis 1.0 (0.9-1.1) 1.0 (1.0-1.2)
Comorbidities d
   Cardiovascular disease 0.9 (0.7-1.3) 0.9 (0.6-1.6)
   Hypertension 0.9 (0.7-1.3) 0.8 (0.5-1.3)
   Cerebrovascular disease 2.0 (1.2-3.3) * 2.5 (1.2-5.1) *
   Pulmonary disease 1.3 (0.8-2.1) 1.1 (0.5-2.5)
   Previous cancer 1.7 (1.2-2.3) * 1.0 (0.6-1.8)
Surgery 
   Yes 1.0 1.0
   No 3.4 (2.0-5.7) ** 4.1 (1.7-9.8) *
Radiotherapy 
   Yes 1.0 1.0
   No 1.0 (0.7-1.3) 1.5 (0.9-2.4)
DM, diabetes mellitus; EC, endometrial cancer; a Proportional hazards model for all-cause mortality is adjusted for DM, 
age at time of diagnosis, FIGO stage, period of diagnosis, cardiovascular disease, hypertension, cerebrovascular disease, 
pulmonary disease, previous cancer, surgery, and radiotherapy; b Proportional hazards model for EC-specific mortality 
is adjusted for DM and FIGO stage; c HR = Hazard Ratio, missing values were included in the multivariate analysis, but 
not shown in the table; d The reference for a specific comorbidity is the absence of the specific comorbidity; * p<0.05; 
** p<0.0001.
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with the extent of disease at EC diagnosis13,14. At diagnosis the tumour has 
infiltrated the myometrium, causing postmenopausal blood loss as first symptom 
in 95% of EC patients, these symptom might be overshadowed by symptoms of 
comorbidities or ignored in DM patients29. In contrast, we hypothesized that DM 
affects myometrial invasion directly by a proliferative or anti-apoptotic effect, 
resulting in blood loss in a more advanced stage. This myometrial invasion may 
be effected by adipokines, which are adipocyte-secreted hormones, as well30,31. 
The plasma concentrations of adiponectin, one of the most abundant adipokines, 
are reduced in obese individuals and interestingly have been reported to have 
anticarcinogenic properties either. Furthermore, in vitro studies have shown that 
adiponectin may inhibit cell proliferation and induce apoptosis of some cancer 
cells. This may explain why EC patients with DM, and a significant higher BMI and 
thus lower adiponectin concentrations, have a more advanced tumour stage than 
their counterparts30,31. Other underlying biological factors are oestrogen, insulin, 
and the free related insulin-like growth factor-I (IGF-I), which may influence the 
effect of DM on EC3,5. Cancer proliferation might be stimulated by IGF-I, a 
biologically active form of growth factor3. Moreover, many cancer cells have an 
increased insulin receptor content, therefore insulin could favour cancer 
progression and facilitate the growth of tumours and early infiltration3,32. In contrast 
with insulin, the DM drug metformin is thought to be a potent inhibitor of cell 
proliferation in EC, thereby reducing cancer risk33. Whether the underlying 
mechanism for this effect is related to the systemic action of this drug, by reducing 
circulating insulin levels, or a direct action on cancer cells is still unknown33. 
Although the rapid tumour growth by insulin could explain the more advanced 
FIGO stages, an effect on presence of recurrence should than be expected as 
well. Even though our EC-specific survival analysis showed no effect of DM after 
adjusting for this more advanced tumour stage, another study did observe lower 
EC-specific survival for EC patients with DM13. However, this study analyzed only 
a small group of 42 EC patients with DM and no stratification for FIGO stage was 
made13. Another study, with 12,000 EC patients, investigated the impact of race 
and comorbidity on EC-specific survival, thereby adjusting for patients, tumour, 
and treatment characteristics34. DM was associated with poorer survival in white 
women, but not in blacks34. 
In our study the hypothesis that EC has a negative effect on the course of DM can 
be rejected when comparing values one year before and up to one year after 
diagnosis of EC. Although assuming that when a patient has EC, attention for DM 
control decreases, EC itself might have an effect on DM. In contrast, weight loss 
due to cancer, cancer therapy, and eating less may improve DM control. In contrast, 
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many breast cancer patients gain weight after diagnosis, resulting in a dysregulation 
of DM35. Since all of the abovementioned hypotheses may affect DM status in 
different ways, an overall effect could possibly be camouflaged.
A limitation of the current study is the retrospective study design, therefore only 
information available in the medical records could be collected, BMIs and HbA1c 
values were not always reported. The BMI was missing in 39% of the EC patients 
in the subcohort. Furthermore, detailed information on DM medication was 
missing, which could be of interest when investigating the specific effect of 
metformin on survival in EC patients. The effect of DM on overall survival in the 
subcohort was suggested to be slightly stronger than in the total cohort. Although 
an explanation for this difference was not found, the number of patients in this 
cohort was small.  A significant effect of DM on EC-specific mortality was not found, 
however, the additional analysis for EC-specific mortality was underpowered due 
to the relatively small number of patients in the subcohort. Therefore, the possible 
effect of DM on FIGO stage and EC-specific mortality has to be further investigated 
in a larger group of patients.
Although the total cohort and subcohort had almost similar baseline characteristics, 
the proportion of EC patients who received lymphadenectomy was higher in the 
subcohort. The seven hospitals selected for the subcohort analysis participated 
in a Dutch study about pelvic lymphadenectomy between 1998 and 200419, in 
which all EC patients with FIGO stage I received this therapy.  Furthermore, the 
proportion of additional comorbidities, especially cardiovascular disease and 
hypertension, in EC patients without DM was higher in the subcohort compared 
to the total cohort, probably because the older age in the subcohort was associated 
with a higher number of comorbid conditions36. 
In summary, this study supports the hypothesis that EC patients with DM have 
worse survival rates than EC patients without DM. Higher FIGO stages and more 
comorbidities in EC patients with DM could explain these survival rates. Future 
studies are needed to reveal the relationship between DM and EC, explaining the 
late onset of symptoms in EC patients with DM compared to EC patients without 
DM. The higher mortality rates for EC patients with DM were most likely caused 
by DM as such, therefore, physicians should be encouraged and motivated to 
rigorously treat and follow these patients with DM also after the EC diagnosis and 
treatment. Furthermore, postmenopausal women with the combination of DM 
and EC might have a more advanced stage at EC diagnosis, resulting in a higher 
EC-specific mortality, so caution is recommended for this subgroup.  
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Abstract
Aims: An increasing number of oncologists will be confronted with individuals 
having diabetes and cancer. We assessed changes in patient-, tumour-, and 
treatment- related variables in colorectal cancer (CRC) patients with and without 
diabetes. 
Methods: All 17,170 cases of primary CRC between 1995 and 2010 in the South-
Eastern Netherlands were included. The Cochrane-Armitage test and logistic 
regression analysis were used to analyse trends. 
Results: 11,893 patients were diagnosed with colon cancer and 5,277 with rectal 
cancer, of whom 1,711 (14%) and 609 (12%), respectively, had diabetes at the 
time of cancer diagnosis. CRC patients with diabetes compared to those without 
were about 5 years older and more often diagnosed with proximal colon tumours 
(60% vs. 54%, p<0.0001). Chemotherapy administration significantly increased 
in stage III colon cancer patients with and without diabetes (from 17% in 1995-1998 
to 50% in 2007-2010, 38% to 63%, respectively, p<0.0001). However, in the most 
recent period and after adjusting for the co-variables age, gender, year of 
diagnosis, and specific comorbidities, stage III colon cancer patients with diabetes 
received adjuvant chemotherapy less frequently than those without (OR 0.7; 95% 
CI 0.5-0.9; p=0.002). The proportion of stage II/III rectal cancer patients with and 
without diabetes who underwent radiotherapy was similar in recent years (91% 
vs. 87%). 
Conclusions: Although the administration of chemotherapy and radiotherapy 
increased between 1995 and 2010 in CRC patients with and without diabetes, 
CRC patients with diabetes continue to receive chemotherapy less frequently than 
those without diabetes. 
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Introduction
Numerous epidemiological studies have shown that colorectal cancer (CRC) occurs 
more commonly in individuals with type 2 diabetes than in the general population 
1-3. The number of newly diagnosed CRC patients, of whom 11-15% have diabetes 
as well, is estimated to increase from 12,755 in 2010 to 17,000 in 2020 in the 
Netherlands4-6. Although the effect of diabetes on CRC risk may be small, given 
the increasing prevalence of both diabetes and CRC, even a modest association 
between the two diseases indicates a considerable effect on public health. 
Due to the high prevalence of diabetes and cancer, the American Diabetes 
Association and American Cancer Society recently reviewed the scientific literature 
concerning the influence of diabetes on cancer diagnosis, treatment and outcome3. 
This consensus report recommended focusing on site-specific cancers instead of 
combining all sites3. CRC patients with diabetes have worse survival rates than 
those without diabetes, which is hypothesised to be the result of less aggressive 
cancer treatment for diabetic individuals6-8. Although no specific data are available 
on the trends in treating CRC patients with diabetes, previous studies have shown 
that elderly CRC patients are being increasingly treated with a more aggressive 
approach, resulting in increased survival9,10. In the last decades, a strong 
improvement in survival was observed in patients with stage III colon cancer, which 
was most likely related to the increased administration of adjuvant chemotherapy9-12. 
In rectal cancer patients, the introduction of the total mesorectal excision (TME) 
technique, the widespread introduction of neo-adjuvant radio-(chemo) therapy 
and the shift from postoperative to preoperative radiotherapy might have improved 
survival rates13,14.
In this study, we analysed trends in diabetes prevalence among CRC patients, and 
compared trends in the treatment of CRC patients with and without diabetes in 
the period between 1995 and 2010.
Methods
Data collection
The Eindhoven Cancer Registry (ECR), maintained by the Comprehensive Cancer 
Centre South (CCCS), records data on all patients newly diagnosed with cancer 
in the South-Eastern part of the Netherlands, an area with 2.4 million inhabitants. 
The registry is notified by six pathology departments, 10 community hospitals (at 
17 locations), and two large radiotherapy departments. Trained registration clerks 
actively collect data on diagnosis, staging, and detailed information about initial 
treatment from hospital medical records. Stage is based on the pathological TNM 
classification15. In rectal cancer patients, the pathological TNM stages II and III are 
combined for the analyses of preoperative radiotherapy and T3 and T4 tumours 
are combined for the analyses of chemo-radiation. Since 1995, the ECR has 
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recorded comorbidity from the medical records according to a slightly adapted 
version of the Charlson Comorbidity Index16. The use of medication serves as an 
indicator for active disease, but comorbidity is only registered when it is described 
in the medical record and is present at the time of cancer diagnosis. Diabetes 
includes both type 1 and type 2 diseases, and is registered as a dichotomous 
variable (yes/no), like all the other concomitant conditions. Patients treated with 
diabetes medication as well as with only dietary measures are registered as having 
diabetes. Completion of registration takes place about nine months after diagnosis. 
The quality of data is high and the completeness is estimated to be at least 95%17.
For the present study, all patients with primary colorectal cancer (C18 and C20) 
were included, while patients with unknown site (C18.8-18.9; 1% of total) and 
unknown stage of the primary tumour, cases diagnosed by autopsy alone and 
patients with rectosigmoid tumours (C19) were excluded. Rectosigmoid tumours 
were excluded, since the treatment decisions in this subtype are inconsistent and 
are sometimes treated as a colon and sometimes as a rectal tumour. Oncological 
treatment was defined as surgery, radiotherapy, chemotherapy, and chemo-
radiation. Surgery included resection of the primary tumour with or without lymph 
node resection. CRC patients with missing data on diabetes status were excluded 
(8% of total). Patients were divided into those with and without diabetes for all 
analyses. The study period was divided into four categories: 1995-1998, 1999-2002, 
2003-2006, and 2007-2010. Tumour localisation was categorised into anatomical 
subsites: proximal colon, consisting of the caecum, appendix, ascending colon, 
hepatic flexure, transverse colon, and splenic flexure (C18.0-C18.5); distal colon, 
consisting of the descending colon and sigmoid colon (C18.6-C18.7); and rectum, 
consisting of the rectum (C20). 
Statistical analyses 
All analyses were stratified for colon and rectal cancer patients. Diabetes 
prevalence rates are shown as 3-year moving averages. Differences in patient 
characteristics and treatment between CRC patients according to diabetes status 
were determined using chi square and t-test when applicable. The proportion of 
patients receiving treatment was reported according to the diabetes status, stage, 
and period of diagnosis. Differences in patient characteristics and treatment over 
time between CRC patients with and without diabetes were tested by the Cochrane-
Armitage trend test and linear regression (only for mean age). Multivariable logistic 
regression analysis was conducted to examine determinants of receiving 
chemotherapy, chemo-radiation, and radiotherapy in colon and rectal cancer 
patients. Variables of interest included in the multivariable analysis were: diabetes, 
age, gender, cardiovascular disease, hypertension, previous cancer, pulmonary 
disease, cerebrovascular disease, and period of diagnosis. Effect modification 
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between diabetes and confounding variables was assessed by adding interaction 
terms diabetes*confounding variable in the multivariable logistic regression 
analysis. A p-value <0.05 was considered statistically significant. 
The SAS computer package (SAS system 9.2, SAS Institute, Cary, NC) was used 
for all analyses. 
Results
Between 1995 and 2010, 17,170 cases of colon and rectal cancer were diagnosed 
in the ECR area. Of all 11,893 colon and 5,277 rectal cancer patients, 1,711 (14%) 
and 609 (12%), respectively, had diabetes at the time of CRC diagnosis. Diabetes 
prevalence among patients with CRC increased from 9% in 1995 to 17% in 2010 
(p<0.0001) (Figure 1). The age-standardisation of these prevalence rates resulted 
in a comparable graph, but since the crude prevalence of diabetes shows the true 
burden of health care best, only the crude rates were shown. CRC patients with 
diabetes were on average 5 years older compared to those without diabetes. In 
time, more patients had two or more comorbidities at the time of CRC diagnosis 
(Table 1). Furthermore, the proportion of patients with stage IV disease increased 
and with stage II disease decreased in both colon and rectal cancer patients with 
and without diabetes (Table 1). Colon cancer patients with diabetes more often 
had a tumour located in the proximal colon compared to those without diabetes 
(60% vs. 54%, p<0.0001). 
Figure 1. Trends in prevalence of diabetes at the time of colon and rectal 
cancer diagnosis (n=17,170).
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During the whole study period, almost all patients with stage I to III colon cancer 
underwent resection of their primary tumour (not shown). Chemotherapy 
administration significantly increased in stage III colon cancer patients with and 
without diabetes (from 17% in 1995-1998 to 50% in 2007-2010, 38% to 63%, 
respectively, p<0.0001). Nevertheless, the utilisation rate of chemotherapy for 
patients with diabetes remained lower compared to patients without diabetes 
(Figure 2a). Multivariable logistic regression analysis, including age, gender, 
specific comorbidities, and period of diagnosis, showed that diabetes was 
associated with less frequent administration of adjuvant chemotherapy in stage 
III colon cancer patients (OR 0.7; 95% CI 0.5-0.9; p=0.002). We observed no 
statistically significant interaction between diabetes and age, gender, and any of 
the specific comorbidities in stage III colon cancer patients who received 
chemotherapy. In metastatic colon cancer patients with and without diabetes 
administration of chemotherapy increased significantly, while the resection rate 
decreased (Figure 2b and c).   
Almost all patients with stage I to III rectal cancer underwent resection of their 
primary tumour (not shown). In rectal cancer patients with T3 and 4 tumours, the 
application of chemo-radiation increased (Figure 2d). Multivariable logistic 
regression analysis showed no significant association between diabetes and the 
rate of chemo-radiation administration (OR 0.8; 95% CI 0.6-1.1) (Table 2). However, 
there was less administration of chemo-radiation in individuals with diabetes 
compared to those without (Figure 2d). Administration of radiotherapy strongly 
increased over time: the proportion of stage II/ III rectal cancer patients with and 
without diabetes who received radiotherapy was comparable in recent years, 81% 
and 87%, respectively (Figure 2e). Multivariable regression analyses showed a 
negative effect of the presence of diabetes on the utilisation rate of radiotherapy 
in rectal cancer, although this was not significant and depended on the period of 
diagnosis (Table 2).  
The resection rate decreased over time in rectal cancer patients with metastatic 
disease, declining from 55% in 1995-1998 to 16% in 2007-2010 in patients with 
diabetes compared to a decline from 56% to 27% for those without. Furthermore, 
stage IV rectal cancer patients with diabetes less frequently received chemotherapy 
and more often received radiotherapy compared to patients without diabetes 
(Figure 2g and 2h). In the multivariable logistic regression analysis, administration 
of chemotherapy correlated with both age and cardiovascular disease, while 
administration of radiotherapy was only associated with the period of diagnosis 
in stage IV rectal cancer (Table 2). 
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Figure 2. Proportion of colon and rectal cancer patients receiving treatment 
according to the diabetes status. 
* Chi square test with p-value < 0.05, tested within subgroup ‘period of cancer diagnosis’.  
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Discussion
In this population-based study covering a period of 16 years and including more 
than 17,000 CRC patients, we observed substantial changes in the treatment of 
CRC patients according to their diabetes status. Although CRC patients with 
diabetes continue to receive chemotherapy less frequently compared to those 
without, the use of chemotherapy in patients with CRC has increased sharply over 
time.  Furthermore, the proportion of stage II/III rectal cancer patients with and 
without diabetes who received radiotherapy increased at a similar rate in recent 
years. Data from recent years show that rectal cancer patients with metastatic 
disease are more likely to receive radiotherapy when they have diabetes, while 
patients without diabetes are more likely to receive chemotherapy. 
The observed trends in the treatment of colon and rectal cancer found in this study 
are in line with previous population-based studies. However, these studies did 
not investigate the potential differences related to diabetes status9-11. Our previous 
study showed similar results6. Interestingly, after including the more recent years, 
CRC patients with diabetes still received chemotherapy less often in the present 
study. Although the findings of the previous Dutch studies showed that the 
proportion of patients receiving radiotherapy increased as well, they did not 
differentiate between patients with and without diabetes9,11,14,18. The observation 
that a similar proportion of patients with and without diabetes received 
radiotherapy was not seen in previous studies. This could be because earlier 
studies were based on less recent data.
The prevalence of diabetes in our cohort showed a similar increase to that in the 
general population, in which the prevalence of diabetes increased from 12% in 
2003 to 16% in 201019. This could be explained by the increasing age and life 
expectancy, as well as the increasing awareness and diagnosis of diabetes. The 
increase in diabetes prevalence may have led to a growing specific knowledge 
of CRC care in patients with diabetes. This is reflected by the fact that medical 
specialists are better in selecting patients who might benefit from a particular 
treatment. Furthermore, chemotherapy-induced toxicity may be better treated. 
This knowledge could shift the approach to using more aggressive treatment and 
multimodal treatment in people with diabetes, as partly confirmed by our data.
Several reasons are given in the literature to explain why cancer patients with 
comorbidity or diabetes  receive chemotherapy less frequently, including older 
age with a shorter life expectancy, decline of adjuvant treatment in the patient, 
and a higher rate of treatment-related complications. However, it should be noted 
that studies have shown conflicting results20-24. We do not know whether the lower 
utilisation rate of aggressive therapies in CRC patients with diabetes indicate that 
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the clinicians appropriately responded to the patients’ diminished life expectancy 
and/or comorbidity or whether this was inappropriate. In view of the growing 
proportion of CRC patients with diabetes and patients with other comorbidities 
that are related to changes in lifestyle factors, clinicians will more often face difficult 
decisions regarding (chemo)therapy. 
For stage III colon cancer, administration of chemotherapy is strongly advised 
because of survival benefits for patients with and without diabetes. However, such 
evidence concerning chemo-radiation is currently lacking for rectal cancer 
patients25,26.  A meta-analysis found no indications of benefit in the four trials 
where all or at least some of the rectal cancer patients had received preoperative 
RT or chemo-radiation26. 
Studies in elderly rectal cancer patients and patients with comorbidity showed a 
good response rate and tolerance to a short pre-operative course of radiotherapy 
or radiotherapy as sole treatment27,28. In recent years, especially in patients with 
comorbidity, radiotherapy is used as downstaging and not directly followed by 
surgery. This trend could partially explain the tremendous increase in radiotherapy 
and the slight increase of chemo-radiation in rectal cancer patients with diabetes. 
Based on good responses in elderly patients with comorbidity, a discussion was 
held in our region, after which awareness for the adequate administration of 
radiotherapy in patients with comorbidity like diabetes increased. The 
implementation of a new national guideline for radiotherapy in rectal cancer 
patients in 2001 was even more important for increasing the administration rate 
of radiotherapy13,18.
For metastatic colon and rectal cancer, resection rates decreased, while 
chemotherapy and radiotherapy administration increased. While resection is the 
only primary curative treatment for CRC in stages I-III CRC, the higher postoperative 
mortality rate in CRC patients with diabetes in stage IV disease may have led to 
the decline of surgery over time20,21,24,27. Patients with metastatic rectal cancer 
and diabetes received chemotherapy less often and radiotherapy more often 
compared to those without diabetes. The national rectal cancer guideline does 
advise administration of chemotherapy in patients with comorbidity, since 
chemotherapy does have a survival benefit in these patients29. Nevertheless, 
radiotherapy is not advised, while the ESMO guideline recommends that 
radiotherapy should be considered as a palliative procedure in selected cases30. 
Consequently, the current study shows that the decision of the medical specialist, 
which is based on clinical experience, plays a major role in the choice of treatment 
administration. 
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The strength of this study is its population-based nature using a quality controlled 
cancer registry system. However, detailed information on the performance status 
of the patients, doses and dose adjustments of chemotherapy, and treatment-
related complications was not available. Specific information about diabetes 
(medication, type, duration and severity) was missing, which may have influenced 
the decision of the clinician. Furthermore, the current study investigated trends 
in primary treatment in a large region in the Netherlands: therefore, the results 
could be different from other countries and only concern the primary treatment 
of a CRC patient.
In conclusion, although this study showed that the proportion of CRC patients 
with diabetes receiving radiotherapy and chemotherapy increased, patients with 
diabetes still received chemotherapy less often than those without. Adherence 
to clinical guidelines is generally considered a measure of quality of care. Deviating 
from these guidelines in the case of an elderly patient with comorbidity does not 
necessarily indicate an inferior quality of care. CRC patients with a good health 
status could benefit from the same treatment chosen for younger patients and 
extensive treatment of elderly patients with a poor health status should be avoided. 
In future studies, we will investigate the influence of more aggressive treatment 
on outcomes in CRC patients with diabetes. In addition, recent linkage of the ECR 
with pharmacy records from the PHARMO31 (Institute for Drug Outcomes Research) 
database will make it possible to investigate the effect of diabetes medication 
and metabolic control on survival rates in CRC patients.  
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Abstract
Background: Several observational studies suggest protective effects of metformin 
on mortality in patients with diabetes and cancer. Trials on metformin exposure 
in non-diabetics are developed on the basis of former studies which failed to take 
cumulative exposure into account. This population-based study aims to assess 
whether metformin use started after colorectal cancer (CRC) diagnosis is associated 
with overall mortality compared with sulfonylurea derivatives use in diabetics. 
Methods: All (n=7,794) primary CRC patients diagnosed between 1998 and 2010 
were selected from the Eindhoven Cancer Registry (ECR) and linked to drug 
dispensing data from the PHARMO Database Network. The association between 
metformin use started after CRC diagnosis and overall mortality, was analysed 
using Cox regression models with time-varying cumulative drug use. 
Results: After CRC diagnosis, 164 patients started with metformin monotherapy 
and 108 patients with sulfonylurea derivatives monotherapy. At the start of glucose 
lowering drugs, multivariate time-dependent analyses showed that metformin 
users had a statistically significant lower hazard of overall mortality compared to 
sulfonylurea derivatives users (HR 0.41; 95% CI 0.21-0.82). However, this survival 
difference was not associated with the use of the drug, since it seemed to disappear 
with increasing cumulative exposure to metformin or sulfonylurea derivatives over 
time (HRdrug*cumulative exposure 1.03; 95% CI 0.99-1.06; per month; p=0.1). 
Conclusions: Cumulative metformin exposure after CRC diagnosis is not 
associated with decreased overall mortality compared with sulfonylurea derivatives 
exposure. However, at the start of glucose lowering drugs we observed lower 
overall mortality among metformin users, suggesting that these patients have 
favourable prognostic factors. 
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Introduction
Numerous epidemiological studies have shown that colorectal cancer (CRC) occurs 
more commonly in individuals with type 2 diabetes than in the general 
population1-4. Given the increasing prevalence of both diseases5-7, even a modest 
association between these two could have a considerable effect on public health. 
In addition, in several studies cancer patients with diabetes had a significantly 
higher overall mortality risk compared with patients without diabetes8-11. 
However, this association seems to vary with glucose lowering drugs, those treated 
with metformin appear to have decreased overall mortality9,12-18. Although these 
studies adjusted for various important confounders, it is unclear whether the 
observed decreased mortality found in metformin users could be attributed to 
the use of metformin before and/or after cancer diagnosis12,14,16-18. Furthermore, 
these studies included metformin use as a dichotomous variable in the 
analyses12,14,16-18. Since the medication use of an individual with diabetes is highly 
variable over time, including cumulative exposure in the analyses is a more 
accurate method to investigate the effect of metformin on mortality19. Also, 
previous studies might have overestimated the protective effect of metformin due 
to biases such as immortal time bias20, since they classified the exposure time 
between CRC diagnosis and the first dispensing of metformin as exposed while 
this should be analysed as unexposed. 
As a consequence of methodological limitations in previous observational studies, 
the debate on whether metformin might be a candidate drug as anti-tumor agent 
is ongoing. The aim of this study was to assess whether, and to which extent, 
cumulative use of metformin started after the diagnosis of CRC is associated with 
decreased overall mortality compared with cumulative use of sulfonylurea 
derivatives. To reduce confounding by indication we compare metformin users 
with sulfonylurea derivative users, both drugs are the most frequently used first 
choice drugs at diabetes diagnosis. We hypothesise that overall mortality will 




Data were obtained from the Eindhoven Cancer Registry (ECR) and linked on a 
patient level to the PHARMO Database Network covering a demographic region 
in the South-Eastern part of the Netherlands of approximately one million 
inhabitants. The construct and validity of the ECR-PHARMO cohort have been 
described elsewhere21. 
The ECR, maintained by the Netherlands Comprehensive Cancer Organisation 
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(IKNL), records data on all patients newly diagnosed with cancer in the South-
eastern part of the Netherlands, an area with 2.4 million inhabitants. The registry 
is notified by ten community hospitals, six pathology and two radiotherapy 
departments. Trained registration clerks actively collect data on diagnosis, patient 
characteristics, staging, and initial treatment from hospital medical records. 
The PHARMO Database Network is a large, patient-centric data network including 
linked observational databases designed for safety and outcomes research of 
drugs. For this study the community pharmacy (out-patient) database was used, 
which includes data on dispensed drug, dispensing date, prescribed dose 
regimens, and duration of use. All drugs are coded according to the Anatomical 
Therapeutic Chemical (ATC) classification22. Both the ECR and the PHARMO 
Database Network are recognised as high quality sources for epidemiological 
research that collect information in overlapping regions in the Netherlands for a 
period of at least 10 years21. 
Study population
The source population included all CRC patients registered in the ECR-PHARMO 
cohort between January 1, 1998 and December 31, 2010. Patients with unknown 
tumour site within the colorectum (C 18.8-18.9) or unknown TNM stage were 
excluded. 
From this source population patients using any type of glucose lowering drug 
(ATC code: A10) after CRC diagnosis were selected. To ensure a study cohort of 
incident glucose lowering drug users, patients needed to have a six month period 
without dispensing of any diabetes drug before CRC diagnosis. Patients who 
started using metformin (ATC-code : A10BA02) or sulfonylurea derivatives 
(ATC-code : A10BB) were selected. Sulfonylurea derivatives users are the most 
straightforward comparators of metformin users. CRC patients who used metformin 
or sulfonylurea derivatives at the time of the first drug dispensing in combination 
with another glucose lowering drug were excluded (e.g. thiazolidinediones or 
insulin). 
Exposure and outcome
The cumulative days of exposure for metformin and sulfonylurea derivatives at 
any point in time during follow-up were calculated for each patient in days since 
the start of the respective glucose lowering drug. This cumulative exposure was 
determined from this time point until death, loss to follow-up, start of another 
drug, or end of study period at 31 October 2011, whichever occurred first. Our 
outcome measure was overall mortality, which was obtained from the municipal 
personal records database.
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Covariates
Age at first glucose lowering drug dispensing, sex, time between CRC diagnosis 
and first drug dispensing, calendar year of first dispensing, stage of cancer, type 
of CRC, administration of surgery, radiotherapy and/or chemotherapy and 
co-medication (lipid modifying agents (ATC-code : C10) and platelet aggregation 
inhibitors (ATC-code : B01AC)22) were considered potential confounders. These 
covariates, determined at cohort entry, were included in the multivariate analyses 
as time-fixed variables. The use of co-medication was defined as use somewhere 
in the first six months after the first dispensing of glucose lowering drugs.
Statistical analysis 
Differences in patient characteristics between metformin and sulfonylurea 
derivatives users were analysed using chi square and the independent samples 
t-test. To illustrate the prognostic effect of baseline differences between the two 
groups, the crude overall survival of CRC patients starting on metformin or 
sulfonylurea derivatives was illustrated with a Kaplan-Meier curve. Multivariable 
Cox proportional hazards models were analysed, with duration of cumulative drug 
use as time-varying determinant, as described earlier19. This model included a 
dichotomous variable of the drug (metformin vs. sulfonylurea derivatives) and a 
continuous time-dependent variable on cumulative exposure per month to either 
metformin or sulfonylurea derivatives. To assess whether the baseline difference, 
which was assessed with the dichotomous variable, changed with cumulative drug 
exposure, an interaction term combining the two was included. This interaction 
term is the variable we are interested in, since it reflects the effect of the drug 
metformin (over time), while this variable is fully adjusted for differences at baseline 
and as a result not influenced by potential confounding by indication. The change 
with cumulative drug exposure was evaluated and illustrated by calculating hazard 
ratios at baseline, and after 6, 12, 18, 24, 30 and 36 months of cumulative exposure 
to the drugs. 
Proportionality of the time-dependent Cox model was assessed by including an 
interaction term with the log of survival, the dichotomous variable of the drug and 
the continuous time-dependent variable time. A p-value <0.05 was considered 
statistically significant. Analyses were performed using SAS software (version 9.2, 
SAS institute, Cary, US). 
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Subgroup- and sensitivity analyses
Colon and rectal cancer patients as well as patients receiving chemotherapy and/
or radiotherapy were analysed in subgroup-analyses. In another subgroup-analysis 
CRC patients with stage IV disease were excluded, since these patients have a 
worse prognosis and could have influenced the results strongly. The effect of dose 
of metformin and sulfonylurea derivatives exposure was assessed in additional 
stratified analyses, in which patients starting on a high dose of metformin 
(DDD>0.25) and sulfonylurea derivatives (DDD>0.67) were compared and those 
starting on a low dose of metformin (DDD≤0.25) and sulfonylurea derivatives 
(DDD≤0.67) were compared. 
To evaluate the robustness of our findings, an ‘intention to treat’ analysis was 
performed in which patients who switched or received an additional drug after 
the drug of the first dispensing were not censored. In another sensitivity analysis 
CRC patients who only had two or fewer drug dispensings were excluded, to 
eliminate the effect of transient diabetes cases. The Medication Possession Ratio 
(MPR) was used as indicator for medication adherence during follow-up and was 
calculated for each patient by dividing the cumulative days of drug exposure by 
the total follow-up23. A result of ≥ 80% was regarded as adherent to the specific 
drug. A sub-analysis was performed in which patients not adherent to diabetes 
treatment (MPR < 80%) were excluded.
Results
Within the ECR-PHARMO cohort, out of 7,794 CRC patients diagnosed between 
1998 and 2010, 337 patients who started using glucose lowering drugs after CRC 
diagnosis were selected (Figure 1). Of this cohort 164 patients started with 
metformin monotherapy and 108 patients started with sulfonylurea derivatives 
monotherapy after CRC diagnosis. Other CRC patients with diabetes, excluded 
in this study, started with monotherapy insulin (n=43), combination treatment with 
metformin and sulfonylurea derivatives (n=13), or another combination treatment 
(n=9). Among CRC patients starting on metformin or sulfonylurea derivatives the 
age and sex ratio were approximately similar, while those who used metformin 
started in more recent years (p<0.0001) (Table 1). In addition, metformin users 
were more often prescribed lipid modifying agents compared to sulfonylurea 
derivatives (55% vs. 31%; p<0.0001). The duration of follow-up and the duration 
of drug exposure was not significantly different between the two groups, although 
metformin users were more often adherent to drug treatment compared to 
sulfonylurea derivatives users (80% vs. 65%; p=0.006). Regarding characteristics 
of CRC, the time between the diagnosis of CRC and the first dispensing of glucose 
lowering drugs was significantly longer for patients using metformin compared 
to those using sulfonylurea derivatives (2.5 years vs. 1.1 years; p<0.0001). 
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Figure 1. Flowchart of patients selected for analysis.
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Table 1. Characteristics of patients with colorectal cancer (n=272).
Metformin Sulfonylurea
derivatives
n (%) n (%) p-value
Characteristics at cohort entry
Age at first dispensing (years; mean, SD) 71 (±9.4) 72 (±9.9) 0.6
Sex
   Male 93 (57) 61 (56)
   Female 71 (43) 47 (44) 1.0
Period of first dispensing (years)
   1998-2001 3 (2) 18 (17)
   2002-2005 29 (18) 47 (43)
   2006-2008 68 (41) 27 (25)
   2009-2011 64 (39) 16 (15) <0.0001
Other medicationa
   Lipid modifying agents (ATC-code : C10) 90 (55) 33 (31) <0.0001
   Platelet aggregation inhibitors (ATC-code : B01AC) 52 (32) 29 (27) 0.4
Follow-up
   Duration of follow-up (years; median, IQR ) 1.2 (0.3-2.7) 1.2 (0.5-3.1) 0.2
   Duration of drug exposure (years; median, IQR) 0.9 (0.2-2.2) 0.7 (0.1-2.3) 0.3
   Patients adherent to medication (> 80% MPR)b 131 (80) 70 (65) 0.006
   End of follow-up (%)
      Dead 39 (23) 48 (44)
      Censoredc 56 (34) 39 (36)
      Loss to follow-up 9 (6) 1 (1)
      End of study (31-10-2011) 60 (37) 20 (19) <0.0001
Characteristics at CRC diagnosis
Time since CRC diagnosis (years; median, IQR) 2.5 (1.1-5.0) 1.1 (0.4-2.8) <0.0001
Type of colorectal cancer
   Proximal colon 40 (24) 39 (36)
   Distal colon 58 (36) 38 (35)
   Rectum 66 (40) 31 (29) 0.06
Stage
   I 44 (27) 25 (23)
   II 60 (37) 39 (36)
   III 43 (26) 24 (22)
   IV 17 (10) 20 (19) 0.3
Therapy
   Surgery 157 (96) 105 (97) 0.5
   Radiotherapy 45 (27) 20 (19) 0.09
   Chemotherapy 39 (24) 32 (30) 0.3
a The use of lipid modifying agents or platelet aggregation inhibitors was defined as the use of this co-medication 
somewhere in the first 6 months after cohort entry; b MPR: Medication Possession Ratio, calculated for each patient by 
dividing the cumulative days of drug exposure by the total follow-up. A MPR of 80% or more was regarded as adherent 
to the specific diabetes drug; c Patients were censored at time of start of another diabetes drug than the drug of the 
first dispensing.
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Overall mortality
CRC patients who started with metformin after CRC diagnosis had lower overall 
mortality at the moment of start of glucose lowering drugs compared to those 
who started on sulfonylurea derivatives (log-rank test: p=0.02) (Figure 2). Since 
this method does not accurately estimate the effect of exposure to metformin and 
is subject to survivorship selection, time dependent analyses were performed 
including cumulative exposure to both drugs (Figure 3 and Table 2). The crude 
time-dependent analyses revealed a difference at the start of glucose lowering 
drugs (i.e. cumulative exposure = 0) of overall mortality in favour of metformin 
compared to sulfonylurea derivatives (HRdrug 0.46; 95% CI 0.25-0.82) (Figure 3a). 
This favourable effect in metformin users seemed to disappear with cumulative 
drug exposure (HRdrug*cumulative exposure 1.02; 95% CI 0.99-1.05; per month). In the 
full model, adjusting for time between CRC diagnosis and start of glucose lowering 
drugs as well as other patient-, tumour-, and co-medication-related variables, the 
difference in overall mortality between users of metformin and sulfonylurea 
derivatives at baseline remained significant (HRdrug 0.41; 95% CI 0.21-0.82) (Figure 
3b). The baseline hazard ratio did change with cumulative drug exposure in favour 
of sulfonylurea derivates, although this was not significant (HRdrug*cumulative exposure 
1.03; 95% CI 0.99-1.06; per month). After 18 months of drug exposure, CRC 
Figure 2. Kaplan-Meier curve of CRC patients exposed to metformin or 
sulfonylurea derivatives (n=272) after CRC diagnosis.


















Metformin  164 94            60 32     21   10
Sulfonylurea
derivatives  108  60    40 29     20   11
Log-rank test: p=0.02
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patients started on metformin did not have a significantly lower overall mortality 
anymore (HRdrug at 18 months 0.65; 95% CI 0.37-1.14) (Figure 3b). In the full model 
proportionality of the time-dependent Cox model was assessed by including an 
interaction with time and it was not significant (p=0.9). 
Subgroup analyses among colon cancer patients (n=177) showed no difference 
in hazard ratio between metformin and sulfonylurea derivatives users at the start 
of glucose lowering drugs, while in rectal cancer patients (n=97) it did show a 
Figure 3. Hazard Ratio’s of overall mortality of CRC patients starting on 
metformin (n=164) compared with starting on sulfonylurea 
derivatives (n=108) according to cumulative drug exposure in 
months.
a) Crude model; b) Full model, adjusted for age, time between 
CRC diagnosis and start of glucose lowering drugs, calendar year, 
stage, surgery, radiotherapy, chemotherapy, type of  tumour, and 
statin and aspirin use within the first 6 months after starting with 
metformin or sulfonylurea derivatives; c) Subgroup analysis among 
colon cancer patients (n=175), adjusted for similar variables as the 
full model; d) Subgroup analysis among rectal cancer patients 
(n=97), adjusted for similar variables as the full model.
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difference in mortality (HRdrug 0.29; 95% CI 0.10-0.82) (Figure 3d). However, in 
this group of patients the lower mortality in metformin users disappeared with 
increased cumulative exposure to metformin or sulfonylurea derivatives 
(HRdrug*cumulative exposure 1.06; 95% CI 1.01-1.12; per month) (Figure 3d). Similar results 
were observed for CRC patients with stage I-III disease (n=235) or those who 
received chemotherapy (n=71) or radiotherapy (n=65) (Table 2). 
When the effect of dose was evaluated, the favourable mortality for metformin 
users compared to that of sulfonylurea derivatives users at the start of glucose 
lowering drugs was absent in patients with a low first dose (HRdrug 0.96; 95% CI 
0.59-1.59) and statistically significant in patients with a high first dose (HRdrug 0.34; 
95% CI 0.14-0.81). However, in those patients using a high first dose the lower 
mortality for metformin users disappeared with increasing cumulative exposure 
(HRdrug*cumulative exposure 1.09; 95% CI 1.01-1.16; per month) (Table 2). 
The ‘intention to treat’ analysis showed comparable results as the full model with 
at baseline a difference in overall mortality in favour of metformin (HRdrug 0.44; 
95% CI 0.24-0.82), that did not significantly change with duration of exposure 
(HRdrug*cumulative exposure 1.03; 95% CI 1.00-1.05; per month). Sensitivity analyses 
excluding CRC patients who only had two or fewer drug dispensings (n=55), or 
sensitivity analysis with patients adherent to diabetes treatment (MPR ≥80%) we 
observed comparable HRs with that of the full model as well (Table 2). 
Discussion 
This study, using a time-dependent Cox regression model, showed that cumulative 
exposure to metformin after CRC diagnosis was not associated with decreased 
overall mortality compared with cumulative exposure to sulfonylurea derivatives. 
However, at the start of glucose lowering drugs CRC patients using metformin 
did have a 59% lower hazard for overall mortality, compared to those starting with 
sulfonylurea derivatives. In contrast to many recently reported studies12,14,16-18 that 
have suggested a beneficial effect of metformin on cancer prognosis, our findings 
suggest that this survival benefit was not induced by the drug, but was likely 
confounded by favourable prognostic factors of CRC patients using metformin, 
for which we could not adjust. 
The association between metformin and mortality is extremely complex, since 
many underlying factors, such as metabolic and lifestyle factors, could be 
associated with both the exposure to metformin as well as with the outcome. 
Previous studies regarding metformin and mortality after CRC included 
dichotomized drug exposure in the analyses as using/non-using a drug12,14,16-18, 
whereas the effect of exposure will depend on dose, duration of use, timing in 
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relationship to the event, concurrent medication, and adherence to therapy19. 
The evidence reported in these previous studies formed the driving force for the 
conduct of randomised metformin trials24,25. In contrast to other studies we avoided 
time-related biases by analysing exposure to metformin as a time dependent 
variable20. As it is likely that our analyses showed more accurate results than 
previous studies in CRC patients12,14,16-18, our findings should trigger more 
observational studies that also include both cumulative exposure as well as 
dichotomous variables26.
The decision of a clinician to prescribe a certain type of glucose lowering drugs 
is based on the characteristics of a patient, such as the Body Mass Index (BMI), 
the HbA1c levels and the presence of contraindications for medication27. In an 
observational study like ours it is therefore likely that the strong survival benefit 
in metformin users compared to sulfonylurea derivatives users, which was 
illustrated by the baseline hazard and not by the cumulative exposure hazard, is 
influenced by confounding by indication9. In this setting those patients selected 
for treatment with metformin may possess favourable characteristics that decrease 
overall mortality compared with sulfonylurea derivatives. This hypothesis is 
supported by our study results. This better prognosis of metformin users at 
baseline could also be influenced by a substantial change in the national guidelines 
on treating individuals with diabetes with different types of glucose lowering drugs. 
Before 1999 sulfonylurea derivatives were advised to all patients as first line 
treatment, while after 1999 they were only advised to patients with a BMI of <27. 
Metformin was advised as first line treatment for patients with a BMI ≥27 after 
1999, and for all patients since 200628,29. Since mortality rates decreased slightly 
for CRC patients between 1998 and 20106, this could have overestimated the 
protective baseline effect of metformin in our study. Besides, the time between 
CRC diagnosis and the first dispensing of glucose lowering drugs was longer for 
metformin users compared with sulfonylurea derivatives users, which resulted in 
survivorship selection in favour of metformin users for which was attempted to 
adjust in our analyses. Due to small numbers in this study, matching on the time 
between cancer diagnosis and the start of glucose lowering drugs was not feasible. 
Besides, metformin, which is administered to those patients with a high BMI, is 
associated with weight loss and as a result may translate into improved 
outcomes30,31. While analyses in this study were adjusted for the year of first 
dispensing, valuable information about BMI and HbA1c was unavailable, therefore 
the potential effect of metformin on weight loss and levels of HbA1c, and thereby 
indirectly on mortality, was not taken into account. Although co-medication, like 
lipid modifying agents or platelet aggregation inhibitors, could play a major role 
in the association between metformin and mortality32,33, an important confounding 
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effect of these drugs on overall mortality when comparing metformin with 
sulfonylurea derivatives was not shown.
In subgroup analyses, unfortunately with small numbers of patients, the hazard 
ratio associated with longer duration of exposure was different for the two types 
of cancer. The effect of metformin did not change with cumulative duration in 
colon cancer patients, whereas in rectal cancer patients this protective effect 
diminished strongly. In general, metformin users have higher BMI than sulfonylurea 
derivatives users users, which is related to the Dutch guidelines28,29. A recent study 
showed that higher BMI before the diagnosis of cancer (mean: 7 years before 
cancer diagnosis) in rectal cancer patients and not in colon cancer patients was 
associated with elevated CRC-specific mortality34. This finding may relate to an 
increased risk of local recurrence in obese patients with rectal cancer, resulting 
in higher mortality over time for the metformin users compared with the 
sulfonylurea derivatives users. Although we had important tumour information at 
the time of cancer diagnosis and regarding this did not found important differences 
between the studied patient groups, in our study we were not able to investigate 
this properly, since information on the presence of recurrence and the cause of 
death was missing. 
Our study revealed a difference in mortality for metformin users compared to 
sulfonylurea derivatives users using a high dose of glucose lowering drugs. Since 
the hazard for drug exposure duration was not in favour of metformin, this does 
not support the hypothesis of a specific drug effect of metformin on mortality in 
CRC patients. Though, those patients using a high dose are likely to be different 
from those using a low dose. First, metformin users with a higher BMI may need 
a high dose of metformin, besides having more reserves at cancer treatment due 
to their higher BMI. Second, sulfonylurea derivatives users with a high dose may 
have an even poorer prognosis as they are likely to have worse glycaemic control 
and more vascular complications. In our study we were able to include the dose 
of metformin and sulfonylurea derivatives in our database, though these doses 
for glucose-lowering are relatively low compared with the doses for anti-cancer 
activity of metformin in preclinical studies, which seemed to be much higher35. 
In conclusion, findings of this observational study suggest that cumulative exposure 
to metformin is not associated with decreased overall mortality compared to 
sulfonylurea derivatives in CRC patients with diabetes. However, patients who 
started with metformin after the diagnosis of CRC already had a decreased overall 
mortality hazard at start of glucose lowering drugs compared to those started with 
sulfonylurea derivatives, suggesting that metformin users have favourable 
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prognostic factors, for which this study could not adjust.
Even though our study design and type of analyses are most accurate, the number 
of patients included was relatively small, therefore additional evidence in a greater 
subset of patients is needed. Nevertheless, this study is in contrast with previous 
reports on the apparent beneficial effect of metformin on survival and provokes 
initiation of studies with comparable analyses, including both cumulative exposure 
as well as dichotomous variables, to better adjust for baseline differences.
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Letter to the editor: 
Association between metformin use and mortality in prostate 
cancer patients: Explained by confounding by indication?
M.M.J. Zanders, 
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Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, et al. Metformin 
use and all-cause and prostate cancer-specific mortality among men with diabetes. 
J Clin Oncol. 2013 Sep 1;31(25):3069-75.
Abstract
Purpose: To evaluate the association between cumulative duration of metformin 
use after prostate cancer (PC) diagnosis and all-cause and PC-specific mortality 
among patients with diabetes.
Patients and methods: We used a population-based retrospective cohort design. 
Data were obtained from several Ontario health care administrative databases. 
Within a cohort of men older than age 66 years with incident diabetes who 
subsequently developed PC, we examined the effect of duration of antidiabetic 
medication exposure after PC diagnosis on all-cause and PC-specific mortality. 
Crude and adjusted hazard ratios (HRs) were calculated by using a time-varying 
Cox proportional hazard model to estimate effects.
Results: The cohort consisted of 3,837 patients. Median age at diagnosis of PC 
was 75 years (interquartile range [IQR], 72 to 79 years). During a median follow-up 
of 4.64 years (IQR, 2.7 to 7.1 years), 1,343 (35%) died, and 291 patients (7.6%) 
died as a result of PC. Cumulative duration of metformin treatment after PC 
diagnosis was associated with a significant decreased risk of PC-specific and 
all-cause mortality in a dose-dependent fashion. Adjusted HR for PC-specific 
mortality was 0.76 (95% CI, 0.64 to 0.89) for each additional 6 months of metformin 
use. The association with all-cause mortality was also significant but declined over 
time from an HR of 0.76 in the first 6 months to 0.93 between 24 and 30 months. 
There was no relationship between cumulative use of other antidiabetic drugs 
and either outcome.
Conclusion: Increased cumulative duration of metformin exposure after PC 
diagnosis was associated with decreases in both all-cause and PC-specific mortality 
among diabetic men.
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To the editor: 
Margel et al.1 recently reported on a population-based retrospective cohort study 
that used a unique large database to investigate patients with prostate cancer 
diagnosed with incident diabetes. Increased cumulative duration of metformin 
exposure after prostate cancer diagnosis was associated with decreases in both 
all-cause and prostate cancer-specific mortality among men with diabetes. The 
study showed that prostate cancer-specific mortality even decreased by 24% for 
each additional 6 months of metformin use after the diagnosis of prostate cancer. 
Although the approach used in this study did circumvent numerous potential 
limitations and biases2, on the basis of the authors’ conclusions and study design, 
we have a few comments and requests for clarification. 
With regard to their statistical analyses, the effects of cumulative duration of 
exposure to metformin on mortality were assessed by using a Cox proportional 
hazards model in which drug exposures after prostate cancer diagnosis were 
modeled as time-dependent covariates. The comparison was not exclusively 
between users who had different durations of exposure, but also between users 
and nonusers of the drug. This means that in the time-dependent model, patients 
not using metformin were included in the analysis as 0 for cumulative use of 
metformin. Modeling the line for this specific hazard ratio (HR) of cumulative 
metformin use could be expected to be greatly influenced by events in the 
nonusers, given that patients using and not using metformin might differ in their 
previous susceptibility to dying as a result of cancer. As a consequence, these 
results might be affected by confounding by indication, which could not be 
avoided by the inclusion of cumulative drug exposure exclusively, as supposed 
in this analysis. 
It can be shown algebraically that with the inclusion of an ever-never term for 
metformin use in the model, the HR of the cumulative effect term does not depend 
on the events in the unexposed group and therefore avoids confounding by 
indication3 (Figure 1). Thus, we believe it would be essential to include ever-never 
terms for drug exposure to avoid confounding by indication. 
The authors acknowledge that for every additional 6 months of metformin 
treatment in patients with prostate cancer, there is a significant decrease in 
all-cause mortality that declines over time. However, the results relating to the 
postdiagnosis cumulative use of metformin should be interpreted with caution. 
In the first 6 months after prostate cancer diagnosis an HR of 0.76 for all-cause 
mortality was shown. Is it biologically plausible that 6 months of metformin use 
reduces mortality by 24%? In a randomized controlled trial, we would most likely 
expect an HR of 1 in the first 6 months. To our knowledge, the HR in this study is 
comparing patients with prostate cancer who used metformin for 6 months with 
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patients not using metformin at all. As previously mentioned, the 24% decreased 
hazard of mortality in users compared with nonusers of metformin is the illustration 
of differences in patients and/or tumor characteristics at baseline. If there is a true 
dose-response relationship between metformin and mortality, then one would 
have expected to observe a decline in HR over time (Table 4 in the article by Margel 
et al.1). Instead, for every 6 months after the baseline HR, the mortality in users of 
metformin is increasing. In our opinion, this should be interpreted as no effect of 
the drug, but solely confounding by indication. 
Despite the fact that the cumulative exposure to metformin was analyzed correctly 
in the study by Margel et al. 1, their results should be interpreted with caution in 
light of the initiation of large-scale, long-term randomized trials of metformin in 
patients with prostate cancer, given that confounding by indication might have 
occurred. 
Figure 1. Schematic figure of the model for cumulative exposure to 
metformin used by Margel et al.1 and the model for cumulative 
exposure that includes a user/nonuser term for metformin, 
resulting in adjustment for baseline differences between patients 
with prostate cancer and diabetes who were prescribed metformin 
compared with those not prescribed metformin.
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Abstract
Objective: Use of metformin, statins and aspirin, all individually have been 
associated with decreased mortality in cancer patients, though, without adjusting 
for one another. Independent effects of these drugs on overall mortality after 
colorectal cancer (CRC) diagnosis within glucose lowering drugs (GLDs) users 
were assessed. 
Methods: Patients with primary CRC (1998-2011) were selected from the 
Eindhoven Cancer Registry (ECR) and linked to drug dispensing data from the 
PHARMO Database Network. GLDs users before cancer diagnosis were included. 
The Cox regression model, with CRC diagnosis as baseline, included 
time-dependent variables of cumulative exposure to metformin, statins and aspirin 
after cancer diagnosis and time-dependent ever-never terms for drug exposure.
Results: In our study, 1,043 patients used GLDs before CRC diagnosis, of whom 
666 (64%) used metformin, 639 (61%) used statins and 490 (47%) used aspirin 
after CRC diagnosis. Multivariable analyses revealed that longer cumulative 
exposure to metformin was not associated with overall mortality (HRCumulative exposure 
per six months 1.02; 95% CI 0.97-1.07), while the favourable effect of statins increased 
with cumulative drug exposure (HRCumulative exposure per six months 0.93; 95% CI 0.89-0.98). 
No association between aspirin use and overall mortality was seen (HRCumulative 
exposure per six months 0.98; 95% CI 0.93-1.03).
Conclusions: This study found no independent association between cumulative 
exposure to metformin, aspirin and overall mortality, while cumulative exposure 
to statins after CRC diagnosis was associated with lower overall mortality. Our 
findings support a drug effect of statins, independent of metformin and aspirin, 
in CRC patients using GLDs. 
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Introduction
While individuals with diabetes appear to have a higher overall mortality after 
CRC, those treated with metformin, a biguanide widely prescribed as first-line 
glucose lowering drug (GLD), appear to have a decreased overall mortality 
compared with other diabetes patients1-7. In addition, other drugs, such as statins 
(HMG-CoA reductase inhibitors) and aspirin (acetylsalicylic acid) have also been 
associated with decreased overall mortality in CRC patients8-14. These drugs are 
frequently prescribed to individuals with diabetes, i.e. around 50% of them use 
statins and 40% use aspirin according to the current international literature15-17. 
As many diabetes patients use a combination of these three types of drugs, it is 
justified to wonder if, the suggested association between metformin use and 
overall mortality among cancer patients is explained by the concomitant use of 
aspirin or statins, and vice versa18. Therefore, the potential individual favourable 
effect of these drugs should be studied taking into account the effects of the other 
drugs. A few researchers have followed this approach, adjusting for the effects of 
other drugs, but always on the basis of dichotomized variables1,3-6 and never as 
time-dependent cumulative exposure terms19. Those studies reported incredibly 
low hazard ratios for the individual effects of the drugs among  patients with cancer, 
suggesting strong protective effects. However, an important limitation in these 
studies was the dichotomisation of use (ever vs. never use) of metformin1-6, 
statins8-10, or aspirin11-14 in the analyses. Despite the fact that this dichotomous 
variable will reveal differences in overall mortality between the groups of patients, 
it will not reveal the effect of the drug over time, since (un)measured differences 
in prognostic factors will overestimate a potential drug effect20. This type of bias 
in pharmaco-epidemiology, known as allocation bias, has received increasing 
attention in the field of diabetes and cancer and experts are debating whether 
the inclusion of the time dependent cumulative exposure is the best option to 
prevent this bias19,21. 
Thus, the primary objective of this study was to assess the independent effect of 
metformin, statins and aspirin on overall mortality among CRC patients with 
diabetes. We hypothesised that overall mortality will decrease with increasing 
cumulative exposure to metformin, statins and aspirin independently of the effects 
of the other studied drugs. 
Methods 
Data sources
Data were obtained from the Eindhoven Cancer Registry (ECR) linked on a patient 
level to the PHARMO Database Network, covering a demographic region in the 
Southern part of the Netherlands of approximately one million inhabitants. The 
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construct and validity of the ECR-PHARMO cohort have been described 
elsewhere22. The ECR, maintained by the Netherlands Comprehensive Cancer 
Organisation (IKNL), records data on all patients newly diagnosed with cancer in 
the Southern part of the Netherlands, an area with 2.4 million inhabitants. The 
registry is notified by six pathology departments, 10 community hospitals, and 
two radiotherapy departments. Trained registration clerks actively collect data on 
patient characteristics, cancer diagnosis, staging, and initial treatment from hospital 
medical records. The PHARMO Database Network is a large, patient-centric data 
network including multiple linked observational databases designed for safety 
and outcomes research of drugs. For this study the community pharmacy 
(out-patient) database was used, which includes data on the dispensed drug, 
dispensing date, amount and regiment dispensed, and thus the duration of use. 
All drugs are coded according to the Anatomical Therapeutic Chemical (ATC) 
classification23. Both the ECR and the PHARMO Database Network are recognised 
as high quality sources for epidemiological research that collect information in 
overlapping regions in the Netherlands for a period of at least 10 years22. 
Study population 
The source population included all CRC patients registered in the ECR-PHARMO 
cohort between January 1, 1998 and December 31, 2011 (n=8,725) (Figure 1). 
From this source population patients using any type of GLD (ATC code: A10) 
before CRC diagnosis were selected (n=1,043). In this study GLD use was used 
as a proxy for diabetes onset. In individuals who used GLD before CRC diagnosis, 
the use of metformin (ATC-code: A10BA02), statins (ATC-code: C10AA, C10BA 
and C10BX) and low dose aspirin (ATC-code: B01AC06, B01AC08 and B01AC30; 
≤100 mg daily) was evaluated. Since we expected that the effect of the drugs on 
mortality was not different for incident (i.e. started with GLD after entrance in the 
ECR-PHARMO cohort, thus known diabetes duration; n=607) compared to 
prevalent (i.e. started with GLD at any time before entrance in the ECR-PHARMO 
cohort, thus unknown diabetes duration; n=436) users, we decided to include 
both types of users and performed a sensitivity analyses for incident users.
Exposure and outcome
For each CRC patient, the number of cumulative days of metformin, statins and 
aspirin exposure before (for incident drug users) and after CRC diagnosis was 
calculated. The cumulative days of drug exposure after CRC diagnosis were 
determined from CRC diagnosis until death of the patient, leaving the 
ECR-PHARMO area, or end of the study period at 31 December 2011, whichever 
occurred first. The Medication Possession Ratio (MPR) was used as indicator for 
medication adherence (MPR ≥80%) during follow-up and was calculated by 
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was overall mortality, which was obtained from the municipal personal records 
database.
Statistical analyses
The association of the effect of metformin, statins and aspirin on overall mortality 
after CRC diagnosis was analysed using a time-dependent multivariable Cox 
proportional hazards model, which included all studied drugs. Time since the 
diagnosis of CRC was used as the underlying timescale in the time-dependent 
Cox proportional hazard model, thus baseline refers to cancer diagnosis. The use 
of metformin, aspirin and statins before CRC diagnosis was included as ever-never 
(1 vs. 0) terms in the model, while the cumulative days of drug use after CRC 
diagnosis were included as time-dependent determinants. Since this study 
included users with different durations of exposure, as well as nonusers of the 
Figure 1. Flowchart of patients selected for analysis.
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drugs, the inclusion of cumulative drug exposure alone might not be sufficient. 
The events for overall mortality for non-users will all be clustered at the cumulative 
exposure of zero months having a great impact on modelling the overall hazard 
ratio for cumulative exposure. It is hypothesised that this will introduce allocation 
bias, which we tried to avoid by including time-dependent ever-never terms for 
drug use after CRC diagnosis20. The change in overall mortality risk with cumulative 
drug exposure to either metformin, statins or aspirin was evaluated and illustrated 
by calculating hazard ratios at baseline, and after 6, 12, 18, 24, 30 and 36 months 
of cumulative exposure to the drugs.
Since our cohort includes patients with diabetes, we need to account for the use 
of other GLDs before and after cancer diagnosis: sulfonylurea derivatives 
(ATC-code: A10BB), insulin (ATC-code: A10A) and other GLDs. The cumulative 
exposures and ever-never terms of these drugs were included in the multivariable 
model using a similar approach as for the other drugs. Age at CRC diagnosis, sex, 
calendar year of CRC diagnosis (year of baseline), stage of cancer, CRC subsite 
(proximal colon, distal colon or rectal), administration of surgery, radiotherapy 
and/or chemotherapy were considered potential confounders. These covariates, 
determined at baseline, were included in the multivariable analyses as time-fixed 
variables. The presence of effect modification between metformin, statin and 
aspirin use was evaluated by including interaction terms in our full model 
(cumulative exposure of studied drug * ever-never term of potential effect 
modifying drug). A two-sided p-value <0.05 was considered statistically significant. 
Analyses were performed using SAS software (version 9.3, SAS institute, Cary, 
US).
Subgroup- and sensitivity analyses 
Cancer subsite (colon or rectal) as well as cancer treatment were evaluated as 
effect modifiers of the drugs under study. To determine whether our results were 
biased by the inclusion of prevalent users (i.e. users with unknown duration) the 
prevalent users of either metformin, statins or aspirin were excluded in an 
additional analysis. To evaluate the effect of metformin, statins and aspirin on long 
term survival, patients who died in the six months after CRC diagnosis and those 
without complete follow-up for these six months were excluded in another 
sensitivity analysis. Since many of the patients in this study used diuretics, beta 
blocking agents and renin-angiotensin system agents, a further sensitivity analysis 
was included in which we adjusted for the use of these drugs by including 
cumulative exposures and ever-never terms. 
CRC patients being less adherent might be different from those being more 
adherent to drugs, to adjust for this, variables for drug adherence (0 = no drug 
use; 1 = MPR ≥80%; 2 = MPR <80%) for all studied drugs were added to the full 
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model in another sensitivity analysis. 
Since especially the effect of statin use on survival might be confounded by sick 
stopper (lower adherence among groups with the highest risk of poor outcomes) 
or healthy user bias (selection of statin users who are more health-conscious)25, 
which as a result might have overestimated the effect of statins, we assessed the 
accuracy of our analyses by performing another sensitivity analysis. The cumulative 
exposure to statins was adjusted when patients were exposed to statins within the 
six months prior to their death. The total period of these six months prior to their 
death, either exposed or unexposed, was then included in this sensitivity model 
as time exposed to statins. 
Results  
The study population consisted of 1,043 patients who used GLDs before their 
diagnosis of CRC (Table 1), of whom 666 (64%) used metformin, 639 (61%) used 
statins and 490 (47%) used aspirin after CRC diagnosis (Figure 1 and Table 1). 
Most patients had an unknown duration of GLD use since they were prevalent 
users when entering the database (42%), whereas 32% of the patients in the total 
cohort had a duration of GLD use which was ≥3 years at the time of CRC diagnosis. 
During a mean follow-up of 3.4 years (SD ± 3.0), 494 patients (47%) died and 11 
(1%) were loss to follow-up before the end of the study, fewer deaths occurred in 
the groups which used one of the studied drugs (Metformin p<0.0001; Statins 
p<0.0001; Aspirin p=0.09; Appendix 1).
After the diagnosis of CRC, the median duration of metformin use was 1.6 years 
(Interquartile range (IQR) 0.5-3.3), for statins this was 2.0 years (IQR 0.6-3.9) and 
for aspirin this was 1.5 years (IQR 0.2-3.4), with a proportion of adherent users 
(MPR ≥ 80%) for all drugs of around 50%. Of the total study cohort, 25% of the 
patients used all drugs under study, while 15% of the patients used none of them 
after CRC diagnosis (Appendix 1). Many CRC patients used other drugs after the 
diagnosis of cancer (mean follow-up 3.4 ± 3.0 years), 58% used sulfonylurea 
derivatives, 47% diuretics, 45% beta blocking agents and 53% renin-angiotensin 
system agents. Metformin, statin and aspirin users, used significantly more beta 
blocking agents and renin-angiotensin system agents compared to those not 
using the studied drugs (Appendix 1). Although the characteristics of CRC were 
comparable for the different drug groups according to Table 1, the proportion 
of statin users with rectal cancer was higher (33% versus 24%; p=0.005), while the 
proportion of statin users with stage IV disease was lower (16% vs 22%; p<0.0001) 
compared to those not using statin during follow-up (Appendix 1).   
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Table 1. Baseline characteristics of the study population according to 








n (%) n (%) n (%) n (%)
Patients 1043 (100) 666 (64) 639 (61) 490 (47)
Age at CRC diagnosis (years; means (SD)) 73.2 (± 9.1) 72.3 (± 8.8) 71.9 (± 8.5) 73.5 (± 8.8)
Male 543 (52) 366 (55) 377 (59) 284 (58)
Duration of GLD use at CRC diagnosis 
   < 1 years 108 (10) 74 (11) 63 (10) 50 (10)
   1 – 3 years 168 (16) 110 (16) 103 (16) 68 (14)
   ≥ 3 years 331 (32) 225 (34) 206 (32) 153 (31)
   Prevalent user 436 (42) 257 (39) 267 (42) 219 (45)
Duration of follow-up (years; means (SD)) 3.4 (± 3.0) 3.7 (± 3.0) 3.8 (± 3.0) 3.9 (± 3.2)
End of follow-up
   Death 494 (47) 272 (41) 223 (35) 219 (45)
   Loss to follow-up 11 (1) 7 (1) 7 (1) 3 (1)
   End of study (31-12-2011) 538 (52) 387 (58) 409 (64) 268 (54)
Use of the drugs under study after CRC diagnosis
   Metformin 666 (64) 666 (100) 469 (73) 336 (69)
      Duration of metformin use (years; median (IQR)) 1.6 (0.5-3.3) 1.6 (0.5-3.3) 1.9 (0.7-3.6) 1.9 (0.6-3.6)
      Adherent users (MPR ≥ 80%) a 364 (55) 364 (55) 260 (55) 178 (53)
   Statins 639 (61) 469 (70) 639 (100) 359 (73)
      Duration of statin use (years; median (IQR)) 2.0 (0.6-3.9) 2.2 (0.8-4.1) 2.0 (0.6-3.9) 2.2 (0.7-4.2)
      Adherent users (MPR ≥ 80%) a 362 (57) 276 (59) 362 (57) 208 (58)
   Aspirin 490 (47) 336 (51) 359 (56) 490 (100)
      Duration of aspirin use (years; median (IQR)) 1.5 (0.2-3.4) 1.6 (0.2-3.5) 1.7 (0.2-3.6) 1.5 (0.2-3.4)
      Adherent users (MPR ≥ 80%) a 235 (48) 167 (50) 174 (48) 235 (48)
Use of the drugs under study before CRC diagnosis
   Metformin 736 (71) 591 (89) 480 (75) 336 (69)
      Prevalent user (% of metformin use) 158 (21) 128 (22) 103 (21) 80 (24)
   Statins 642 (61) 437 (66) 556 (87) 342 (70)
      Prevalent user (% of statin use) 182 (28) 111 (25) 164 (29) 111 (32)
   Aspirin 478 (46) 305 (46) 326 (51) 386 (79)
      Prevalent user (% of aspirin use) 189 (40) 108 (35) 131 (39) 156 (40)
a MPR: Medication Possession Ratio, calculated for each patient by dividing the cumulative days of drug exposure by 
the total follow-up, CRC diagnosis until end of follow-up. A MPR of 80% or more was regarded as adherent to the specific 
drug. 
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Table 1. Baseline characteristics of the study population according to 








n (%) n (%) n (%) n (%)
Use of other frequently prescribed drugs in 
individuals with diabetes after CRC diagnosis b
   Sulfonylurea derivatives 606 (58) 439 (66) 384 (60) 301 (61)
   Insulin 368 (35) 224 (34) 251 (39) 189 (39)
   Other GLDs 82 (8) 65 (10) 61 (10) 49 (10)
   Diuretics 491 (47) 321 (48) 325 (51) 256 (52)
   Beta blocking agents 465 (45) 334 (50) 337 (53) 276 (56)
   Renin-angiotensin system agents 557 (53) 405 (61) 416 (65) 307 (63)
Type of CRC
   Proximal colon 439 (42) 267 (40) 251 (39) 193 (39)
   Distal colon 295 (28) 194 (29) 176 (28) 144 (30)
   Rectal 309 (30) 205 (31) 212 (33) 153 (31)
TNM stage c
   I 204 (20) 133 (20) 138 (22) 99 (20)
   II 325 (31) 209 (31) 207 (32) 170 (35)
   III 251 (24) 172 (26) 153 (24) 112 (23)
   IV 189 (18) 112 (17) 100 (16) 73 (15)
Period of CRC diagnosis
   1998-2002 123 (12) 67 (10) 45 (7) 65 (13)
   2003-2007 402 (39) 260 (39) 252 (39) 196 (40)
   2008-2011 518 (50) 339 (51) 342 (54) 229 (47)
Treatment of CRC
   Surgery 891 (85) 580 (87) 571 (89) 430 (88)
   Chemotherapy 225 (22) 157 (24) 149 (23) 92 (19)
   Radiotherapy 196 (19) 134 (20) 140 (22) 99 (20)
b Ever use of other drugs after CRC diagnosis (mean follow-up 3.4 ± 3.0 years): sulfonylurea derivatives (ATC-code: 
A10BB), insulin (ATC-code: A10A), other GLDs, diuretics (ATC-code: C03), beta blocking agents (ATC-code: C07) and 
drugs for renin-angiotensin system (ATC-code: C09); c Does not add up to total due to missings.
110 | Chapter 7
7
Full model  
The multivariable time-dependent analysis seemed to suggest that ever-users of 
metformin had lower overall mortality compared to those never using metformin 
after CRC diagnosis, though this did not reach statistical significance 
(HRDrug ever/never 0.78; 95% CI 0.59-1.01; p=0.06) (Table 2 and Figure 2). However, 
in patients using metformin after CRC diagnosis longer cumulative exposure was 
not associated with overall mortality (HRCumulative exposure per six months 1.02; 95% CI 
0.97-1.07; p=0.4). Furthermore, analysis revealed that overall mortality was in 
Figure 2. Hazard Ratio’s of overall mortality of CRC patients using metformin, 
statins or aspirin compared to those not using the specific drug 
after CRC diagnosis according to cumulative drug exposure per six 
months.*
* Full model, adjusted for use of metformin, sulfonylurea derivatives, insulin, other diabetes medication, statins and 
aspirin after diagnosis as time-dependent cumulative exposure and as time-dependent ever-never terms, the use of 
these drugs before diagnosis as a dichotomised variable, and the time-fixed variables: sex, age at CRC diagnosis, 
calender year of CRC diagnosis, type of CRC, stage at CRC diagnosis and administration of surgery, radiotherapy and/
or chemotherapy.
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favour of ever-users of statins compared to those never using statins after cancer 
diagnosis (HRDrug ever/never 0.73; 95% CI 0.54-0.99; p=0.04). Importantly, cumulative 
exposure to statins was also associated with better overall mortality 
(HRCumulative exposure per six months 0.94; 95% CI 0.89-0.98; p=0.01). We did not observe 
differences between ever and never-users of aspirin (HRDrug ever/never 0.96; 95% CI 
0.73-1.26; p=0.7) nor an effect of cumulative exposure on overall mortality 
(HRCumulative exposure per six months 0.98; 95% CI 0.94-1.03; p=0.5). 
In the full model, the cumulative exposures to other GLDs that were included did 
not show any association with overall mortality (Appendix 2). Moreover, no 
significant interactions were found between metformin, statins and aspirin use 
after CRC diagnosis.
 
Subgroup- and sensitivity analyses
The effect of metformin on overall mortality in the full model was comparable with 
the hazard ratios found for ever-never use of metformin and cumulative exposure 
to metformin in subgroup- and sensitivity analyses (Table 2). The HR of 0.94 for 
the association between cumulative exposure to statins and overall mortality was 
approximately similar in all subgroup- and sensitivity analyses and seemed to be 
even more protective among CRC patients who received chemotherapy (HRCumulative 
exposure per six months 0.84; 95% CI 0.70-1.00; p=0.05) (Table 2). In sensitivity analyses, 
excluding prevalent users, patients with less than 6 months of follow up, if adjusted 
for important cardiovascular co-medication or for drug adherence, the hazard 
ratios remained borderline significant for the effect of cumulative exposure to 
statins on overall mortality (Table 2). In the sensitivity analysis in which we adjusted 
the cumulative exposure to statins when patients stopped with statins in the six 
months prior to their death, cumulative exposure to statins was still associated 
with overall mortality, though less clear (HRCumulative exposure per six months 0.95; 95% CI 
0.90-1.00; p=0.03) (Table 2). Subgroup- or sensitivity analyses did not reveal 
different effects of aspirin use on overall mortality than was seen already in the 
full model (Table 2).
Discussion
This population based study revealed that among CRC patients who started using 
GLDs before cancer diagnosis, cumulative exposure to metformin or aspirin was 
not associated with overall mortality, while longer cumulative exposure to statins 
was independently associated with lower overall mortality, suggesting a drug 
effect of statins in CRC patients with diabetes. In contrast, we did not observe an 
independent association between metformin or aspirin use and overall mortality. 
This might imply that the survival benefit, seen in recently reported studies1,4-7,11-14, 
may not be induced by these drugs, but could be the result of suboptimal 
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methodology or confounded by the prognostic differences between ever and 
never users of metformin and aspirin. Regarding the use of aspirin and statins, it 
should be noted that this study only investigated a subgroup, i.e. the diabetic 
individuals, though a large one, of all statin and aspirin users. 
Although many of the earlier observational studies supported the hypothesis that 
metformin is linked with lower overall mortality in patients with CRC1-7, today we 
understand that many of them with impressive hazard rates contained time-related 
biases and other limitations that artificially made metformin look like a ‘wonderdrug’ 
for the survival after cancer19,21,26,27. The most important limitation of these studies 
is that they did not include a time-dependent cumulative exposure variable for 
drug exposure, which was needed since the effect of exposure depends on 
duration of use and timing in relationship to the event28. Nevertheless, they formed 
the driving force for the conduct of randomised metformin trials29,30. Similar 
considerations should have been made in studies on aspirin use and mortality 
after cancer, while some of these studies used pharmacy records, unfortunately, 
exposure was not analysed as continuous cumulative exposure11-14. As a result, it 
is likely that our analyses showed results more comparable with randomised 
controlled trials than previous studies in CRC patients1,4-7,11-14. Although with the 
inclusion of time-dependent ever-never terms for the studied drugs in the model, 
the hazard ratio of the cumulative effect term seems to be not dependent on the 
events in the unexposed group31, the inclusion of these terms is still subject of 
recent debate. Some experts in the field fear that the inclusion of both cumulative 
exposure and ever-never terms in a model introduces collinearity. Nevertheless, 
per six months of cumulative metformin use or aspirin use the hazard rate for 
overall mortality in CRC patients did not change, thus in this study the use of 
metformin and aspirin was not associated with mortality.    
Observational studies have investigated the association between statin use and 
outcomes among CRC patients regardless of diabetes status, but findings were 
inconsistent8-10. Such discrepancies are likely a result of methodological limitations 
within observational studies comparable with those in studies on metformin effect. 
A pooled meta-analysis of 27 randomised trials of statin therapy, did not reveal 
an effect of statin on cancer risk and mortality32. In the current study we investigated 
a selection of statin users from daily practice, thus comparing our results with 
previous studies on statin use and mortality after cancer patients might be incorrect. 
Statins are drugs of prevention and sicker patients with a poorer prognosis might 
be more likely to discontinue preventative treatments for non-symptomatic 
illness25. Since pharmacy records provide no ascertainment whether patients are 
compliant with their medication prescriptions, our results might be biased. In our 
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study after adjusting for the medication possession ratio and after dealing with 
the discontinuation of statin treatment just before death (by changing unexposed 
time after discontinuation into exposed time), this study still revealed a protective 
effect of statins on overall mortality among CRC patients. Unfortunately there is 
no consensus on the optimal approach to avoid sick stopper bias25,33,34, thus this 
remains an important limitation of our study. Although we performed several 
corrections for time-exposure related confounding risk factors, these findings do 
not necessarily imply a causal relationship between the use of statins and better 
overall mortality in CRC patients. Our analyses do not exclude that the association 
between the use of statins and the reduced risk of mortality in our dataset are 
partly due to residual confounding.
Several epidemiological studies have been interested in the potential of statins 
as a chemo preventative, since statins may interact with various signaling pathways 
that are critical for CRC development as well as progression35-39. The favourable 
effect of statins seemed to increase more clearly with cumulative drug exposure 
among patients who received chemotherapy, but the effect was only borderline 
statistically significant. However, our study seems to support the hypothesis that 
statins (HMG-CoA reductase inhibitors), widely used for the treatment of 
hypercholesterolemia, might act as a chemo preventative agent40. Statins inhibit 
the conversion of HMG-CoA to the cholesterol precursor mevalonate, which is 
the rate-limiting step in cholesterol biosynthesis35. Mevalonate is the precursor 
compound for other isoprenoids, which are critical for the modification of proteins 
involved in cell growth, including both the RAS and RHO oncogenes35. These 
potential antineoplastic benefits of statins were studied with regard to 
chemotherapy and radiotherapy administration, though this was only studied 
irrespective of diabetes status36-39. Two studies in rectal cancer patients revealed 
that the use of statins was associated with improved pathologic response after 
neoadjuvant chemoradiation36,37. These findings were supported by cell line 
studies, since lovastatin augmented apoptosis induced by chemotherapeutic 
agents such as 5-FU and cisplatin in colon cancer cells38,39. 
Unfortunately, the number of patients included for sub-analyses was rather small 
and the follow-up was short, therefore additional evidence in a greater subset of 
patients with longer follow-up is needed. In addition, since no information was 
available on cause of mortality, we were not able to verify whether use of metformin, 
statins and aspirin is associated with a decreased cancer specific mortality. The 
protective effect of statin use on overall mortality in this study might be highly 
attributed to the decrease in cardiovascular deaths instead of cancer deaths in 
this group of patients40. Since the data from clinical laboratories were only available 
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for a subpopulation of the cohort, we were not able to include information on 
cholesterol levels, values and body mass index in the analyses which is a major 
limitation. The influence of these metabolic factors on overall mortality in GLD 
users might be of interest and should be evaluated in future studies. 
In conclusion, longer cumulative exposure to metformin or aspirin was not 
associated with overall mortality among CRC patients. But, longer cumulative 
exposure to statins after the diagnosis of CRC was associated with lower overall 
mortality among CRC patients starting on GLDs before cancer diagnosis. Our 
findings support a protective effect of statins, independent of metformin and 
aspirin use, in CRC patients using GLDs. As this study had an observational design 
our results are based on the decision of a clinician to prescribe a certain type of 
drugs, based on the patient characteristics together with the experience of the 
clinician. The findings of the current study requires to elucidate this association 
in future randomized, and in-depth studies, with larger study populations dealing 
with the mentioned pharmaco-epidemiological challenges, sick stopper bias and 
adjusting for additional metabolic characteristics.
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Appendix 1. Baseline characteristics of the study population according to  







n (%) n (%) n (%)
Age at CRC diagnosis (years; means (SD)) 72.3 (± 8.8) 74.8 (± 9.5) ** 71.9 (± 8.5)
Male 366 (55) 177 (47) * 377 (59)
Duration of GLD use at CRC diagnosis 
   < 1 years 74 (11) 34 (9) 63 (10)
   1 – 3 years 110 (16) 58 (15) 103 (16)
   ≥ 3 years 225 (34) 106 (28) 206 (32)
   Prevalent user 257 (39) 179 (48) * 267 (42)
Duration of follow-up (years; means (SD)) 3.7 (± 3.0) 2.9 (± 2.9) ** 3.8 (± 3.0)
End of follow-up (%)
   Death 272 (41) 222 (59) 223 (35)
   Loss to follow-up 7 (1) 4 (1) 7 (1)
   End of study (31-12-2011) 387 (58) 151 (40) ** 409 (64)
Use of the drugs under study after CRC diagnosis
   Metformin 666 (100) 0 (0) 469 (73)
      Duration of metformin use (years; median (IQR)) 1.6 (0.5-3.3) 1.9 (0.7-3.6)
      Adherent users (MPR ≥ 80%) a 364 (55) 260 (55)
   Statins 469 (70) 170 (45) 469 (100)
      Duration of statin use (years; median (IQR)) 2.2 (0.8-4.1) 1.2 (0.2-3.4)* 2.0 (0.5-3.9)
      Adherent users (MPR ≥ 80%) a 273 (58) 83 (49) * 356 (56)
   Aspirin 336 (51) 154 (41) * 359 (56)
      Duration of aspirin use (years; median (IQR)) 1.6 (0.2-3.5) 1.0 (0.2-2.8)* 1.7 (0.2-3.6)
      Adherent users (MPR ≥ 80%) a 167 (50) 68 (44) 174 (48)
Use of the drugs under study before CRC diagnosis
   Metformin 591 (89) 145 (38) ** 480 (75)
      Prevalent user (% of metformin use) 128 (22) 30 (21) 103 (21)
   Statins 437 (66) 200 (53) ** 556 (87)
      Prevalent user (% of statin use) 111 (25) 71 (35) * 164 (29)
   Aspirin 305 (46) 162 (43) 326 (51)
      Prevalent user (% of aspirin use) 108 (35) 81 (49) * 131 (39)
a MPR: Medication Possession Ratio, calculated for each patient by dividing the cumulative days of drug exposure by 
the total follow-up, CRC diagnosis until end of follow-up. A MPR of 80% or more was regarded as adherent to the 









None of drugs used
(n=155; 15%)
n (%) n (%) n (%) n (%) n (%)
75.3 (± 9.6) ** 73.5 (± 8.8) 72.9 (± 9.4) 72 (± 8.2) 75.1 (±10.2) *
166 (41) ** 284 (58) 259 (47) * 167 (65) 58 (37) **
45 (11) 50 (10) 58 (11) 32 (12) 19 (12)
65 (16) 68 (14) 100 (18) 36 (14) 25 (16)
125 (31) 153 (31) 178 (32) 84 (33) 47 (30)
169 (42) 219 (45) 217 (39) 105 (41) 64 (41)
2.7 (± 2.9) ** 3.9 (± 3.2) 2.9 (± 2.7) ** 4.1 (± 3.0) 2.0 (± 2.3) **
271 (67) 219 (45) 275 (50) 80 (31) 103 (67)
4 (1) 3 (1) 8 (1) 2 (1) 2 (1)
129 (32) ** 268 (54) 270 (49) 175 (68) 50 (32) **
197 (49) ** 336 (69) 330 (60) * 666 (100) 0 (0)
1.1 (0.2-2.4)** 1.9 (0.6-3.6) 1.4 (0.4-3.0)* 2.1 (0.7-3.7)
104 (53) 178 (53) 186 (56) 139 (54)
0 (0) 359 (73) 280 (51) ** 469 (100) 0 (0)
2.2 (0.7-4.2) 1.8 (0.5-3.6)* 2.4 (1.0-4.4)
204 (57) 152 (54) 153 (60)
131 (32) ** 490 (100) 0 (0) 490 (100) 0 (0)
0.9 (0.1-2.3) * 1.5 (0.2-3.4) 1.9 (0.3-3.6)
61 (47) 235 (48) 130 (51)
256 (63) ** 336 (69) 400 (72) 227 (88) 73 (47) **
55 (21) 80 (24) 78 (20) 53 (23) 11 (15)
81 (20) ** 342 (70) 295 (53) ** 222 (86) 40 (26) **
18 (22) 111 (32) 71 (24) * 68 (30) 10 (24)
141 (35) ** 386 (79) 81 (15) ** 199 (77) 27 (17) **
58 (40) 156 (40) 33 (37) 72 (36) 10 (33)
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n (%) n (%) n (%)
Age at CRC diagnosis (years; means (SD)) 72.3 (± 8.8) 74.8 (± 9.5) ** 71.9 (± 8.5)
Male 366 (55) 177 (47) * 377 (59)
Duration of GLD use at CRC diagnosis 
   < 1 years 74 (11) 34 (9) 63 (10)
   1 – 3 years 110 (16) 58 (15) 103 (16)
   ≥ 3 years 225 (34) 106 (28) 206 (32)
   Prevalent user 257 (39) 179 (48) * 267 (42)
Duration of follow-up (years; means (SD)) 3.7 (± 3.0) 2.9 (± 2.9) ** 3.8 (± 3.0)
End of follow-up (%)
   Death 272 (41) 222 (59) 223 (35)
   Loss to follow-up 7 (1) 4 (1) 7 (1)
   End of study (31-12-2011) 387 (58) 151 (40) ** 409 (64)
Use of the drugs under study after CRC diagnosis
   Metformin 666 (100) 0 (0) 469 (73)
      Duration of metformin use (years; median (IQR)) 1.6 (0.5-3.3) 1.9 (0.7-3.6)
      Adherent users (MPR ≥ 80%) a 364 (55) 260 (55)
   Statins 469 (70) 170 (45) 469 (100)
      Duration of statin use (years; median (IQR)) 2.2 (0.8-4.1) 1.2 (0.2-3.4)* 2.0 (0.5-3.9)
      Adherent users (MPR ≥ 80%) a 273 (58) 83 (49) * 356 (56)
   Aspirin 336 (51) 154 (41) * 359 (56)
      Duration of aspirin use (years; median (IQR)) 1.6 (0.2-3.5) 1.0 (0.2-2.8)* 1.7 (0.2-3.6)
      Adherent users (MPR ≥ 80%) a 167 (50) 68 (44) 174 (48)
Use of the drugs under study before CRC diagnosis
   Metformin 591 (89) 145 (38) ** 480 (75)
      Prevalent user (% of metformin use) 128 (22) 30 (21) 103 (21)
   Statins 437 (66) 200 (53) ** 556 (87)
      Prevalent user (% of statin use) 111 (25) 71 (35) * 164 (29)
   Aspirin 305 (46) 162 (43) 326 (51)
      Prevalent user (% of aspirin use) 108 (35) 81 (49) * 131 (39)
a MPR: Medication Possession Ratio, calculated for each patient by dividing the cumulative days of drug exposure by 
the total follow-up, CRC diagnosis until end of follow-up. A MPR of 80% or more was regarded as adherent to the 









None of drugs used
(n=155; 15%)
n (%) n (%) n (%) n (%) n (%)
75.3 (± 9.6) ** 73.5 (± 8.8) 72.9 (± 9.4) 72 (± 8.2) 75.1 (±10.2) *
166 (41) ** 284 (58) 259 (47) * 167 (65) 58 (37) **
45 (11) 50 (10) 58 (11) 32 (12) 19 (12)
65 (16) 68 (14) 100 (18) 36 (14) 25 (16)
125 (31) 153 (31) 178 (32) 84 (33) 47 (30)
169 (42) 219 (45) 217 (39) 105 (41) 64 (41)
2.7 (± 2.9) ** 3.9 (± 3.2) 2.9 (± 2.7) ** 4.1 (± 3.0) 2.0 (± 2.3) **
271 (67) 219 (45) 275 (50) 80 (31) 103 (67)
4 (1) 3 (1) 8 (1) 2 (1) 2 (1)
129 (32) ** 268 (54) 270 (49) 175 (68) 50 (32) **
197 (49) ** 336 (69) 330 (60) * 666 (100) 0 (0)
1.1 (0.2-2.4)** 1.9 (0.6-3.6) 1.4 (0.4-3.0)* 2.1 (0.7-3.7)
104 (53) 178 (53) 186 (56) 139 (54)
0 (0) 359 (73) 280 (51) ** 469 (100) 0 (0)
2.2 (0.7-4.2) 1.8 (0.5-3.6)* 2.4 (1.0-4.4)
204 (57) 152 (54) 153 (60)
131 (32) ** 490 (100) 0 (0) 490 (100) 0 (0)
0.9 (0.1-2.3) * 1.5 (0.2-3.4) 1.9 (0.3-3.6)
61 (47) 235 (48) 130 (51)
256 (63) ** 336 (69) 400 (72) 227 (88) 73 (47) **
55 (21) 80 (24) 78 (20) 53 (23) 11 (15)
81 (20) ** 342 (70) 295 (53) ** 222 (86) 40 (26) **
18 (22) 111 (32) 71 (24) * 68 (30) 10 (24)
141 (35) ** 386 (79) 81 (15) ** 199 (77) 27 (17) **
58 (40) 156 (40) 33 (37) 72 (36) 10 (33)
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n (%) n (%) n (%)
Use of other frequently prescribed drugs in individu-
als with diabetes after CRC diagnosis b
   Sulfonylurea derivatives 439 (66) 167 (44) ** 384 (60)
   Insulin 224 (34) 144 (38) 251 (39)
   Other GLDs 65 (10) 17 (5) * 61 (10)
   Diuretics 321 (48) 170 (45) 325 (51)
   Beta blocking agents 334 (50) 131 (35) ** 337 (53)
   Renin-angiotensin system agents 405 (61) 152 (40) ** 416 (65)
Type of CRC
   Proximal colon 267 (40) 172 (46) 251 (39)
   Distal colon 194 (29) 101 (27) 176 (28)
   Rectal 205 (31) 104 (27) 212 (33)
TNM stage c
   I 133 (20) 71 (19) 138 (22)
   II 209 (31) 116 (31) 207 (32)
   III 172 (26) 79 (21) 153 (24)
   IV 112 (17) 77 (20) 100 (16)
Period of CRC diagnosis
   1998-2002 67 (10) 56 (15) 45 (7)
   2003-2007 260 (39) 142 (38) 252 (39)
   2008-2011 339 (51) 179 (47) 342 (54)
Treatment of CRC
   Surgery 580 (87) 311 (82) * 571 (89)
   Chemotherapy 157 (24) 68 (18) * 149 (23)
   Radiotherapy 134 (20) 62 (16) 140 (22)
 b Ever use of other drugs after CRC diagnosis (mean follow-up 3.4 ± 3.0 years): sulfonylurea derivatives (ATC-code: 
A10BB), insulin (ATC-code: A10A), other GLDs, diuretics (ATC-code: C03), beta blocking agents (ATC-code: C07) 










None of drugs used
(n=155; 15%)
n (%) n (%) n (%) n (%) n (%)
222 (55) 301 (61) 305 (55) * 170 (66) 58 (37) **
117 (29) * 189 (39) 179 (32) * 97 (37) 40 (26) *
21 (5) * 49 (10) 33 (6) * 29 (11) 4 (3) *
166 (41) * 256 (52) 235 (43) * 129 (50) 45 (29) **
128 (32) ** 276 (56) 189 (34) ** 155 (60) 25 (16) **
141 (35) ** 307 (63) 250 (45) ** 182 (71) 31 (20) **
188 (47) 193 (39) 246 (45) 94 (37) 77 (50)
119 (29) 144 (30) 151 (27) 72 (28) 38 (24)
97 (24) * 153 (31) 156 (28) 91 (35) 40 (26) *
66 (16) 99 (20) 105 (19) 58 (23) 22 (14)
118 (29) 170 (35) 155 (28) 88 (34) 42 (27)
98 (24) 112 (23) 139 (25) 60 (23) 38 (25)
89 (22) ** 73 (15) 116 (21) 34 (13) 37 (24) *
78 (19) 65 (13) 58 (11) 18 (7) 26 (17)
150 (37) 196 (40) 206 (37) 107 (42) 50 (32)
176 (44) ** 229 (47) 289 (52) 132 (51) 79 (51) *
320 (79) ** 430 (88) 461 (83) * 230 (89) 120 (77) *
76 (19) 92 (19) 133 (24) * 56 (22) 33 (21)
56 (14) * 99 (20) 97 (18) 60 (23) 21 (14) *
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n (%) n (%) n (%)
Use of other frequently prescribed drugs in individu-
als with diabetes after CRC diagnosis b
   Sulfonylurea derivatives 439 (66) 167 (44) ** 384 (60)
   Insulin 224 (34) 144 (38) 251 (39)
   Other GLDs 65 (10) 17 (5) * 61 (10)
   Diuretics 321 (48) 170 (45) 325 (51)
   Beta blocking agents 334 (50) 131 (35) ** 337 (53)
   Renin-angiotensin system agents 405 (61) 152 (40) ** 416 (65)
Type of CRC
   Proximal colon 267 (40) 172 (46) 251 (39)
   Distal colon 194 (29) 101 (27) 176 (28)
   Rectal 205 (31) 104 (27) 212 (33)
TNM stage c
   I 133 (20) 71 (19) 138 (22)
   II 209 (31) 116 (31) 207 (32)
   III 172 (26) 79 (21) 153 (24)
   IV 112 (17) 77 (20) 100 (16)
Period of CRC diagnosis
   1998-2002 67 (10) 56 (15) 45 (7)
   2003-2007 260 (39) 142 (38) 252 (39)
   2008-2011 339 (51) 179 (47) 342 (54)
Treatment of CRC
   Surgery 580 (87) 311 (82) * 571 (89)
   Chemotherapy 157 (24) 68 (18) * 149 (23)
   Radiotherapy 134 (20) 62 (16) 140 (22)
 b Ever use of other drugs after CRC diagnosis (mean follow-up 3.4 ± 3.0 years): sulfonylurea derivatives (ATC-code: 
A10BB), insulin (ATC-code: A10A), other GLDs, diuretics (ATC-code: C03), beta blocking agents (ATC-code: C07) 










None of drugs used
(n=155; 15%)
n (%) n (%) n (%) n (%) n (%)
222 (55) 301 (61) 305 (55) * 170 (66) 58 (37) **
117 (29) * 189 (39) 179 (32) * 97 (37) 40 (26) *
21 (5) * 49 (10) 33 (6) * 29 (11) 4 (3) *
166 (41) * 256 (52) 235 (43) * 129 (50) 45 (29) **
128 (32) ** 276 (56) 189 (34) ** 155 (60) 25 (16) **
141 (35) ** 307 (63) 250 (45) ** 182 (71) 31 (20) **
188 (47) 193 (39) 246 (45) 94 (37) 77 (50)
119 (29) 144 (30) 151 (27) 72 (28) 38 (24)
97 (24) * 153 (31) 156 (28) 91 (35) 40 (26) *
66 (16) 99 (20) 105 (19) 58 (23) 22 (14)
118 (29) 170 (35) 155 (28) 88 (34) 42 (27)
98 (24) 112 (23) 139 (25) 60 (23) 38 (25)
89 (22) ** 73 (15) 116 (21) 34 (13) 37 (24) *
78 (19) 65 (13) 58 (11) 18 (7) 26 (17)
150 (37) 196 (40) 206 (37) 107 (42) 50 (32)
176 (44) ** 229 (47) 289 (52) 132 (51) 79 (51) *
320 (79) ** 430 (88) 461 (83) * 230 (89) 120 (77) *
76 (19) 92 (19) 133 (24) * 56 (22) 33 (21)
56 (14) * 99 (20) 97 (18) 60 (23) 21 (14) *
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Appendix 2. Multivariable Cox regression analyses with the hazard ratios for 
the full model. 
Variables within full model HR (95% CI)
Ever use after cancer diagnosis (ever versus never)
   Metformin 0.78 (0.59-1.01)
   Statins 0.73 (0.54-0.99) *
   Aspirin 0.96 (0.73-1.26)
   Sulfonylurea derivatives 0.83 (0.63-1.10)
   Insulin 2.09 (1.52-2.88) **
   Other GLDs 0.69 (0.38-1.26)
Cumulative exposure per six months of use after cancer diagnosis
   Metformin 1.02 (0.97-1.07)
   Statins 0.94 (0.89-0.98) *
   Aspirin 0.98 (0.94-1.03)
   Sulfonylurea derivatives 1.02 (0.97-1.07)
   Insulin 1.00 (0.95-1.06)
   Other GLDs 1.10 (0.93-1.31)
Ever use before cancer diagnosis (ever versus never)
   Metformin 1.10 (0.85-1.45)
   Statins 0.95 (0.71-1.27)
   Aspirin 1.33 (1.03-1.67) *
   Sulfonylurea derivatives 1.27 (0.97-1.67)
   Insulin 0.47 (0.33-0.67) **
   Other GLDs 0.72 (0.50-1.03)
Age (years) 1.04 (1.03-1.05) **
Male (female is reference) 1.40 (1.16-1.70) *
Year of cancer diagnosis (years) 0.96 (0.93-0.99) *
Cancer treatment
   Received surgery (no is reference) 0.24 (0.18-0.32) **
   Administration of chemotherapy (no is reference) 0.59 (0.46-0.77) **
   Administration of radiotherapy (no is reference) 0.61 (0.44-0.83) *
Cancer stage
   I Ref
   II 0.86 (0.65-1.13)
   III 2.37 (1.79-3.14) **
   IV 4.49 (3.31-6.10) **
Cancer type
   Proximal colon tumour Ref 
   Distal colon tumour 0.97 (0.77-1.21)
   Rectal tumour 1.11 (0.84-1.46)
 * p<0.05; ** p<0.0001.




Impact of cancer diagnosis and treatment 
on glycaemic control among individuals 









126 | Chapter 8
8
Abstract
Aims: In our search to understand why patients with diabetes and cancer have 
deteriorated survival rates, this study aims to evaluate the impact of cancer 
diagnosis and its treatment on HbA1c-values among individuals with colorectal 
cancer (CRC) using glucose lowering drugs (GLDs).
Materials and methods: Patients with primary CRC (1998-2011) were selected 
from the Eindhoven Cancer Registry and linked to drug dispensing data from the 
PHARMO Database Network. GLDs users for more than two years prior to cancer 
diagnosis were selected. Linear mixed effects models were conducted to evaluate 
changes in HbA1c for colon cancer (CC) and rectal cancer (RC) patients separately 
in the four years around CRC diagnosis.
Results: From all CRC patients (n=4,714), 294 (6%) users of GLDs with CC and 
144 (3%) with RC were selected. In the crude model, the mean HbA1c at cancer 
diagnosis was 6.9% (51.6 mmol/mol) among CC patients and 7.1% (53.5 mmol/
mol) among RC patients. In the adjusted model HbA1c decreased with 0.12% per 
year (1.3 mmol/mol; p=0.0002) before cancer diagnosis for CC patients and after 
cancer diagnosis it increased with 0.12% per year (1.3 mmol/mol; p=0.02). Before 
the diagnosis of RC HbA1c decreased with 0.18% per year (2.0 mmol/mol; 
p=0.0006), whereas after cancer diagnosis it changed not-significantly with +0.04% 
per year (0.4 mmol/mol; p=0.59). Effects on HbA1c were more pronounced in 
those with proximal colon tumours and users of anti-anaemic preparations before 
CC diagnosis.
Conclusions: Among CRC patients who used GLDs, HbA1c levels before cancer 
diagnosis decreased with 0.12%-0.18% (1-2 mmol/mol) per year and after cancer 
diagnosis they increased only among CC patients (0.12% per year; 1.3 mmol/
mol). Physicians should be aware that HbA1c levels among diabetics might decrease 
because of cancer diagnosis. However, the HbA1c measure might be inappropriate 
for visualising glycaemic control in (un)diagnosed cancer patients that frequently 
use anti-anaemic preparations.  
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Introduction
Accumulating evidence suggests that colorectal cancer (CRC) is more common 
in individuals with diabetes than in those without1-4 and also, that individuals with 
diabetes have worse overall survival after CRC compared to those without diabetes, 
with five-year survival rates of 35% and 48%, respectively5-13. Although numerous 
hypotheses for this worse survival were studied, all of them focussed on the effect 
of diabetes and its treatment on cancer, while the development of a tumour and 
the treatment of cancer may also influence diabetes control. The presence of 
cancer might result in worse glycaemic control, changes in glucose lowering drugs 
(GLDs), patient adherence and diabetes complications, indirectly resulting in worse 
survival. However, to our knowledge, till now these hypotheses are only 
speculations and not investigated properly. The glycaemic control in individuals 
with diabetes is checked every three to six months, depending on the degree of 
glycaemic control, by using the HbA1c measurement14. HbA1c is the most widely 
used clinical test and represents the average amount of change in glycated 
haemoglobin, thereby indicating the mean blood glucose concentration over the 
life span of a red blood cell, which is approximately three months15. Changes in 
this lifespan can affect HbA1c, rapid red cell turnover leads to a greater proportion 
of younger red cells and falsely low HbA1c levels. Consequently, the treatments 
for anaemia and iron deficiency might influence the levels of HbA1c16 and need 
to be considered since they are frequently prescribed in patients with CRC17. 
The HbA1c-value, as a marker of glycaemic control, might be influenced by cancer, 
leading to (required or inappropriate) changes in medication. Moreover, the HbA1c 
measure might be associated with mortality, since studies showed that individuals 
with diabetes and HbA1c values <6.5% (48 mmol/mol) or with HbA1c values >9.0% 
(75 mmol/mol) had higher mortality in the year after these values compared to 
those with recent ‘normal’ HbA1c values between 6.5% and 9%18,19. The higher 
mortality among individuals with low HbA1c values might be the result of morbidity 
and the frequent occurrence of hypoglycaemia, whereas among those with high 
HbA1c values the increased risk of diabetes complications might cause the higher 
mortality20,21. If the presence of cancer results in steep decreases and/or increases 
of  HbA1c, this will strengthen the hypothesis that the overall worse survival seen 
in patients with diabetes and cancer might also be explained by changes in 
glycaemic control due to cancer. 
For the current research, the aim was to assess whether, and to which extent, 
HbA1c -values change during the process of cancer detection and initial treatment, 
evaluated in a period of 4 years around the diagnosis of colon cancer (CC) and 
rectal cancer (RC). Since the treatment for CC and RC differs, i.e. mainly 
chemotherapy for CC and radiotherapy for RC, these tumours might impact HbA1c 
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differently. We hypothesised that cancer development and treatment will increase 
the value of HbA1c, i.e. glycaemic control, during this 4-year period.
Methods
Data sources
Data were obtained from the Eindhoven Cancer Registry (ECR) linked on a patient 
level to the PHARMO Database Network, covering a demographic region in the 
Southern part of the Netherlands of approximately one million inhabitants. The 
construct and validity of the ECR-PHARMO cohort have been described 
elsewhere22. The ECR, maintained by the Netherlands Comprehensive Cancer 
Organisation (IKNL), records data on all patients newly diagnosed with cancer in 
the Southern part of the Netherlands, an area with 2.4 million inhabitants. The 
registry is notified by six pathology departments, 10 community hospitals, and 
two radiotherapy departments. Trained registration clerks actively collect data on 
patient characteristics, cancer diagnosis, staging, and initial treatment from hospital 
medical records. The PHARMO Database Network is a large, patient-centric data 
network including multiple linked observational databases designed for safety 
and outcomes research of drugs. For this study the community (out-patient) 
pharmacy database was used, which includes data on the dispensed drug, 
dispensing date, amount and regiment dispensed, and thus the duration of use. 
All drugs are coded according to the Anatomical Therapeutic Chemical (ATC) 
classification23. In addition, the longitudinal data obtained from the clinical 
laboratories was used, which was available for a sub-cohort of the patients included 
in the PHARMO Database Network. Both the ECR and the PHARMO Database 
Network are recognised as high quality sources for epidemiological research that 
collect information in overlapping regions in the Netherlands for a period of at 
least 10 years22. 
Study population
The source population included all CC and RC patients registered in the 
ECR-PHARMO cohort between January 1, 1998 and December 31, 2011. To be 
eligible these patients needed to have a two-year history in the PHARMO database 
before their cancer diagnosis and at least one clinical laboratory test result in the 
four years around their cancer diagnosis (n=4,714) (Figure 1). From this population 
patients who used any type of glucose lowering drug (GLD; ATC code: A10) for 
more than two years prior to cancer diagnosis were selected (n=507). These 507 
patients were linked to the database of the clinical laboratories with information 
on HbA1c: only individuals with two or more HbA1c measures in the 4 years around 
cancer diagnosis were selected for the analyses (n=438). While for all users of 
GLDs the duration of use was at least two years, only for  incident users (n=249; 
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Figure 1. Flowchart of patients selected for analysis.
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57%) the exact duration after these two years was known. For this study, CC (n=294) 
and RC (n=144) patients were analysed separately. 
Co-variables
Patient, tumour and treatment related variables included for adjustment were 
selected a priori or had shown an independent association (p<0.05) with HbA1c. 
Age at CRC diagnosis, sex, period of CRC diagnosis (year of diagnosis), stage of 
cancer, receiving surgery, administration of radiotherapy (only for RC) and/or 
chemotherapy and duration of GLD use at cancer diagnosis (2-4 years; 4-6 years; 
≥ 6 years; prevalent use) were considered potential confounders. All covariates 
were included in the multivariable analyses as time-fixed variables. 
Statistical analysis
Using crude data, we illustrated mean changes in HbA1c during the four years 
around cancer diagnosis as three-months moving averages in Figure 2. 
Linear mixed effects models were analysed to evaluate the course in HbA1c for 
cancer patients. The multilevel model used had random intercepts and slopes 
and an unstructured covariance matrix. Time was analysed as a continuous variable, 
and for the analyses divided into time before and time after cancer diagnosis 
within one statistical model, because these had different directions of effects on 
the HbA1c measures. The baseline or intercept of the analyses was set on the 
diagnosis of CC and RC, respectively, as a result the time (per year) before and 
after cancer was set off with respect to this baseline. A p-value <0.05 was 
considered statistically significant. 
Subgroup- and sensitivity analyses
To determine the effect of duration of use of GLDs on the association between 
HbA1c and CRC, users with unknown duration were excluded in these sub-analysis. 
The presence of effect modification between cancer treatment and HbA1c was 
evaluated by including interaction terms in our full model (variable of interest * 
linear time pre diagnosis or * linear time post diagnosis). For interaction terms a 
p-value <0.1 was considered statistically significant. Since anti-anaemic 
preparations (ATC-code: B03) might influence HbA1c and are frequently used by 
CC patients, the use of these preparations before the cancer diagnosis was 
assessed for effect modification. 
Moreover, the type of GLD use was assessed as confounder and potential effect 
modifier in the association between HbA1c and CRC and divided into those using 
metformin (ATC-code: A10BA02), sulfonylurea derivatives (ATC-code: A10BB), 
insulin (ATC-code: A10A) and other GLDs before and after cancer diagnosis 
separately (i.e. yes-no terms). In two other sensitivity analyses the effect of mean 
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body mass index (BMI) and haemoglobin (Hb) at the time of cancer on the 
association between HbA1c and CRC was determined by including BMI and Hb 
as continuous variables in the full model. They were defined as the mean BMI (Kg/
m2) and Hb (mmol/mol) of the measures within the 6 months around CRC diagnosis. 
In another analyses, the impact of cancer stage (I-III vs. IV) on the association 
between HbA1c and cancer was explored. All statistical analyses were performed 
using SAS software (version 9.3, SAS institute, Cary, US).
Results
Within the ECR-PHARMO cohort, out of 4,714 CRC patients diagnosed between 
1998 and 2011, 838 patients (18%) were registered using GLDs (Figure 1). Of 
these, 294 (35%) CC and 144 (17%) RC patients used GLDs more than two years 
before the diagnosis of cancer. For the proposed analyses mean age at cancer 
diagnosis was 74.5 ± 8.6 years for CC patients and  72.6 ± 9.1 years for RC patients 
(Table 1). 
The number of HbA1c measurements registered, during the follow-up of four years, 
was 9.2 ± 5.5 and 9.4 ± 4.5, for CC and RC patients, respectively (Table 1). 
Moreover, mean Hb at CRC diagnosis was slightly lower for CC compared to RC 
Figure 2. Values of HbA1c during follow-up as three-months moving 
averages.






















Colon cancer Rectal cancer
132 | Chapter 8
8
Table 1. Characteristics of study population (n=438).
Colon (n=294) Rectal (n=144)
n (%) n (%)
Patient characteristics
Age at first GLD dispensing (years; Mean (± SD)) a 67.9 (± 8.8) 66 (± 9.4)
Age at cancer diagnosis (years; Mean (± SD)) 74.5 (± 8.6) 72.6 (± 9.1)
Duration of GLD use at cancer diagnosis b
   Incident use: 2 – 4 years 53 (18) 23 (16)
   Incident use: 4 – 6 years 58 (20) 23 (16)
   Incident use: ≥ 6 years 65 (22) 27 (19)
   Unknown duration, albeit ≥ 2 years 118 (40) 71 (49)
Male 156 (53) 95 (66)
Glucose lowering drug use (yes/no)
Two years before cancer diagnosis till cancer diagnosis
   Metformin 192 (65) 102 (71)
   Sulfonylurea derivatives 177 (60) 86 (60)
   Insulin 73 (25) 49 (34)
   Other glucose lowering drugs 39 (13) 17 (12)
From cancer diagnosis till two years after cancer diagnosis
   Metformin 157 (53) 90 (63)
   Sulfonylurea derivatives 148 (50) 75 (52)
   Insulin 89 (30) 60 (42)
   Other glucose lowering drugs 26 (9) 10 (7)
Laboratory measures
Number of HbA1c measurements (Mean (± SD))
   Total number during follow-up 9.2 (± 5.5) 9.4 (± 4.5)
   Before cancer diagnosis 5.5 (± 3.0) 5.4 (± 2.5)
   After cancer diagnosis 4.8 (± 3.1) 5 (± 2.7)
Mean first HbA1c (%) during follow-up 
   < 6.5 95 (32) 38 (27)
   ≥ 6.5 and < 7.0 57 (19) 22 (15)
   ≥ 7.0 and < 7.5 58 (20) 35 (24)
   ≥ 7.5 84 (29) 49 (34)
Mean BMI at cancer diagnosis (n=167; Kg/m2; Mean (± SD)) c 28.1 (± 4.4) 28.6 (± 5.3)
Mean Hb at cancer diagnosis (n=80; mmol/L; Mean (± SD)) c 7.0 (± 1.1) 7.7 (± 1.2)
Use of anti-anaemic preparations 87 (30) 17 (12)
GLD: glucose lowering drug; SD: standard deviation; BMI: body mass index; Hb: haemoglobin. a Age at first GLD 
dispensing  was defined as age of first GLD dispensing in this cohort, i.e. for prevalent users the age of first GLD 
dispensing ever is different; b Incident users were defined as those that started with GLD after entrance in the 
ECR-PHARMO cohort, thus with known diabetes duration. Prevalent users were defined as those that started with GLD 
at any time before entrance in the ECR-PHARMO cohort, thus with unknown diabetes duration; c BMI and Hb at diagnosis 
were defined as BMI and Hb measures within the 6 months around CRC diagnosis and included in the model as 
continuous variables.
Impact of colorectal cancer on glycaemic control | 133
8
patients (7.0 ± 1.1 vs. 7.7 ± 1.2). Before cancer diagnosis, 87 (30%) CC and 17 
(12%) RC patients were dispensed anti-anaemic preparations. Compared to RC 
patients, those with CC more often had stage II disease and less frequently stage 
I disease. During a median follow-up of 2.0 years, 81 (28%) patients with CC died 
and 37 (26%) with RC (data not shown). 
Colon cancer
In the crude linear model the intercept, i.e. HbA1c at cancer diagnosis, was 6.9% 
(51.6 mmol/mol) (Table 2). The full model showed that in the period before cancer 
diagnosis, the mean HbA1c decreased with 0.12% per year (95% CI 0.06-0.18; 1.3 
mmol/mol; p=0.0002), whereas after cancer diagnosis the mean HbA1c increased 
with 0.12% per year (95% CI 0.02-0.21; 1.3 mmol/mol; p=0.02), which is also 
illustrated in Figure 2 with the crude data. Among subgroup analyses in CC 
patients, the effects on HbA1c were more clear for incident GLD users; before the 
cancer diagnosis a decrease in mean HbA1c of 0.16% per year (95% CI 0.08-0.24; 
1.7 mmol/mol; p<0.0001) and after the cancer diagnosis an increase of 0.20% per 
year (95% CI 0.05 to 0.34; 2.1 mmol/mol; p=0.008) was seen. Subgroup analyses 
among insulin users showed a higher baseline HbA1c at cancer diagnosis (7.5%; 
57.9 mmol/mol), while before and after cancer diagnosis no significant effects on 
HbA1c were seen (Table 2). The HbA1c values before the diagnosis of cancer 
seemed to be strongly associated with the presence of a proximal tumour and 
the use of anti-anaemic preparations (Table 2). In patients using these preparations 
before cancer diagnosis, the mean HbA1c decreased with 0.25% per year (95% CI 
Table 1. Characteristics of study population (n=438) (Continued).
Colon (n=294) Rectal (n=144)
n (%) n (%)
Tumour characteristics
Type of colon cancer
   Proximal 166 (56) n.a.
   Distal 128 (44) n.a.
TNM stage
   I 55 (19) 46 (32)
   II 108 (37) 28 (19)
   III 78 (26) 47 (33)
   IV 53 (18) 23 (16)
Period of diagnosis
   2000-2007 100 (34) 53 (37)
   2008-2009 102 (35) 52 (36)
   2010-2011 92 (31) 92 (27)
Treatment of cancer
   Surgery 267 (91) 125 (87)
   Chemotherapy 74 (25) 32 (22)
   Radiotherapy 3 (1) 100 (69)
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0.10-0.40; 2.7 mmol/mol; p=0.001) (Table 2). Although in other sensitivity analyses 
the mean HbA1c did not change tremendously, when adjusting for Hb at cancer 
diagnosis the mean HbA1c after cancer diagnosis increased with 0.39% per year 
(95% CI 0.18 to 0.60; 4.2 mmol/mol; n=53; p=0.0006). In patients with stage IV 
CC, the mean HbA1c decreased with 0.17% (95% CI 0.29-0.05; 1.9 mmol/mol; 
p<0.0001; not shown)  per year before cancer diagnosis, while after cancer 
diagnosis the mean HbA1c did not change (0.03%; 95% CI -0.25 to 0.31; 0.3 mmol/
mol; p=0.8; not shown).
Rectal cancer
For RC patients the crude linear model had an intercept, the estimate for HbA1c 
at cancer diagnosis, of 7.1% (53.5 mmol/mol) (Table 2). Before cancer diagnosis 
the mean HbA1c decreased with 0.18% per year (95% CI 0.08 to 0.28; 2.0 mmol/
mol; p=0.0006), whereas per year after cancer diagnosis the mean HbA1c changed 
not-significantly with +0.04% (95% CI -0.09 to 0.16; 0.4 mmol/mol; p=0.59). Among 
subgroups, the effects of time in relation to cancer diagnosis on HbA1c were less 
clear for incident GLD users, with a decrease in mean HbA1c of 0.13% per year 
(95% CI -0.01 to 0.26; 1.4 mmol/mol; p=0.07) before cancer diagnosis and a still 
non-significant change in mean HbA1c of 0.06% per year (95% CI -0.14 to 0.25; 
0.6 mmol/mol; p=0.56) after cancer diagnosis. Among insulin users the mean 
HbA1c decreased with 0.32% per year (95% CI 0.17 to 0.48; 3.5 mmol/mol; 
p=0.0001) before cancer diagnosis. After adjusting for baseline BMI, mean HbA1c 
increased with 0.18% per year (95% CI -0.01 to 0.37; 2.0 mmol/mol; p=0.07) (Table 
2). In patients with stage IV RC, the mean HbA1c did not change before cancer 
diagnosis (-0.02%; 95% CI -0.30 to 0.27; 0.2 mmol/mol; p=0.9; not shown), while 
after cancer diagnosis the mean HbA1c decreased sharply, although this was not 
significant (-0.26%; 95% CI -0.97 to 0.44; 2.9 mmol/mol; p=0.4; not shown).
Discussion
This population based study revealed that among CC and RC patients that used 
GLDs more than two years prior to cancer diagnosis, mean HbA1c levels decreased 
from two years before cancer diagnosis till cancer diagnosis with 0.1%-0.2% (1 to 
2 mmol/mol) per year. After the diagnosis of cancer, only among CC patients, 
mean HbA1c levels increased statistically significant with 0.1% (1 mmol/mol) per 
year within the two years after cancer diagnosis and thus returned to the levels as 
before. The effects seen both pre and post cancer diagnosis were more 
pronounced in patients with proximal colon tumours and users of anti-anaemic 
preparations before the diagnosis of CC. 
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For the decrease of HbA1c before the diagnosis of cancer various hypotheses 
could be given, regarding both direct and indirect effects of the tumour on glucose 
metabolism in individuals with diabetes. Compared with normal cells, cancer cells 
use a disproportional share of the nutrients in their environment, partly because 
they metabolize glucose by aerobic glycolysis, i.e. the Warburg effect24. Since this 
pathway of obtaining energy is very inefficient, cancer cells need more glucose 
for the same amount of Adenosine triphosphate (ATP), the principal molecule that 
drives all energy-dependent cellular processes24. The abnormal metabolism due 
to the tumour and the reduced intake of food often observed in patients with 
cancer might cause cancer cachexia, since they result in a negative protein and 
energy balance with loss of adipose tissue, skeletal muscle and weight loss25. 
Indirectly this may all lower the glucose levels and as a result the levels of HbA1c. 
Studies on weight changes before the diagnosis of cancer are rare, but that weight 
loss is common among CRC patients is well known26,27. Moreover, an older study 
showed that the achievement of modest weight loss of ±10 kg in one year through 
a behavioural weight loss programme was associated with reductions in HbA1c of 
1.1%28. Nevertheless, the weight loss of ±10 kg as a result of cancer might have 
a totally different impact on HbA1c-values compared with the weight loss among 
individuals with diabetes involved in a weight loss programme. Baseline BMI was 
missing for 60% of the patients, although this was rather high, this seems to be at 
random, because data from clinical laboratories was missing for geographical 
regions within the cohort and reflects no specific patient selection. However, the 
lack of longitudinal data for BMI is an important limitation in our study, future 
studies should investigate the impact of weight loss instead of baseline weight 
on the decrease in HbA1c in cancer patients. 
After cancer diagnosis, HbA1c was increasing and returning to comparable levels 
as seen 2 years before cancer diagnosis. This rapid increase might be the result 
of patients returning to their normal food intake and lifestyle habits. Also, the 
natural course of diabetes has been described, showing an HbA1c increase per 
year of 0.05% (0.5 mmol/mol)29. Although we hypothesised that surgery and the 
administration of chemotherapy would result in increased HbA1c levels30,31, HbA1c 
over time was not different in the different treatment groups. On the other hand, 
the administration of chemotherapy might indirectly result in decreased HbA1c 
levels, because the important side effect of chemotherapy, the loss of appetite, 
might lower the glucose levels32. Thus, the administration of chemotherapy is 
hypothesised to result in decreased as well as increased HbA1c-levels and together 
the net result on HbA1c can be zero. 
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In our study, patients with CC and RC were different from one another with regard 
to their HbA1c trajectory, as well as with regard to the number of users of insulin 
and anti-anaemic preparations, the age distribution and the proportion of males. 
After adjusting for these baseline differences, the effects among both tumour 
types seemed more comparable. 
CC patients who had a proximal colon tumour or used anti-anaemic preparations 
before cancer diagnosis had a more profound decrease in HbA1c pre-cancer 
diagnosis. In line with the potential correlation between proximal colon tumours 
and anaemia in our study, a study found that the prevalence of anaemia diminished 
gradually as the location of the tumour was more distal towards the rectum, 
prevalence percentages were 68%, 40% and 30% for proximal colon, distal colon 
and RC, respectively33. Since HbA1c levels reflect changes in glucose during the 
lifespan of an erythrocyte, changes in this lifespan can affect HbA1c. An increase 
in the mean age of erythrocytes will increase HbA1c, while rapid red cell turnover 
leads to a greater proportion of younger red cells and falsely low HbA1c levels. 
Haemolysis, anaemia, iron, vitamin B12, or folate deficiency, or the treatments for 
these, all will be able to influence the levels of HbA1c16. Interestingly, anaemia and 
iron deficiency are frequently present in patients with CRC, according to one study, 
in respectively 35% and  52% of the CRC patients17. The observed decrease and 
increase of HbA1c in this study might just reflect the effects of these factors on 
HbA1c, while the actual glucose metabolism does not change. In the sub analysis 
in which patients who were dispensed an anti-anaemic treatment before cancer 
diagnosis were excluded, the effect of time on HbA1c almost disappeared, which 
supports the hypothesis that HbA1c is not a valid measure in patients treated for 
anaemia. Accordingly, it would be of interest to see the change in HbA1c in light 
of the change in Hb, unfortunately, in our analyses we were not able to investigate 
this, because of low patients numbers when analysing the Hb longitudinally as 
well. For this study we used data from daily practice. As a consequence of this, 
evaluating the changes in glucose levels due to cancer would not have given 
reliable results, since the decision of the physician to measure the bloodglucose 
is already biased.
In summary, this study revealed that HbA1c-values change around the diagnosis 
of CC and RC, with levels decreasing from two years before cancer diagnosis till 
cancer diagnosis for both cancer types and increasing within the two years after 
cancer for CC. The most profound HbA1c changes were seen for those patients 
who had a proximal colon tumour or used anti-anaemic preparations before cancer 
diagnosis. Thus, the observed decrease and increase of HbA1c in this study might 
just reflect the effects of anaemia, iron deficiency and the treatment for these on 
HbA1c, while the actual glucose metabolism did not change. This study addressed 
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that among individuals that use GLDs and have beside a decrease in HbA1c also 
anaemia and weight loss, physicians should be aware of the possible presence 
of cancer.  In addition, physicians should be aware that the HbA1c measure to 
monitor glycaemic control might be an inappropriate test in those with an (un)
diagnosed cancer and thus need to be careful when stopping GLDs because of 
improved levels of HbA1c. Nevertheless, against our hypothesis, the presence of 
cancer did not result in worse glycaemic control in our studied population. 
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Abstract
Aims: Adherence to glucose lowering drugs (GLDs) is crucial for metabolic control 
and improving prognosis. Because a diagnosis of cancer might impact medication 
adherence, this study explored changes in adherence to GLDs following a cancer 
diagnosis.
Methods: All new users of GLDs between 1998 and 2011 who lived in the ECR- 
PHARMO catchment area were selected. Those with a primary cancer diagnosis 
during follow-up were considered cases and matched with eligible controls without 
cancer during follow-up. Medication Possession Ratio (MPR) was used as indicator 
for medication adherence. Segmented linear auto-regression analysis with 
interrupted time-series was used to assess changes in MPR for cases compared 
to controls (i.e. overall trend) due to (any) cancer diagnosis and specific cancer 
types. 
Results: From the 52,228 GLDs users selected, 3,281 cases with cancer and 12,891 
controls without cancer during follow-up were included in the study. In our 
analyses, before cancer diagnosis the MPR increased by 0.10% per month (95% 
CI 0.10% to 0.10%). Besides a significant drop in MPR at the time of cancer 
diagnosis of -6.3% (95% CI -6.5% to -6.0%), there was an ongoing, yet lower, 
monthly decline in MPR (-0.20%; 95% CI -0.21% to -0.20%) after cancer diagnosis. 
The largest drops in MPR at the time of cancer diagnosis, in the range of 12-15%, 
were seen among patients with stage IV disease and gastrointestinal or pulmonary 
cancers. 
Conclusions: Our findings indicate a clear decline in adherence to GLDs following 
a cancer diagnosis. The reason for the decline in MPR needs to be further 
elucidated. 
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Introduction
Cancer patients with diabetes have a significantly higher overall mortality risk 
compared with patients without diabetes1-3. To understand the association 
between diabetes and cancer, the American Diabetes Association and American 
Cancer Society reviewed the state of science regarding this in 20104. One of the 
key goals of the review was to gain a better understanding of whether diabetes 
influences cancer prognosis above and beyond the prognosis conferred by each 
disease independently. Since that report, most research has focussed on the 
influence of diabetes and glucose lowering drugs (GLDs) on outcomes after cancer 
diagnosis; on the contrary, cancer might affect outcomes associated with diabetes. 
Achievement of normal or near normal glycaemia (HbA1c goal of <7%; 53 mmol/
mol5) among individuals with diabetes is strongly linked with medication 
adherence6,7. Overall, only 65%-85% of GLDs users are regarded as adherent8,9; 
this might decrease even more due to the diagnosis of cancer. If the presence of 
a cancer diagnosis can influence medication adherence among GLDs users, this 
could also affect HbA1c levels leading to poor metabolic control, higher risk of 
diabetes complications and worse overall mortality. Today, only one – very recent 
– study has examined the impact of a cancer diagnosis on medication adherence. 
Among 509 individuals with diabetes, the diagnosis of breast cancer has been 
associated with a decline in medication adherence – measured with the medication 
possession ratio (MPR) – from 86% to 49%10. Although the investigators measured 
the MPR among those with breast cancer, the natural course of adherence to GLDs 
among diabetic patients without cancer is unknown. Therefore, we aimed to 
evaluate changes in adherence to GLDs due to a cancer diagnosis, taking into 
account the changes in adherence to GLDs among those without cancer.
Methods
Data sources
Data were obtained from the PHARMO Database Network and linked at the 
individual patient level to the Eindhoven Cancer Registry (ECR). The data covered 
a demographic region in the Southern part of the Netherlands, for approximately 
one million inhabitants. The construction and validity of the ECR-PHARMO cohort 
have been described elsewhere11. The PHARMO Database Network is a large, 
patient-centric data network including multiple linked observational databases 
designed for safety and outcomes research of drugs. For this study the community 
pharmacy (out-patient) database was used, which includes data on the dispensed 
drug, dispensing date, amount dispensed, and thus the duration of use could be 
calculated. All drugs are coded according to the Anatomical Therapeutic Chemical 
(ATC) classification12. The ECR, maintained by the Netherlands Comprehensive 
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Cancer Organisation (IKNL), records data on all patients newly diagnosed with 
cancer in the Southern part of the Netherlands, an area with 2.4 million inhabitants. 
Six pathology departments, 10 community hospitals, and two radiotherapy 
departments notify the registry. Trained registration clerks actively collect data 
on patient characteristics, cancer diagnosis, staging, and initial treatment from 
hospital medical records. Both the ECR and the PHARMO Database Network are 
recognised as high quality sources for epidemiological research that collect 




The source population included all patients living in the geographical region of 
the ECR-PHARMO cohort and being aged over 30 years with a dispensing of GLDs 
(ATC code: A10) between January 1, 1998 and December 31, 2011 (n=81,928). 
From this source population, we selected incident users of GLDs who had two or 
more dispensings of GLDs preceded by a six-month period without any GLDs 
dispensing (n=52,228). 
Users of GLDs with a primary diagnosis of any cancer (except non-melanoma skin 
cancer) were considered cases and the date of the first cancer diagnosis (i.e. a 
confirmed cancer by pathology) was set as the time of the event. Those GLDs 
users without a diagnosis of cancer were eligible as controls. By including controls 
we were able to account for the overall course (i.e. secular trend) in medication 
adherence seen in individuals with diabetes. Cases and controls were matched 
- with replacement and a maximum of 4 controls per case – on age (according to 
five-year age groups), sex, duration of follow-up (controls needed to have a similar 
or longer duration of follow-up than the total follow-up time for their cases), 
calendar year of first GLDs dispensing (according to two-year periods) and type 
of first dispensed GLDs (metformin monotherapy, sulfonylurea derivatives 
monotherapy, any insulin or other GLDs groups). Both the time till the diagnosis 
of cancer and the total time of follow-up for the cases was then set as the same 
time for their controls. Because controls did not have an ‘actual’ cancer diagnosis, 
we needed to define an index date for the controls. We assigned this as the date 
associated with the same duration of GLDs use at cancer diagnosis as for their 
case.
For the primary analysis we were interested in the change in medication adherence 
potentially associated with any cancer diagnosis, but also associated with one of 
the six most frequent cancer types/groups classified according to the International 
Classification of Diseases of Oncology (ICD-O): colorectal (C18-20), other gastro-
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intestinal (C15-17, C21-C26; oesophageal, stomach, pancreas and liver), prostate 
(C61), breast (C50), pulmonary (C33-34, C45) and urinary (C64-68) cancer13. 
Drug episodes for measuring medication adherence
For each oral drug dispensing (i.e. except insulin: ATC-code A10A12) the duration 
of use was calculated by dividing the number of tablets dispensed by the number 
of tablets to be used per day, as defined in the outpatient pharmacy database. 
For insulin, the duration of use is not often registered in the pharmacy. The 
intended period of use for which insulin was dispensed was set to 90 days when 
the duration of use was missing or considered unlikely. 
All dispensings for GLDs, regardless of type, were converted into episodes of 
uninterrupted use. For each dispensing, the duration of use was calculated and 
converted into episodes of consecutive use based on the method of Catalan14. In 
this method, the time span was the date of the first dispensing until the end date 
of the final dispensing together with the permissible gap. This gap was determined 
to be either half the period of the given dispensing or seven days, whichever was 
greater. Because many patients resumed the same treatment within two months 
of the end of the previous episode, we expanded the permissible gap between 
drug dispensings of the same drug with an additional 45 days. 
We used the Medication Possession Ratio (MPR) as an indicator for medication 
adherence, representing the amount of medication patients had in possession 
over a certain time period. Thus, a 10% decline in MPR translates to a difference 
of 3 days in a 30 day month that is not covered by the use of GLDs due to the 
cancer diagnosis. The MPR was calculated every month for both cases and controls 
by dividing the cumulative days of drug exposure by the total number of days in 
that time window15. Lastly, for every month (i.e. every time window) the MPR for 
cases was compared with the MPR for matched controls, these controls represented 
the overall trend among individuals with diabetes but without cancer. Thus, the 
impact of cancer on MPR for cases was set against this background trend. 
Statistical analyses
Differences in demographic and clinical characteristics between users of GLDs 
with any cancer and their controls were analysed using chi square and the t-test 
where applicable. 
We used the method for interrupted time-series analysis16, with monthly time- 
windows for the MPR in cases and controls. A segmented linear auto-regression 
analysis was used to statistically measure the changes in MPR in intercept and 
slope in the post-cancer period compared to the pre-cancer period. The regression 
model used to fit our data included a continuous variable for time from first 
dispensing of GLDs until the end of that time window, a binary variable for time 
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occurring before or after the diagnosis of cancer, and a continuous variable for 
time after cancer. The parameter estimates for the binary variable as well as for 
the variable for the time after cancer are of main interest, whereas the parameter 
for time from first dispensing of GLDs controls for the overall trend in MPR 
regardless of a cancer diagnosis. We calculated the Durbin-Watson statistic to 
test for the serial autocorrelation of the error terms in the regression models. We 
corrected for any autocorrelation according to the order (number of lags), which 
was given by the Durbin-Watson statistic to be significant. All final models had a 
Durbin-Watson statistic value close to the preferred value of 217. A p-value <0.05 
was considered statistically significant. Analyses were performed using SAS 
software (version 9.4, SAS institute, Cary, US).
Regression analyses were performed for all cancers combined and for the 
previously mentioned cancer types separately. In addition, we stratified the 
analyses for the TNM stage of cancer as well as for the cancer treatment received, 
to explore their effects on the medication adherence in our study population. 
Additional subgroup analyses were performed, in which we stratified according 
to age groups (<60, ≥60 and <70, ≥70) and according to the type of GLDs used 
at cancer diagnosis, because a cancer diagnosis might impact adherence different 
in these subgroups.
Because patients with a recent start of GLDs might differ in their medication 
adherence compared to long time users, users of GLDs who started using GLDs 
in the 6 months prior to cancer diagnosis were excluded in a sensitivity analyses. 
To evaluate whether medication adherence was influenced directly by mortality, 
a sensitivity analyses was performed in which only those patients who died during 
follow-up were included. 
Results
From the ECR-PHARMO cohort, 3,281 cases with cancer and 12,891 controls 
without cancer were selected (Table 1). The mean (standard deviation (SD)) age 
at the start of GLDs use was 67.6 (9.7) years for cases and 67.7 (9.8) years for 
controls (p=0.3). Most patients started with their GLDs use before 2005. Time 
between the start of GLDs use and the date of cancer diagnosis (or index date for 
controls) was 3.7 (3.0) years for both groups and the total duration of follow-up 
was 6.6 (3.5) years for cases and 6.5 (3.5) years for controls (Table 1). Before cancer 
diagnosis or index date for the controls, 33% of the cases stopped with the use 
of GLDs and among the controls the number of patients that used insulin or 
combination treatment increased (Table 1).
In our analyses, before cancer diagnosis the MPR increased by 0.10% per month 
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(95% CI 0.10% to 0.10%) (Table 2, Figure 1). Besides a significant drop in MPR at 
the time of cancer diagnosis of -6.3% (95% CI -6.5% to -6.0%), there was an 
ongoing, yet lower monthly decline in MPR (-0.20%; 95% CI -0.21% to -0.20%) 
after cancer diagnosis, both indicating a clear decline in medication adherence 
because of cancer. 
When we stratified the analysis for the type of cancer, different effects were seen 
for the various tumour types (Table 2, Figure 2). While no important decline in 
MPR was seen at the time of diagnosis for prostate (2.1%; 95% CI 1.4% to 2.8%) 
and breast cancer (-0.5%; 95% CI -1.2% to 0.3%), large drops were seen among 
patients with oesophageal, stomach, pancreas or liver cancer (-12.5%; 95% CI 
-13.4% to -11.6%) and pulmonary cancers (-15.2%; 95% CI -16.0% to -14.4%) 
(Figure 2). Among those patients with large drops, the MPR after cancer diagnosis 
decreased approximately 0.5% monthly, indicating ongoing declining medication 
adherence in cases (oesophageal, stomach, pancreas or liver cancer -0.45%; 95% 
Figure 1. Change in MPR (%) due to cancer, in which the diagnosis of any 
cancer was set on 42 months (3.5 years).*
*The change in MPR for cases was set against the background trend, i.e. the overall trend in MPR among individuals 
with diabetes/ the controls.
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Table 1 Characteristics of study population (n=16,172).
Users of GLDs who 
developed cancer
(n=3,281)
Matched users of 
GLDs without cancer
(n=12,891)
n (%) n (%) p-value
Patient characteristics
Age at first GLDs dispensing (years; Mean (SD)) 67.5 (±9.7) 67.7 (±9.8) 0.3
Male 1839 (56) 7218 (56) 1.0
Year of initiation of GLDs use
   1998-2001 1030 (32) 4030 (31)
   2002-2005 1286 (39) 5059 (39)
   2006-2009 860 (26) 3386 (27)
   2010-2011 105 (13) 416 (3) 1.0
Use of GLDs
At start of use of GLDs
   Metformin monotherapy 1627 (50) 6442 (50)
   Sulfonylurea derivatives monotherapy 1308 (40) 5163 (40)
   Insulin (monotherapy or combination with) 199 (6) 742 (6)
   Other GLDs 147 (4) 544 (4) 0.8
At cancer diagnosis/index date
   Metformin monotherapy 836 (25) 4144 (32)
   Sulfonylurea derivatives monotherapy 826 (25) 3434 (27)
   Combination of metformin and sulfonylurea derivatives 155 (5) 1032 (8)
   Insulin (monotherapy or combination with) 280 (9) 1438 (11)
   Other GLDs 112 (3) 620 (5)
   No use of GLDs 1072 (33) 2223 (17) <0.0001
Cancer
Specific types of cancer 
   Colorectal cancer 549 (17) n.a.
   Oesophageal, stomach, pancreas or liver cancer 387 (12)
   Prostate cancer 377 (11)
   Breast cancer 415 (13)
   Pulmonary cancers 425 (13)
   Urinary cancer 390 (12)
   Other types of cancer 738 (22)
Time between GLDs start and cancer/index date 
(years; means (SD))
3.7 (±3.0) 3.7 (±3.0) 0.8
TNM stage
   Non-invasive 249 (8) n.a.
   I 679 (21)
   II 972 (20)
   III 498 (15)
   IV 612 (19)
   Unknown 571 (17)
Received cancer treatment
   Surgery 1725 (53) n.a.
   Chemotherapy 719 (22)
   Radiotherapy 827 (25)
GLDs: glucose lowering drugs; SD: standard deviation. Index date: Because controls did not have an ‘actual’ cancer 
diagnosis, we needed to define an index date for the controls. We assigned this as the date associated with the same 
duration of GLDs use at cancer diagnosis as for their case.
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CI -0.47% to -0.42%; pulmonary cancers -0.54%; 95% CI -0.56% to -0.52%). In 
patients with oesophageal, stomach, pancreas or liver cancer, the largest declines 
were seen for liver and oesophageal cancer (-35.3%; 95% CI -39.1 to -31.5 and 
-19.2%; 95% CI -20.9% to 17.4%; respectively) (Appendix 1). Within the group of 
pulmonary cancers both small cell and non-small cell lung cancer had comparable 
declines in MPR (Appendix 1). However, for each extra month after cancer 
diagnosis, the MPR declined further with almost 1% each month among pancreas 
and small cell lung cancer (-0.97%; 95% CI -1.01% to -0.93% and -0.89%; 95% CI 
-0.95% to -0.84%, respectively) (Appendix 1). When comparing colon and rectal 
cancer patients, the degree of drop in MPR at cancer diagnosis remained for colon 
cancer patients, whereas it disappeared for rectal cancer patients (Appendix 1). 
The higher the TNM stage, the greater the observed decline in medication 
adherence at cancer diagnosis (Table 3). Among patients with stage IV disease, 
the drop in MPR was -10.7% (95% CI -11.3% to -10.1%), while each extra month 
after cancer diagnosis the MPR declined an additional -0.64% (95% CI -0.66% to 
-0.62%). Although no effect modification by chemotherapy or radiotherapy 
administration was seen, cancer patients who did not receive surgery had a more 
pronounced drop in MPR at cancer diagnosis (-10.8%; 95% CI -11.2% to -10.4%), 
compared to those who did receive surgery (-2.8%; 95% CI -3.1% to -2.4%; Table 
3). The impact of cancer on medication adherence was significant for all age 
groups, but with larger decreases in MPR with increasing age. Moreover, after 
cancer diagnosis, the decline in MPR was larger with increasing age (Table 3). The 
impact of a cancer diagnosis on MPR was most apparent among patients that used 
sulfonylurea derivatives in combination with metformin and among patients that 
used insulin as monotherapy or combination therapy at cancer diagnosis (Table 
3). The inclusion of only long time GLDs users or the inclusion of those who died 
during follow-up resulted in comparable estimates for the MPR at cancer diagnosis 
and for the monthly MPR change after cancer diagnosis (Table 3). 
Table 1 Characteristics of study population (n=16,172) (Continued).




of GLDs without 
cancer
(n=12,891)
n (%) n (%) p-value
Follow-up
Duration of follow-up (years; means (SD)) 6.6 (±3.5) 6.5 (±3.5) 0.5
End of follow-up
   Death 1189 (36) n.a.
   Loss to follow-up 42 (1)
   End of follow-up 2050 (63)
GLDs: glucose lowering drugs; SD: standard deviation.
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Figure 2. Change in MPR (%) due the different cancer types, in which the
diagnosis of cancer was set on 42 months (3.5 years).* 
*The change in MPR for cases was set against the background trend, i.e. the overall trend in MPR among individuals 
with diabetes/ the controls.
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Discussion
This population-based study revealed that among new GLDs users, the diagnosis 
of cancer negatively influenced medication adherence, with a decrease in MPR 
of 6% at the time of cancer diagnosis. Importantly, the influence of cancer on GLDs 
adherence seemed to be influenced by the type of cancer, with more pronounced 
effects among patients with oesophageal, stomach, pancreas or liver cancer and 
pulmonary cancers. Also, more advanced cancer stages at diagnosis resulted in 
substantially lower MPRs at the time of cancer diagnosis. 
In this study, the MPR drop of 6% at the time of any cancer diagnosis translates to 
a difference of 2 days in a month that is not covered by the use of GLDs due to 
the diagnosis of any cancer. The sensitivity of the MPR as an indicator for medication 
adherence has been assessed in many studies. In general, a MPR of over 80% is 
indicative of being adherent to the drug15,18. Consequently, a 20% MPR drop 
because of cancer would be considered the cut-off for an adherent compared to 
a non-adherent GLDs user. Based on these values, it may be that the overall decline 
of 6% we observed may not be considered clinically important. On the other hand, 
the decline in MPR observed in patients with more severe or advanced cancers 
may be considered clinically important.  
Interestingly, previous studies showed that relatively small changes in MPR are 
associated with changes in metabolic control6,7. In one study, a statistically 
significant 48% decrease in the odds of poor glycaemic control (HbA1c >8%) was 
found for each percentage increase in MPR (OR 0.5; 95% CI 0.4-0.6)6. A previous 
study showed that individuals with diabetes and recent HbA1c values >9.0% (OR 
1.5; 95% CI 1.3-1.7) had higher mortality compared to those with recent ‘normal’ 
HbA1c values between 6.5% and 9%19. Thus, the drop in MPR observed among 
patients with cancer in our study might have negatively influenced survival via the 
mechanisms as mentioned-above and may (partly) explain the established 
association between diabetes, cancer and survival1-3.
The diagnosis of prostate and breast cancer seemed to have no influence on 
medication adherence in GLDs users, which is the opposite of what was previously 
observed among 509 American breast cancer patients10. In this study, one year 
before the cancer diagnosis the MPR was 85% in these patients, while during the 
treatment period of cancer (cancer diagnosis until 210 days after) it declined to 
49%10. Although this decline in MPR is remarkable, the absence of a control group 
without breast cancer and lack of information on drug duration are limitations of 
this study10. The control group is needed, because generally, the MPR does tend 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































156 | Chapter 9
9
having drug durations of <10 years, approximately two-thirds of the patients had 
a MPR under 65%20. 
In our study, among oesophageal, stomach, pancreas or liver cancer and 
pulmonary cancer, the impact of cancer on adherence was large. While it is 
indisputable that drops of around 15% in MPR have their influence on metabolic 
control and mortality, we need to understand how medication adherence among 
users of GLDs was particularly influenced by these types of cancer. Compared to 
the other types of cancer under study, these cancer types are associated with the 
worst prognosis and with the lowest rates of tumour resections21. The hypothesis 
that the prognosis of cancer is associated with medication adherence is 
strengthened by our results revealing that the TNM stage22, which is the most 
important prognostic factor in cancer patients, also seems to be associated with 
medication adherence. Evidence suggests that medication adherence in users of 
GLDs seems to decrease following major life events or when people are under 
stress9,23. A diagnosis of stage IV disease, could be considered such a major life 
event. Users of GLDs with more lethal cancers might prioritize the fight against 
cancer over the effort required to have a good metabolic control for their diabetes. 
This ‘life chaos’ due to another disease was investigated among post-myocardial 
patients24. After adjusting for other potential factors associated with medication 
non-adherence, life chaos, according to questions whether they had a stable or 
organized life, was significantly associated with non-adherence to drugs for 
cardiovascular disease24. Lastly, the prognosis seemed to only partly explain the 
impact of cancer on medication adherence, because among oesophageal cancer 
patients (3-year survival of 17%21), the diagnosis of cancer had a stronger impact 
on medication adherence compared to patients with the most lethal form of cancer, 
pancreas cancer (3-year survival of 6%21). This difference may also be explained 
by symptoms of cancer that might result in intolerable intake of oral drugs, leading 
to discontinuation of GLDs therapy. In addition, the administration of chemotherapy 
might be expected to influence medication adherence, although this was not 
found in our subgroup analyses with patients who did or did not receive 
chemotherapy. In this study, the impact of a cancer diagnosis on adherence 
seemed to depend on the age at first use of GLDs and on the type of GLDs used 
at cancer diagnosis. Although we matched our cases and controls on these criteria, 
the age and the type of GLDs used, i.e. the complexity of the treatment scheme, 
remain important factors to consider when assessing medication adherence.  
Among liver cancer patients (n=23), the diagnosis of cancer strongly influenced 
the MPR with a 35% decline at cancer diagnosis. The association between diabetes 
and liver cancer might reflect some degree of ‘reverse causality’, with liver cancer 
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itself or its related liver diseases (such as cirrhosis) leading to the onset of 
diabetes25. Once the tumour is removed, the insulin resistance might resolve, the 
physician stops the GLDs and the medication adherence declines. Moreover, 
metformin might be stopped, because it is contraindicated in patients with 
advanced liver diseases with associated cirrhosis, ascites, or encephalopathy26. 
Although the real risk is minimal27, the potential of metformin to cause lactatic 
acidosis might lead physicians to withhold metformin in patients with advanced 
liver disease26.
This study had many strengths, such as the inclusion of only new GLDs users with 
a known duration of GLDs use and the inclusion of a matched control group without 
cancer. However, pharmacy records provide no ascertainment whether patients 
were compliant with their medication prescriptions. 
The MPR might be a good indicator for medication adherence, although the 
physician could have advised the patient to stop the treatment with GLDs, which 
could not be investigated. With our data, reasons for stopping their treatment for 
diabetes are unknown - is it because of frequent hypoglycaemic events due to 
cancer28 or intolerable oral intake of drugs? Due to the lack of longitudinal HbA1c 
data, we were not able to understand whether this might be explained by an 
improvement in metabolic control; however, our previous research (unpublished 
data) showed that HbA1c values improved around the diagnosis of cancer. For 
this study we only had information from outpatient pharmacies, these do not 
include drugs used within the hospital or within nursing homes. This might have 
resulted in an overestimation of MPR decline. Another limitation was that for some 
patients we missed information on the duration of the dispensed insulin, we might 
have wrongly estimated these dispensings on 90 days.
The interrupted time series analysis is only valid to the extent that the cancer 
diagnosis was the only event that changed over time and the only event that was 
able to change the monthly calculated MPR16. In this study, the visit of an 
endocrinologist by the patient because of vague complaints of an undiagnosed 
cancer might be a competing event29. Moreover, missing dispensing data – for 
example because of hospitalisations –might  falsely give the impression that 
medication adherence had fallen when in fact the data was simply missing. Because 
the database of PHARMO was linked to the ECR for the cancer incidence years 
1998-2011, we were not able to exclude the users of GLDs with a previous or 
recent cancer diagnosis. Thus, at the start of use of GLDs the medication adherence 
might already have been influenced by cancer.  
In summary, this study revealed that the medication adherence among users of 
GLDs was influenced by cancer diagnosis. Although the impact of cancer was 
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more pronounced among cancers with a worse prognosis and among those with 
more advanced TNM stages, the difference in prognosis associated with these 
cancers seemed to only partly explain the impact of cancer on medication 
adherence. The decline in adherence seen among users of GLDs with cancer 
might negatively impact survival and (partly) explain the established association 
between diabetes, cancer and survival1-3. In future studies, the reason for the 
decline in MPR needs to be further elucidated among the different cancer types 
-  is it the patient who prioritizes the fight against cancer or the advice of the 
physician to stop the treatment? 
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Summary of results 
The research underlying this thesis aimed to understand how the combined effect 
of cancer and diabetes results in a worse mortality than the sum of the individual 
effects of cancer and diabetes.
The main objectives of the studies described in this thesis were:
• To assess the impact of diabetes on cancer treatment, cancer recurrence, 
cancer-specific and overall mortality in cancer patients.
• To assess whether, and to which extent, metformin, statin and aspirin use is 
associated with overall mortality in colorectal (CRC) patients with diabetes.
• To explore changes in glycaemic control and medication adherence among 
individuals with diabetes at the time of cancer diagnosis.
This thesis started with a general review in which we investigated the role of many 
factors that seem to be related with the association between diabetes, cancer and 
deteriorated outcomes among those with both diseases (Chapter 2). These factors 
are the presence of comorbidities and common risk factors, like ageing, smoking, 
unhealthy diet, obesity and physical inactivity. Moreover, newly designed studies 
should account for the stage of cancer and treatment differences and need to 
focus on tumour-related outcomes such as the risk of recurrence and cancer-
specific survival. Thus, understanding the relationship between diabetes, cancer 
and prognosis is a major challenge, since new studies should adjust for the 
abundance of factors associated with diabetes, cancer and survival. 
If diabetes affects the tumour characteristics at diagnosis, the administration of 
cancer treatment or cancer-specific outcomes, then diabetes may have a major 
impact on mortality among cancer patients. Within this thesis, the influence of 
diabetes on cancer stage at diagnosis, cancer recurrence, and survival of EC 
patients was investigated among endometrial cancer (EC) patients (Chapter 3). 
The population-based Eindhoven Cancer Registry (ECR) was used to select all 
1,644 newly diagnosed EC patients between 2000-2008 with FIGO stage I-III. 
Patients with diabetes were diagnosed more often with a higher FIGO stage and 
had worse overall survival compared to patients without diabetes. Additionally, 
we collected data for a subgroup of 193 EC patients with diabetes and an 
age-matched sample of 195 EC patients without diabetes. In this subgroup, no 
association between diabetes status and recurrence rates was found. Moreover, 
after adjusting for a higher FIGO stage at diagnosis, no influence of diabetes on 
the EC-specific higher mortality was found. 
Since the administration of cancer treatment impacts the chances of cure and 
survival, we investigated whether CRC patients with diabetes were treated less 
aggressively for their cancer compared to patients without diabetes (Chapter 4). 
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In this study we included 11,893 patients diagnosed with colon cancer and 5,277 
with rectal cancer, of whom 1,711 (14%) and 609 (12%), respectively, had diabetes 
at the time of cancer diagnosis. Stage III colon cancer patients with diabetes 
received chemotherapy less often compared to those without diabetes (Odds 
Ratio (OR) 0.7; 95% CI 0.5-0.9; p=0.002). In addition, in both groups of patients 
the use of chemotherapy in patients with colon cancer increased sharply over 
time. Furthermore, the proportion of stage II/III rectal cancer patients with and 
without diabetes who received radiotherapy increased to a similar rate in recent 
years (81% and 87%, respectively). In conclusion, this study showed that the 
proportion of CRC patients with diabetes receiving radiotherapy and chemotherapy 
increased. Nevertheless, patients with diabetes still received chemotherapy less 
often than those without.
In the last decade the evidence accumulated that the association between diabetes 
and mortality among cancer patients varied with glucose lowering drugs (GLDs). 
In this thesis we aimed to assess whether CRC patients who used metformin or 
sulfonylurea derivatives after cancer diagnosis differed in the risk of overall 
mortality (Chapter 5). In our multivariate time-dependent Cox proportional hazards 
model, we observed that cumulative metformin exposure after CRC diagnosis 
was not associated with decreased overall mortality compared with sulfonylurea 
derivatives exposure. However, at the start of use of GLDs CRC patients using 
metformin already had a 59% lower hazard for overall mortality compared to those 
starting with sulfonylurea derivatives, suggesting that these users have favourable 
prognostic factors at the start of their drug use. 
This thesis includes a published correspondence to the authors of another study 
on metformin, cancer and survival (Chapter 6) as it describes some methodological 
problems that arise in these pharmaco-epidemiological analyses. The results of 
the study by Margel et al.1 – using Cox proportional hazards model with drug 
exposures after prostate cancer diagnosis as time-dependent covariates – might 
be affected by allocation bias (those prescribed and not prescribed the drug differ 
in their prior susceptibility to die), which could not be avoided by the inclusion of 
cumulative drug exposure exclusively as supposed by the authors. 
Statins and aspirin are two medications frequently prescribed to individuals with 
diabetes, that have also been associated with decreased overall mortality in cancer 
patients. We assessed the independent effects of metformin, statins and aspirin 
after CRC diagnosis on overall mortality within GLDs users that started their 
treatment before cancer diagnosis (Chapter 7). The Cox regression model, with 
CRC diagnosis as baseline, included time-dependent variables of cumulative 
exposure to metformin, statins and aspirin after cancer diagnosis and time- 
dependent ever-never terms for drug exposure. Longer cumulative exposure to 
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metformin was not associated with overall mortality, while the favourable effect 
of statins increased with cumulative drug exposure. No statistically significant 
association between aspirin use and overall mortality was observed. Our findings 
support a drug effect of statins, independent of metformin and aspirin, in CRC 
patients using GLDs.
Most of the previous studies on the association between diabetes, cancer and 
mortality focussed on the effect of diabetes and its treatment on cancer, while the 
reverse effect of cancer and its treatment on diabetes controls has received very 
limited attention. In this thesis we aimed to evaluate the impact of cancer and its 
treatment on HbA1c-values among individuals using GLDs for more than two years 
prior to their CRC diagnosis (Chapter 8). HbA1c-values changed at the time of 
diagnosis of colon and rectal cancer, with levels decreasing from two years before 
cancer diagnosis till cancer diagnosis for both cancer types and increasing within 
the two years after cancer for colon cancer. The most profound HbA1c changes 
were seen for patients with proximal colon tumours or those using anti-anaemic 
preparations before colon cancer diagnosis. These findings mean that the 
observed changes of HbA1c in this study might just reflect the effects of anaemia 
and anti-anaemic preparations on HbA1c, while the actual glucose metabolism 
does not change. Moreover, physicians should be aware of the possible presence 
of cancer among individuals that use GLDs and have a decrease in HbA1c.
Since a diagnosis of cancer might impact medication adherence and good 
adherence to GLDs is crucial for achieving glycaemic control, in this thesis the 
impact of cancer on medication adherence among new users of GLDs was explored 
(Chapter 9). GLDs users who developed cancer during follow-up (cases) were 
matched with GLDs users without cancer during follow-up (controls). The 
Medication Possession Ratio (%; MPR) was used as indicator for medication 
adherence. While the difference in MPR between cases and controls changed 
significantly at the diagnosis of any type of cancer, the highest impact of cancer 
diagnosis on medication adherence was seen for patients with oesophageal, 
stomach, colon, pancreas and liver cancer and those with small-cell and non-small 
lung cancer, in which the difference in MPR at cancer diagnosis changed around 
15%. In addition, more advanced cancer stages at diagnosis resulted in larger 
changes in MPR at the time of cancer diagnosis. The reason for the decline in MPR 
needs to be further elucidated among the different cancer types -  is it the patient 
who prioritizes the fight against cancer or the advice of the physician to stop the 
treatment?
This thesis contributed to the evidence that the combined effect of cancer and 
diabetes results in a worse mortality than the sum of the individual effects of cancer 
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and diabetes. We revealed that higher mortality rates for EC patients with diabetes 
were most likely caused by diabetes as such. Thus, physicians should be 
encouraged to carefully treat these patients for their diabetes control to prevent 
the development of diabetes complications. Moreover, diabetes affects the 
proportion of CRC patients that received cancer treatment, which in turn might 
affect their chance of cure and thus the prognosis. Our and other studies 
increasingly suggest that there is no association between metformin and mortality 
among CRC patients, while the effects of statin use on mortality among cancer 
patients seems more promising. We showed that glycaemic control among 
individuals with diabetes improved and the adherence to GLDs decreased due 
to cancer. For the day-to-day clinical oncology and endocrinology practice the 
results of this thesis contribute to the awareness of the dangerous liaison between 
diabetes and cancer, with all his facets. 
General discussion
As a result of the dramatic increase in the number of patients with cancer or 
diabetes2-4, the number of newly diagnosed cancer patients who also have 
diabetes is expected to rise from about 5,500 per year in 2000 to 10,000 per year 
in 2015 in the Netherlands2. Therefore, it is of utmost importance to understand 
which factors contribute to the higher overall mortality seen among cancer patients 
with diabetes compared to those without diabetes5-7. 
The objective of this thesis was to understand how the combination of diabetes 
and cancer results in a worse mortality than the sum of the effects of the individual 
diseases. In this chapter, the main findings of the studies performed in this thesis 
will be discussed in a broader context. Several methodological issues are discussed 
that should be considered when interpreting the findings of the studies presented 
in this thesis. Future direction and implications of the research presented are 
discussed as well. 
Main findings 
Impact of diabetes on cancer treatment and outcomes 
Many studies showed that endometrial cancer (EC) patients with pre-existing 
diabetes have a significant increased overall mortality compared to those without 
diabetes5,7-11. Whether this is the result of diabetes on EC-specific outcomes 
remains unknown. In this thesis, no association between diabetes status and 
recurrence rates was found. Furthermore, after adjusting for a higher FIGO stage 
at cancer diagnosis, no influence of diabetes on the EC-specific higher mortality 
was found. It has been suggested that a rapid tumour growth by insulin could 
explain the more advanced FIGO stages among diabetes patients12, but an effect 
on recurrence rate should than be expected as well. After the publication of our 
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study, results of new studies were combined in a meta-analyses which showed no 
association between diabetes and EC-specific mortality either13. Since patients 
with EC have a good prognosis and the number of events for EC-specific outcomes 
is relatively low, this study question might require an even larger dataset than 
available for the published meta-analysis. Nevertheless, the higher mortality rates 
for EC patients with diabetes were most likely caused by diabetes as such. In 
summary, our study as well as others underline that physicians should be 
encouraged and motivated to carefully treat and follow EC patients with diabetes 
for their diabetes control to prevent the development of diabetes complications. 
Furthermore, postmenopausal women with diabetes might have a more advanced 
stage at EC diagnosis, resulting in a higher EC-specific mortality, so extra vigilance 
by the general practitioner for symptoms of EC is needed in this subgroup of 
patients.  
Based on the results among CRC patients, it seems that CRC patients with diabetes 
are still treated less aggressively with regard to chemotherapy. CRC patients who 
do not receive optimal treatment for their cancer have less chance of cure and 
surviving this disease. However, we do not know whether the less aggressive 
treatment indicates that the clinicians appropriately responded to the potential 
higher risk of treatment complications or whether this was inappropriate. In 
contrast, the proportion of stage II/III rectal cancer patients with and without 
diabetes who received radiotherapy increased at a similar rate in recent years. In 
recent years, especially in patients with comorbidity, the overall well tolerated 
radiotherapy15,16 is used as downstaging and not directly followed by surgery. 
This trend could partially explain the tremendous increase in radiotherapy in rectal 
cancer patients with diabetes. 
Impact of drug exposure on mortality after cancer
The current literature regarding metformin as an anti-tumour agent is 
inconclusive14-16. We observed no protective effect of metformin on mortality 
among CRC patients, while others did. Direct comparison between our and other 
studies among CRC patients is difficult given the differences in study population 
and methodology that will be discussed later. However, one study that investigated 
the role of metformin on survival in breast cancer patients used a similar approach 
as we did and had comparable results17. This study failed to show a significant 
association between every additional year of cumulative exposure to metformin 
and overall and breast cancer-specific mortality17. In contrast, a recent study among 
prostate cancer patients showed that prostate cancer-specific mortality decreased 
by 24% for each additional 6 months of metformin use after the diagnosis of 
prostate cancer1. Is it biologically plausible that 6 months of metformin use reduces 
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mortality by 24%? Later in this general discussion I will explain how we came to 
the assumption that the hazard ratio in this study does not exclusively reflect the 
effect of metformin and might be subject to bias.
As many diabetes patients use a combination of metformin, statins and aspirin (in 
our cohort of GLDs users this proportion was 25%), it is justified to wonder if the 
suggested association between metformin use and overall mortality among cancer 
patients is explained by the concomitant use of aspirin or statins, and vice versa18-20. 
Within our analyses, the favourable effect of statins increased with cumulative 
drug exposure, supporting a drug effect of statins, independent of metformin and 
aspirin, in CRC patients using GLDs. Regarding the use of aspirin and statins, it 
should be noted that this study only investigated a subgroup, i.e. the individuals 
with diabetes. Thus, we have to be careful when comparing the results seen for 
statin users directly with other studies on statin use and overall mortality after 
cancer. Results from a study with a comparable methodology indicated that 
post-diagnostic use of statins was associated with a 24% decrease in prostate 
cancer mortality among newly diagnosed non-metastatic patients, with dose 
response relationships in terms of cumulative duration of use and cumulative 
dose19. This study had many strengths, since it circumvented many biases and 
one of the study outcomes was cancer-specific mortality19.
Impact of cancer on glycaemic control and glucose lowering drug use
Most of the previous studies on the association between diabetes, cancer and 
mortality focussed on the effect of diabetes and its treatment on cancer, while the 
reverse effect of cancer and its treatment on diabetes control has received limited 
attention so far. In contrast to our hypothesis that the development of cancer and 
its treatment would increase the value of HbA1c, the presence of cancer lowered 
HbA1c with clear drops at the time of cancer diagnosis. According to a study on 
HbA1c and survival, not only individuals with diabetes and recent HbA1c values 
>9% (75 mmol/mol), but also those with recent HbA1c values <6.5% (48 mmol/
mol; OR 1.3; 95% CI 1.2-1.4) had higher mortality compared to those with recent 
‘normal’ HbA1c values between 6.5% and 9%21. The decrease of HbA1c before the 
diagnosis of cancer might be the result of an abnormal metabolism due to the 
tumour, reduced food intake or weight loss, all associated with cancer cachexia22-24. 
Colon cancer patients who had a proximal colon tumour or used anti-anaemic 
preparations before cancer diagnosis had an even more profound decrease in 
HbA1c pre-cancer diagnosis. In a study among 1,189 CRC patients, anaemia was 
prevalent in 30%, 40% and 68% of rectal, distal colon and proximal colon cancer, 
respectively25. Thus, patients with proximal colon tumours frequently use 
anti-anaemic preparations for their anaemia. Therefore, the rapid red cell turnover 
(i.e. great proportion of younger red cells) due to the treatment of anaemia might 
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result in falsely low HbA1c levels in those with proximal colon tumours26. The 
observed changes of HbA1c in this study might just reflect the effects of these 
factors on HbA1c, while the actual glucose metabolism does not change. 
Consequently, physicians should be aware that the HbA1c measure to monitor 
glycaemic control might be an inappropriate test in this subgroup of patients.
In this thesis a change in medication possession ratio (MPR) of 6% at the time of 
any cancer diagnosis was found. This difference translates to a difference of 2 
days in a month that is not covered by the use of GLDs between patients with and 
without cancer. A 20% MPR difference between patients with and without cancer 
would be considered the cut-off for an adherent compared to a non-adherent 
GLDs user27. The difference in MPR at cancer diagnosis reached almost 20% among 
patients with gastro-intestinal cancers (colon, oesophagus, stomach, pancreas 
and liver cancer) and among patients with pulmonary cancers in which it was over 
15%. Based on 20% to be considered non-adherent, would the observed 
differences of 6% and 15% be clinically significant? Interestingly, previous studies 
showed that relatively small changes in MPR are associated with changes in 
glycaemic control28,29. In one study, a statistically significant 48% decrease in the 
odds of poor glycaemic control (HbA1c >8%; 64 mmol/mol) was found for each 
percentage increase in MPR (OR 0.52; 95% CI 0.44-0.62)28. Nevertheless, we 
previously showed that HbA1c levels decreased at the time of cancer diagnosis, 
suggesting improved glycaemic control. Consequently, the physician might decide 
to discontinue GLDs because of improved glycaemic control, resulting in lower 
MPR (‘worse’ medication adherence) among individuals with diabetes. In 
conclusion, although we observed a lower medication adherence among GLDs 
users because of cancer the clinical implication has to be studied in more detail 
as many factors could have influenced this finding. 
Methodological considerations
The investigation of the association between diabetes, GLDs, cancer and mortality 
is complex, and the studies in this thesis encounter some methodological strengths 
and weaknesses. The accurate analyses of diabetes status and drug exposure are 
important elements of studies in this research field, and are as important as other 
features of study design, adequate sample size and patient selection, appropriate 
adjustment for confounders, and the use of validated data sources30. In this 
chapter, the most important elements with regard to the methodological 
considerations of studies in this thesis are discussed. 




Patients included in the studies described in this thesis may have different cancer 
characteristics compared to other regions in the Netherlands. The region of the 
Eindhoven Cancer Registry (ECR) contains 10 community hospitals and no 
academic or specialized cancer hospitals, does not include one of the top three 
largest cities in the Netherlands and the population is somewhat older than the 
total Dutch population31,32. The ECR is worldwide unique in the registration of the 
presence of comorbid conditions at time of cancer diagnosis33, which was essential 
for several of our studies. 
However, while the ECR collects extensive data on the primary tumour and the 
initial treatment, it does not yet collect information on the presence of recurrent 
disease and the cause of death. The information on cause of death was additionally 
collected for our study among EC patients. This data collection was time-consuming, 
whereas defining the exact cause of death was difficult and subjective as confirmed 
by experts in the field34. Unreliable cause of death information may provide 
misleading results35, which was illustrated by a previous study on CRC-specific 
survival, in which 34% of the rectal cancer patients were registered with colon 
cancer as the underlying cause of death36. Thus, although it is a strength of the 
study that we collected additional data regarding EC-specific survival, the found 
rate of EC-specific survival might be an over- or underestimation. The protective 
effect of statin use on overall mortality in this thesis might be highly attributed to 
the decrease in cardiovascular deaths instead of cancer deaths in this group of 
patients37,38. Since we could not investigate whether the lower over mortality 
among statin users was explained by the potential decrease in cardiovascular 
deaths, the lack of cause of death information is a major limitation. Another 
limitation is that this thesis missed important information on performance status 
of the patients, doses and dose adjustments of chemotherapy and treatment-
related complications. The finding that CRC patients with diabetes less often 
received chemotherapy than those without diabetes might be an underestimation 
of the problem: Based on clinical experience it would be expected that many dose 
adjustments had taken place among cancer patients with diabetes that have not 
been registered and analysed in our studies39. 
PHARMO
A general problem using dispensing data to assess drug use is that we do not 
know if and when the dispensed drugs are actually ingested by patients40. 
Moreover, the out-patient pharmacy database does not include drugs used within 
the hospital or within nursing homes. This may have resulted in an overestimation 
of the effect of statins seen in this thesis, as patients who are sicker will be 
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hospitalised more often and thus have missing dispensing data more often.  
The pharmacy database has information for drugs on prescriptions, while over 
the counter drugs, such as aspirins, could not be captured by our data. Thus, in 
this thesis only aspirin dispensings with the indication “platelet aggregation 
inhibition” (defined by their ATC code41) and considered low dose aspirin 
dispensings (≤100 mg daily) are included. Consequently, the misclassification of 
exposure due to over the counter low dose aspirin use is likely to be minimal, 
because low dose aspirin for this indication is only available on prescription in the 
Netherlands. 
Combined ECR-PHARMO database
In this thesis the overall effects of drug exposure on mortality in a certain type of 
cancer could be investigated. However, subgroup analyses have been of limited 
value because of the relatively small sample size after careful selection of the study 
population. These subgroup analyses could be important to better understand 
the underlying mechanism for the association. Although the combined cohort 
now consists of 13 years of follow-up, after selecting patients that met all the 
criteria which were needed to give reliably results, the mean follow-up periods of 
about 2-3 years for overall mortality were relatively short. For the research 
questions within this thesis a longer duration and larger sample sizes are required 
to better assess the effect of cumulative exposure to metformin, statin and aspirin 
on mortality. In the near future, linkage of the Netherlands Cancer Registry with 
PHARMO will give more opportunities for new research with a cohort four times 
the current size. 
Also, collaboration with international research groups in this field could improve 
our understanding of the association between diabetes, cancer and mortality. For 
example, the established network of the EASD Diabetes and Cancer Study Group 
(previously the Diabetes and Cancer Research Consortium (DCRC)) has a good 
infrastructure to combine data and to collaborate, especially when outcomes are 
rare6,42. This group, in which our research group participates, aims to develop and 
optimize methodological approaches required to address the complex 
relationships between diabetes, GLDs and cancer. 
Bias and confounding 
In 2005, a large observational study was published that reported a significant 
reduction in the cancer incidence with metformin use among 2,829 patients with 
type 2 diabetes43. This publication resulted in great interest in metformin as an 
anti-tumour agent and generated the hypothesis that metformin might lower 
cancer risk among patients with diabetes43. In the years after this study, many 
other studies showed similar effects of metformin on the risk of cancer44,45. In 
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addition, metformin seemed to have a protective effect on overall mortality among 
cancer patients as well46,47. But, today we understand that many of the earlier 
observational studies with too impressive hazard rates contained time-related 
biases and other limitations that artificially made metformin look like a ‘wonderdrug’ 
for the survival after cancer6,16,30,48. In this paragraph I will discuss the most 
important biases and discuss how was dealt with them in this thesis. 
Allocation bias and cumulative drug exposure
Since the medication use of an individual with diabetes varies over time and the 
effect of exposure will depend on duration of use, dose and adherence to therapy, 
a dichotomized variable for drug use frequently used in previous studies39,42-45 
will not be sufficient49. Moreover, the use versus the non-use of a drug is based 
on the decision of a physician, who might even base his decision on the prognosis 
of the patient. This type of bias in pharmaco-epidemiology, known as allocation 
bias (those prescribed the drug of interest may differ in their prior susceptibility 
to survive after cancer when compared to those not prescribed the drug), has 
received increasing attention in the field of diabetes and cancer. It is now advised 
to analyse cumulative exposure in order to prevent this bias30,48. The cumulative 
drug exposure represents the daily or monthly drug use and is not influenced by 
the differences between users and non-users of the drug of interest30,48. The 
inclusion of this cumulative exposure in our studies strengthens the results while 
the hazard ratio for the cumulative exposure to the specific drug gives the effect 
of this drug on survival for every additional day or month of use.
Incident versus prevalent users
To calculate the cumulative exposure of a specific type of drug, the exact duration 
of drug use needs to be known. Since this duration is known for incident users 
(i.e. new users; started with GLDs after entrance in the ECR-PHARMO cohort) and 
not for prevalent users (i.e. started with GLDs at any time before entrance in the 
ECR-PHARMO cohort), prevalent users would ideally be excluded50. Due to the 
sample sizes we were not always able to exclude the prevalent users for all studies 
described in this thesis. Nevertheless, sensitivity analyses excluding prevalent 
users were always performed. Moreover, CRC patients without metformin use 
before cancer might differ from those who did use metformin before cancer. These 
patients might differ in their diabetes severity, cancer stage at diagnosis and 
administration of cancer treatment and thus have a different prognosis already at 
cancer diagnosis. Also, CRC patients who started with GLDs after cancer diagnosis 
might start as a result of the well-known prednisone induced hyperglycaemia 
during cancer treatment51. In our study investigating the effects of metformin, 
statins and aspirin, we were able to adjust for many confounding factors, but not 
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for the presence of diabetes complications, BMI, cholesterol levels and other 
laboratory results. Therefore, residual confounding most likely remained.   
Immortal time bias
The most important type of bias that has been criticized regarding previous studies 
on metformin and mortality after cancer is immortal time bias48. If the exposure 
time between cancer diagnosis and the first dispensing of metformin is classified 
as exposed time, than this time is ‘immortal’, since the patient must be alive to 
receive the first metformin dispensing48. This bias is known to overestimate the 
effect of a drug: the drug seems to be protective while it might have no ‘real’ 
effect48,52. To overcome this bias the exposure variables in Cox proportional 
hazards models need to be time-dependent, which was done in the studies 
presented in this thesis48. In these analyses the person-time is classified as 
unexposed until the first metformin dispensing and the remaining time (after the 
first dispensing) is classified as exposed to metformin48.
Often in studies that investigate effects of drug exposure, cumulative exposure 
represents users with different drug exposures, but also non-users with a 
cumulative exposure equal to zero. In that situation, the events for overall mortality 
for non-users will all be clustered at the cumulative exposure of zero months. As 
a result this point probably represents the majority of events and is therefore 
particularly important in the calculation of the hazard ratio for cumulative exposure. 
As a consequence, the most important comparison of events is the one between 
zero months and for example 6 months of cumulative exposure. The hazard ratio 
of cumulative exposure for the first 6 months of use influences to a large extent 
the slope of the hazard for every following 6 months. Thus, in this study setting, 
the hazard ratio of cumulative exposure is strongly influenced by the prior 
susceptibility to die for non-users compared to users, as previously described, 
known as allocation bias. With the inclusion of time-dependent ever-never terms 
for the studied drugs in the model, the hazard ratio of the cumulative effect term 
seems to be not dependent on the events in the unexposed group53. However, 
the inclusion of time-dependent ever-never terms is still subject of recent debate. 
Some experts in the field fear that the inclusion of both cumulative exposure and 
ever-never terms in a model introduces collinearity (i.e. two variables are highly 
correlated), since never users always have a cumulative exposure of zero days, 
while ever users have cumulative exposures of at least one day. Epidemiologist 
currently debate about this problem and for now it is advised for new studies to 
show different kind of models54-56. Although in the studies in this thesis not all 
models were shown, for our study in chapter 7 this recent discussion has stimulated 
us to additionally conduct the analyses without ever-never terms. It appeared then 
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that the use of statin was even more protective. 
Dose of exposure of a drug of interest
One further methodological consideration is the association between dose and 
duration of exposure – to how many milligrams of the drug was the patient exposed 
during the time studied30? The construction of a combined measure can be carried 
out for the product of dose and duration. The corresponding analyses are even 
more complex than the analyses with time-dependent cumulative exposure. But, 
these analyses might show a dose-response relationship for metformin, statins or 
aspirin use, thus the absence of them was a weakness of our pharmaco-
epidemiological studies. However, peaks of intense exposure to the drug might 
have a greater impact on the outcome than the average exposure, and a simple 
dose-duration product cannot show substantial variations in exposure with time30. 
Current epidemiological studies investigate doses safely obtained in the clinical 
setting, while it has become clear that many preclinical studies use concentrations 
of metformin considerably higher than those57,58. The doses of metformin currently 
used in many oncology trials are those shown to be effective for glucose control. 
If metformin has an effect on mortality, then there is a need to establish the 
appropriate dose of metformin for its proposed anti-cancer effects58. 
Sick-stopper bias
Sick-stopper bias is the result of the fact that sicker patients with a poorer prognosis 
might be more likely to discontinue preventative treatments for non-symptomatic 
illness. This type of bias may be important for different types of medications used 
by patients under study in this thesis. For example, among individuals with 
diabetes, the use of statin as secondary prevention is advised to certain patient 
groups with low-density lipoprotein (LDL) >2,5 mmol/l and ≥10% chance of 
cardiovascular disease or mortality in 10 years based on a risk assessment59,60. 
Because statins are prescribed to prevent and not to treat cardiovascular disease, 
the non-adherence to statins is reasonably high61,62. Thus, especially the effect of 
statin use on survival might be confounded by sick stopper bias, because sicker 
patients with a poorer prognosis might be more likely to discontinue preventative 
treatments for non-symptomatic illness63. In our study after adjusting for the 
medication adherence and after dealing with the discontinuation of statin treatment 
just before death (by changing unexposed time after discontinuation into exposed 
time), this study still revealed a protective effect of statins on overall mortality 
among CRC patients. Since we were not able to verify which patients indeed 
discontinued their statin treatment, these analyses are suboptimal. 
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Healthy user bias
Another bias typical of research on effects of statins is healthy user bias, as statin 
users have been previously described as a selection of individuals who are more 
health-conscious than those who do not use this drug (while needing it)63,64. This 
could have influenced our results and might have overestimated the protective 
effect of statins on overall mortality, since individuals that are more health-
conscious are also likely to pay more attention to other prognostic lifestyle factors64. 
But in contrast to this hypothesis, in our cohort and other studies statin users 
seemed to be less healthy than non-statin users, with higher numbers of 
co-medication, indicating a higher prevalence of comorbidities19.
Unfortunately there is no consensus on the optimal approach to avoid sick stopper 
bias and healthy user bias63,65,66, thus the potential presence of both remains an 
important limitation of the studies in this thesis and might have overestimated the 
protective effect of statins. 
Results from a study with comparable methodology as in chapter 7 indicated that 
the post-diagnostic use of statins was associated with a 24% decrease in prostate 
cancer mortality among newly diagnosed non-metastatic patients19. This study 
had many strengths, it circumvented many biases and included a latency period 
of 1 year, to take into account a biologically meaningful latency time window given 
that short duration exposures are unlikely to be associated with the mortality 
outcomes19,67. In our analyses in chapter 5 and 7 we were not able to include this 
latency period because our follow-up time was rather short which is a weakness 
of our studies. Nonetheless, it remains questionable what the right duration of 
this period is among cancer patients. 
Residual confounding
The review in this thesis underlined that the association between diabetes and 
prognosis in cancer patients is extremely complex, since many underlying risk 
factors, such as age, lifestyle factors, smoking status, comorbidities and/or 
metabolic factors play a role in this association68,69. In this thesis using the 
ECR-PHARMO cohort information about many important factors was available. 
However, as we only had access to clinical data for a small proportion of our 
patients, we were not able to include information on cholesterol level, HbA1c and 
BMI in all our analyses. The influence of these metabolic factors on overall mortality 
in GLDs users might be of interest and should be evaluated in future studies. 
Moreover, the HbA1c goal attainment might be more important for the prognosis 
of a patient than the dose and duration of exposure to metformin or sulfonylurea 
derivatives in which we are interested. Likewise, the protective effect of statins 
observed in this thesis could be the result of improvements in cholesterol levels 
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and in that way indirectly influence the cardiovascular mortality59,60. 
Because of the high proportion of comorbid diseases, diabetes guidelines advice 
an abundance of co-medication for individuals that already use GLDs70. Statins 
and aspirin are two of these co-medications frequently prescribed to individuals 
with diabetes, i.e. around 50% of them use statins and 40% use aspirin according 
to the current international literature71-74. In the study described in chapter 7 of 
this thesis, 25% of the CRC patients used a combination of metformin, statins and 
aspirin. Interestingly, metformin, statin and aspirin users, also used significantly 
more of the frequently prescribed beta blocking agents and renin-angiotensin 
system agents compared to those not using the studied drugs. Although we 
included a sensitivity analyses that adjusted for the cumulative exposures to these 
other co-medications that still showed protective results for statins, it is questionable 
whether this abundance of cumulative exposures in the model in combination 
with the small sample size might have flawed the model75. Ideally, new studies 
should take into account all the different co-medications prescribed to the diabetes 
population, when studying one of them19. 
 
Matching
In this thesis, in two studies it appeared best to match cases and controls within 
the ECR and ECR-PHARMO cohort to efficiently answer the research question. 
‘Matching’ is defined as any method that aims to balance the distribution of 
covariates in the group of cases and controls76,77. In our study in chapter 3 the 
outcome values were not yet available and matching was preferred to select 
subjects for additional data collection, since it was not possible to collect the data 
for all 1,644 EC patients. Although matching was highly efficient, as a result of the 
matching on age our findings are less comparable with previous studies, because 
in our study older EC patients without diabetes were overrepresented. 
In chapter 8 we applied a matching approach to reduce bias and confounding in 
estimating the impact of cancer on medication adherence. Users of GLDs with a 
primary diagnosis of any cancer were considered cases and those without a 
diagnosis of cancer were eligible as controls. Cases and controls were matched 
- with replacement and a maximum of 4 controls per case – on five different criteria 
which needed to be the same for cases and their controls. A strength of that 
approach was that we were able to match on five important variables which 
improved statistical efficiency. Nonetheless, by matching on these 5 variables, the 
potential effect of any of these 5 factors can no longer be studied directly76. Thus, 
with this approach we were not able to show if the impact of cancer is for example 
different for patients that used metformin compared with sulfonylurea derivatives, 
because we matched patients on the type of GLDs they used. The optimal ratio 
in which to sample cases and controls is still subject of discussion77. When controls 
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are easier to obtain as in our study with retrospective data it is more common to 
sample more controls than cases. At first we sampled as much controls as possible, 
which resulted in an imbalance, because of the matching criteria some controls 
and cases were overrepresented. The maximum for controls was set on four, more 
than four controls did not increase our power, while the analyses with less than 
four controls resulted in less clear point estimates, such an influence of number 
of controls was already demonstrated a long time ago77. 
Medication adherence
Since medication adherence, measured every month as the medication possession 
ratio (MPR)78, is a continuous variable, ranging from 0% - 100%, linear regression 
was performed to test statistically the impact of cancer. The interrupted time series 
analysis is only valid to the extent that the cancer diagnosis was the only event 
that changed over time and the only that was able to change the monthly calculated 
MPR79. In our study, described in chapter 9, the visit of an endocrinologist by the 
patient because of vague complaints of an undiagnosed cancer might be a 
competing event, since medication adherence might be affected by this visit80. 
Moreover, missing dispensing data – for  example because of hospitalisations for 
cancer– might  falsely give the impression that medication adherence had fallen 
when in fact the data was simply missing. Thus, due to the presence of competing 
events and the missing dispensing data because of hospitalisations for cancer, 
the impact of cancer on adherence to GLDs might have been overestimated in 
chapter 9.    
The impact of different types of cancer
The first studies that evaluated the impact of diabetes on cancer often grouped 
all cancer patients in their analyses. Nowadays the importance of evaluating the 
reciprocal impact of diabetes and different types of cancer on mortality is 
acknowledged.  Findings of this thesis demonstrate that even between different 
types of colon cancers the effect can be different, colon cancer patients with 
diabetes had more often a tumour located in the proximal colon compared to 
those without diabetes. Furthermore, the presence of prostate and breast cancer 
seemed to have no influence on medication adherence in GLDs users, while among 
gastrointestinal cancers and pulmonary cancer the impact of cancer was large. 
Whereas a strength of our study was that we was able to study the cancer types 
separately, for the future it is of great value to even study different subgroups 
within a cancer type. Consequently, large cohorts, both national and international, 
are required.  
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Implications of the study findings and future direction
The results presented in this thesis have several implications for clinical practice 
and future research. Recommendations for future research are based on questions 
that remain after or are evoked by studies in this thesis. Some of the future research 
questions can be answered with the expansion of the ECR-PHARMO cohort or 
with the linkage of this cohort with new datasets, as will be discussed below.  
Implications for practice
• Results of the studies in this thesis indicate that there exists a dangerous liaison 
between diabetes and cancer. The prevalence of diabetes among many types 
of cancer appears to be higher than in an age-matched group without cancer. 
Also, physicians should be aware that patients with both diseases have higher 
overall mortality and might have a higher stage at cancer diagnosis, while 
they should criticize their own choices since these patients are treated less 
aggressively for their cancer. 
• From the diabetes point of view, this thesis showed no evidence for changes 
in practice among those who also were diagnosed with cancer in terms of 
GLDs or the co-medications statins and aspirin to control for macrovascular 
complications of diabetes. 
• Glycaemic control improved around the time of cancer diagnosis and 
adherence to GLDs decreased due to cancer among individuals with diabetes. 
A physician might decide to discontinue GLDs because of the improved 
glycaemic control, resulting in ‘worse’ medication adherence among 
individuals with diabetes. However, physicians should be aware that measuring 
HbA1c to monitor glycaemic control might be an inappropriate test in patients 
with diabetes and (un)diagnosed cancer because the use of anti-anaemic 
preparations seems to falsely lower HbA1c.
Implications for research
• This thesis suggests that between the different groups of GLDs users major 
differences in prognosis exist that are not related to the drug use itself, but 
rather to patient characteristics. There is a need for studies that investigate 
the difference in co-medication, hospitalisations, laboratory results and 
lifestyle between metformin and sulfonylurea derivatives users and between 
patients with and without diabetes to understand the impact of these on the 
observed mortality differences. 
• To study the effects of drug use and diabetes status on mortality among cancer 
patients in more detail, the effects on cancer-specific outcomes and quality 
of life might be more important than those on overall mortality. New studies 
should invest in additional data collection to give more insight into the role 
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of metformin and co-medications in the diabetes population on patient 
reported and disease-specific outcomes, such as cancer-specific mortality 
and recurrence risk. 
• With the studies in this thesis the evidence is now mounting against an 
association between metformin, CRC and mortality. A careful reassessment 
of the previous observational studies and the methods used in these studies 
is now warranted before more randomised controlled trials of metformin as 
a treatment for cancer are initiated. 
• Although this thesis showed promising results for statin use, additional 
well-conducted observational studies with large sample sizes are needed that 
optimal deal with sick stopper bias to confirm our findings. After this, the 
launch of expensive randomized controlled trials assessing the effect of statins 
in the adjuvant setting will be justified and of great value to change practice.
• As hypothesised, this thesis showed that cancer impacts the use of GLDs and 
glycaemic control among individuals with diabetes. These findings substantiate 
the relevance for further research that assesses the influence of cancer on 
diabetes aspects, such as glucose control and diabetes complications, and 
indirectly survival. 
Future research 
Datasets and future studies
The expansion of the ECR-PHARMO cohort in the near future is of utmost 
importance for the implications for research as mentioned above and for studying 
less frequent cancer types and drug types. Besides that the cohort will expand 
every annual update, resulting in longer follow-up of existing cancer patients, the 
PHARMO Institute will further stimulate pharmacists, general practitioners and 
others to share their data. More interestingly is the upcoming linkage of the 
Netherlands Cancer Registry (managed by the Netherlands Comprehensive 
Cancer Organisation (IKNL)) with PHARMO, which will result in an overlapping 
area in the Netherlands of an estimated 4 million inhabitants. This expansion gives 
opportunities for future research, since a key limitation of the studies in this thesis 
is the small cohort size in certain subgroups studied. With the geographical 
increase the possibilities to focus on clinical laboratory values are immense, for 
example, among statin users, we might be able to see if the improvements in 
cholesterol levels due to statins explain the protective effects on overall mortality. 
In addition, with this data we could explore patterns of Hb and BMI around the 
diagnosis of cancer, to see if they follow a similar pattern as HbA1c. 
In addition to the increase in cohort size, new linkages with other databases will 
increase the value of the established ECR-PHARMO link. For this thesis the 
out-patient pharmacy database and the clinical laboratory database from PHARMO 
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was used, while these databases can be additionally linked with a general 
practitioner (GP) database and the database of the Dutch Medical Registry (LMR)81. 
The GP database captures additional information on physician-linked indications 
for therapy, comorbidity, lifestyle factors (such as smoking status), drug 
prescriptions, laboratory values, and referrals to specialists. With this database, 
researchers are able to investigate whether smoking is an effect modifier in the 
association between diabetes and cancer outcomes. The records of the Dutch 
Medical Registry include detailed information about admission and discharge 
dates, primary and secondary discharge diagnoses, diagnostic, surgical and 
treatment procedures, consultations with medical specialists and the length of 
stay. With these extra databases one would be able to provide an comprehensive 
overview of the differences between subgroups of diabetes patients, such as the 
differences between metformin and sulfonylurea derivatives users and between 
cancer patients with and without diabetes. 
The association between diabetes, GLDs and cancer-specific outcomes is important 
in the overall association between diabetes and mortality in CRC patients. The 
metastatic spread of CRC might give further clues, since a recent study with ECR 
data and information on CRC recurrence observed different patterns of metastatic 
spread between colon and rectal cancer patients82. In the future we will be able 
to link this dataset with the PHARMO Database Network to investigate differences 
in risk of recurrence as well as patterns of metastatic spread between patients with 
and without diabetes and those using specific types of drugs. In addition, these 
risks and patterns could be studied in relation to cancer-specific mortality, as cause 
of death information can be obtained from Statistics Netherlands (CBS)83. 
Health-related quality of life
The impact of diabetes and GLDs among cancer patients should also be studied 
with regard to patient-reported outcomes such as health-related quality of life 
(HRQoL). Recently, in cancer research, more attention is being paid to HRQoL of 
cancer survivors, where previously the focus was more on objective outcome 
measures such as mortality84. Previous research reported that both cancer and 
diabetes individually affect HRQoL. However, it remains unclear to what extent 
the combination of cancer and diabetes has an independent negative effect on 
HRQoL.
Previous studies that investigated this, used the PROFILES (Patient Reported 
Outcomes Following Initial treatment and Long term Evaluation of Survivorship) 
registry, which is linked with the ECR85. Within the PROFILES registry cancer 
survivors are selected from the ECR and via questionnaires patient-reported 
outcome data are available85. A previous study with these data assessed the 
difference in explained variance of HRQoL between comorbidity, sociodemographic 
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characteristics and cancer characteristics among patients with thyroid cancer, CRC 
and (non-)Hodgkin lymphoma84. This study showed that in comparison with 
sociodemographic and cancer characteristics, comorbidity explained more 
variance in physical function, emotional function, pain, and fatigue. Another study 
using the PROFILES data assessed the impact of having both CRC and the 
comorbidity, diabetes, on HRQoL and sexual functioning86. Having both CRC and 
diabetes did not result in lower HRQoL and sexual functioning than the sum of 
the individual effects of both diseases86. However, when including only CRC 
patients, CRC patients with diabetes reported lower physical functioning and 
more male sexual problems than CRC patients without diabetes86.
The two studies provide an insight into the effect of cancer and comorbidities, 
especially diabetes, on problems with HRQoL and sexual functioning84,86. Although 
these patient-reported outcomes are becoming more important, more research 
is needed to prove their relevance in evaluation of treatments86.  In addition, to 
study the effects of specific GLDs on quality of life among cancer patients, the 
PROFILES registry together with the expansion of the ECR-PHARMO cohort would 
be perfect85. 
Concluding remarks
The higher mortality among cancer patients with diabetes compared to those 
without diabetes is worrying as the number of individuals diagnosed with both 
diseases is expected to increase even more. In this thesis, I described that among 
EC patients the higher mortality rates for EC patients with diabetes were most 
likely caused by diabetes as such. Physicians should thus be encouraged to 
carefully treat these patients for their diabetes control to prevent the development 
of diabetes complications. Moreover, having diabetes affects the chance of 
receiving certain cancer treatment, which in turn affects the prognosis. From the 
diabetes point of view, there is no call for changes in clinical practice in terms of 
metformin, while more research on the effect of statin use on overall mortality in 
cancer patients is needed. Journal editors and reviewers in the diabetes and 
cancer fields must be aware of methodological pitfalls and support the pursuit of 
unbiased interpretations. In this thesis, I revealed that the diagnosis of cancer 
does impact diabetes and its treatment, thus the lack of interest from the field 
regarding this is unfortunate and in the future this should be overtaken. For the 
day-to-day clinical oncology and endocrinology practice the results of my thesis 
increase the evidence that physicians should be aware of the dangerous liaison 
between diabetes and cancer, with all its facets. 
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Inleiding
Kanker en diabetes (in de volksmond ook wel ‘suikerziekte’ genoemd) zijn twee 
veel voorkomende ziekten die wereldwijd de gezondheid van veel mensen 
beïnvloedt. Van zowel diabetes als kanker is nog niet geheel bekend hoe de ziekte 
ontstaat en waardoor deze wordt veroorzaakt. Diabetes en kanker zijn elk het 
onderwerp van vele studies wereldwijd.   
Kanker
Kanker, ook wel een kwaadaardige tumor genoemd, wordt ingedeeld op basis 
van de plaats in het lichaam waar de kanker ontstaat. Zo noemen we kanker die 
uitgaat van de dikkedarm, dikkedarmkanker. In 2013, kregen mannen in Nederland 
het vaakst: prostaat- (21%), huid- (14%) en dikkedarmkanker (14%). Vrouwen 
kregen het vaakst borst- (30%), huid- (14%) en dikkedarmkanker (12%). In dit 
proefschrift heb ik mij vooral op dikkedarmkanker gericht, omdat dit type kanker 
veel voorkomt en wordt gezien bij zowel mannen als vrouwen. 
Kanker kan zich verspreiden naar verschillende delen van het lichaam via het 
bloed of het lymfestelsel. Het stadium van de kanker is een maat voor de 
verspreiding van de kanker en de grootte van de tumor. Kanker wordt meestal 
behandeld met chirurgie, radiotherapie (bestraling) en/of chemotherapie. 
Diabetes
Bij volwassenen met diabetes is type 2 diabetes veruit de meest voorkomende 
soort diabetes. Mensen met diabetes hebben hoge glucosespiegels in het bloed. 
Bij gezonde mensen zorgt insuline - gemaakt in de alvleesklier - ervoor dat het te 
veel aan glucose in het bloed wordt opgenomen in de lever en spieren. Maar bij 
mensen met type 2 diabetes werkt insuline niet goed en is er ook een tekort aan 
insuline. Hierdoor blijven de glucosespiegels in het bloed hoog. 
De meeste patiënten met diabetes hebben bij de vaststelling van de ziekte (de 
diagnose) geen klachten. Bij een bloedonderzoek wordt toevallig een verhoogde 
glucosewaarde gevonden. De meest voorkomende klachten die mensen met 
diabetes bij hun diagnose hebben zijn: veel plassen, dorst, wazig zien en soms 
gewichtsverlies. De diagnose diabetes wordt meestal gesteld op basis van een 
nuchtere bloedglucose die hoger is dan 7,0 mmol/L. Nadat diabetes is vastgesteld 
bij een persoon, wordt de bloedglucose elke 3 tot 6 maanden gecontroleerd 
door het meten van de Hemoglobine A1c (HbA1c)-waarde in het bloed. Deze 
waarde geeft aan hoeveel glucose zich in het bloed gehecht heeft aan 
hemoglobine, het zuurstoftransporteiwit in de rode bloedcellen. Een rode bloedcel 
leeft gemiddeld drie maanden. Hierdoor geeft de HbA1c-waarde de gemiddelde 
glucosespiegel in het bloed van de afgelopen drie maanden weer. De behandelend 
arts probeert met behulp van geneesmiddelen een normale of bijna normale 
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glucosespiegel te bereiken. De arts wil daarom de HbA1c-waarde onder de 7% 
(53 mmol/mol) hebben. 
De Nederlandse richtlijn voor de behandeling van diabetes adviseert het 
geneesmiddel metformine als eerste behandeling naast leefstijladviezen, zoals 
een dieetwijziging, meer lichaamsbeweging en gewichtsverlaging. Als met deze 
therapieën de bloedglucose nog niet goed genoeg is gedaald, zullen andere 
geneesmiddelen worden toegevoegd, zoals bijvoorbeeld insuline. 
Patiënten met diabetes krijgen vaak hart- en vaatproblemen. Om deze problemen 
te voorkomen, gebruiken patiënten met diabetes vaak bloeddrukverlagende 
middelen, cholesterolverlagende middelen (statines) en middelen die de stolling 
van het bloed remmen (aspirine). In dit proefschrift worden ook deze genees-
middelen bestudeerd.
Toename van het aantal patiënten met kanker en diabetes
Het aantal mensen dat kanker overleeft is de afgelopen jaren aanzienlijk 
toegenomen. In 2009 hebben meer dan 400.000 patiënten ooit de diagnose 
kanker gehad en in 2020 zullen dit meer dan 600.000 patiënten zijn. Deze toename 
komt gedeeltelijk doordat mensen steeds ouder worden en mensen juist op 
oudere leeftijd vaker kanker krijgen. Daarnaast zorgt de betere behandeling van 
kanker ervoor dat minder mensen sterven aan kanker en meer mensen genezen 
van kanker. 
Ook het aantal patiënten met diabetes neemt toe doordat mensen ouder worden 
en diabetes meestal pas na de leeftijd van 70 jaar ontstaat. Daarnaast heeft de 
toename van overgewicht en het gebrek aan lichaamsbeweging in de maatschappij 
hierin ook een belangrijke rol. 
Doordat steeds meer mensen ooit één van deze twee ziekten krijgen, zal ook het 
aantal mensen dat beide ziekten krijgt stijgen. In de afgelopen 15 jaar is in 
Nederland het aantal kankerpatiënten mét diabetes zelfs al verdubbeld. Dus, 
artsen zullen steeds meer patiënten op hun spreekuur zien die beide ziekten 
hebben.
Diabetes en kanker – een gevaarlijke combinatie?
Diabetes en kanker komen veel vaker samen voor dan we op basis van kans zouden 
verwachten. In 2009 liet een studie zien dat sommige kankersoorten zich vaker 
ontwikkelen in patiënten met diabetes. Mensen met diabetes krijgen twee keer 
zo vaak lever-, alvleesklier- of baarmoederkanker dan mensen zonder diabetes. 
Ook hebben ze meer kans op het krijgen van dikkedarm-, borst- en blaaskanker. 
Als gevolg hiervan, heeft inmiddels bijna 1 op de 5 kankerpatiënten op het 
moment van de kankerdiagnose ook al diabetes. 
Deze patiënten met diabetes én kanker lijken daarnaast ook vaker te overlijden 
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dan kankerpatiënten zonder diabetes. Omdat deze patiënten aan beide ziekten 
kunnen overlijden, is het wel begrijpelijk dat ze vaker overlijden dan patiënten 
die maar één van de twee ziekten hebben. Maar misschien zorgt de combinatie 
van beide ziekten ervoor dat patiënten nog vaker overlijden. Dit zou kunnen komen 
doordat kanker een slechte invloed heeft op diabetes óf diabetes een slechte 
invloed heeft op kanker. Dus, beïnvloeden deze ziekten elkaar zo, dat er andere 
(onbekende) factoren nu zorgen voor deze slechtere overleving van patiënten 
met kanker én diabetes?
Doordat beide ziekten vaak samen voorkomen en doordat patiënten met diabetes 
én kanker vaker overlijden dan patiënten met één van de twee ziekten, is het van 
groot belang deze groeiende groep van patiënten te bestuderen.  
Doel van dit proefschrift
In dit proefschrift wordt de relatie tussen diabetes, kanker en overleving 
onderzocht. De belangrijkste doelstellingen van de in dit proefschrift beschreven 
studies zijn:
• Evalueren van het effect van diabetes op de behandeling van kanker, de 
terugkeer van kanker en het overlijden aan kanker bij patiënten.
• Bepalen of en hoe het gebruik van de geneesmiddelen: metformine, statines 
en aspirine, de overleving beïnvloedt van patiënten met dikkedarmkanker 
én diabetes. 
• Bekijken of de bloedglucosewaarden en de therapietrouw van patiënten met 
diabetes die glucoseverlagende geneesmiddelen gebruiken verandert op 
het moment van een diagnose kanker. 
Onderzoeksgegevens
Om de onderzoeksvragen te beantwoorden heb ik gegevens gebruikt van de 
Eindhovense kankerregistratie. Voor de meeste studies zijn deze gegevens 
gekoppeld met de databanken van het PHARMO Instituut. Deze gekoppelde 
databanken overlappen wat betreft patiënten gedeeltelijk. Samen dekken ze een 
geografische regio in het Zuidoostelijke deel van Nederland van ongeveer één 
miljoen inwoners. Gedetailleerde gegevens over een tumor (ernst tumor, soort 
tumor en kankerbehandeling) van deze patiënten zijn beschikbaar via de 
kankerregistratie. Gegevens van de geneesmiddelen die zijn opgehaald bij de 
apotheek, zijn beschikbaar via de PHARMO databanken van zowel de periode 
voor als na de kankerdiagnose. Van een deel van de patiënten hebben we ook 
de laboratoriumresultaten voor het onderzoek ter beschikking. Alle studies zijn 
uitgevoerd bij het Integraal Kankercentrum Nederland (IKNL), locatie Eindhoven, 
in samenwerking met het PHARMO Instituut in Utrecht en de 10 ziekenhuizen in 
de regio van het voormalige Integraal Kankercentrum Zuid (IKZ). 
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Belangrijkste bevindingen van dit proefschrift
Literatuuroverzicht
Dit proefschrift start met een overzichtsartikel waarin we hebben bekeken welke 
al bekende factoren mogelijk de relatie tussen diabetes, kanker en het hogere 
risico om te overlijden bij mensen met beide ziekten kunnen verklaren (Hoofdstuk 
2). In dit artikel vonden we dat de aanwezigheid van bijkomende ziekten en 
bekende risicofactoren van diabetes én kanker, zoals oudere leeftijd, roken, 
ongezond eten, overgewicht en onvoldoende lichaamsbeweging, een rol spelen 
bij de onderzochte relatie. Verder is het belangrijk dat nieuwe studies, die de 
relatie tussen diabetes, kanker en overleving onderzoeken, rekening houden met 
de uitgebreidheid van de tumor en de verschillen in de gekregen kanker-
behandeling. Ook zullen nieuwe studies zich vooral moeten richten op specifieke 
problemen na een kankerdiagnose, zoals het risico op terugkeer van kanker en 
het risico om te overlijden aan de kanker. Dus, het is een grote uitdaging om de 
relatie tussen diabetes, kanker en overleving geheel te begrijpen. Nieuwe studies 
moeten rekening houden met heel veel factoren die een rol kunnen spelen in 
deze relatie.
Invloed diabetes op de kankerbehandeling en overleving van kankerpatiënten
De aanwezigheid van diabetes kan invloed hebben op de tumorkarakteristieken 
op het moment van de kankerdiagnose, op het krijgen van een kankerbehandeling 
of op kanker gerelateerde uitkomsten. Wanneer dit zo is, zal diabetes waarschijnlijk 
een groot effect hebben op de kans om te overleven voor kankerpatiënten. In dit 
proefschrift werd het effect van diabetes op de uitgebreidheid van de tumor op 
kankerdiagnose, de kans op terugkeer van kanker en de overleving onderzocht 
bij patiënten met baarmoederkanker (Hoofdstuk 3). Voor het onderzoek werden 
1.644 nieuwe patiënten met baarmoederkanker tussen 2000 en 2008 geselecteerd 
uit de Eindhovense Kankerregistratie. Patiënten met baarmoederkanker én 
diabetes hadden een minder goede overleving dan patiënten zonder diabetes. 
Na vijf jaar leefde nog 68% van de patiënten met baarmoederkanker én diabetes 
en nog 84% van de patiënten met baarmoederkanker zonder diabetes. Diabetes 
leek invloed te hebben op de tumorkarakteristieken bij de kankerdiagnose. 
Patiënten met diabetes hadden namelijk vaker een verder gevorderde ziekte dan 
patiënten zonder diabetes. Nadat we rekening hielden met dit verschil in de 
uitgebreidheid van kanker in de statistische analyse, hadden patiënten met 
diabetes ten opzichte van patiënten zonder diabetes, geen grotere kans om te 
overlijden aan baarmoederkanker zelf. De aanwezigheid van diabetes zorgde 
ook niet voor een grotere kans op het terugkeren van kanker. 
De minder goede overleving in baarmoederkankerpatiënten met diabetes ten 
opzichte van patiënten zonder diabetes, lijken we dus niet geheel te kunnen 
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verklaren door een invloed van diabetes op de kanker zelf. Waarschijnlijk overlijden 
baarmoederkankerpatiënten vaker aan andere oorzaken dan kanker, zoals hart- en 
vaatziekten of complicaties van diabetes, zoals nierziekten.
Als een kankerpatiënt niet behandeld wordt voor zijn kanker, zal zijn kans op 
genezing en overleving dalen. We onderzochten in dit proefschrift of patiënten 
met dikkedarmkanker én diabetes minder vaak werden behandeld voor hun 
kanker in vergelijking met patiënten zonder diabetes (Hoofdstuk 4). Voor deze 
studie selecteerden we 11.893 patiënten met dikkedarmkanker en 5.277 patiënten 
met endeldarmkanker tussen 1995 en 2010 uit de Eindhovense Kankerregistratie. 
Van de patiënten met dikkedarmkanker had 14% diabetes op het moment van 
kankerdiagnose en bij de endeldarmkankerpatiënten was dit 12%. Patiënten met 
dikkedarmkanker (ziektestadium III) én diabetes kregen minder vaak chemo-
therapie dan patiënten zonder diabetes. Echter bij zowel dikkedarmkankerpatiënten 
met als zonder diabetes nam het gebruik van chemotherapie sterk toe over de 
jaren. Endeldarmkankerpatiënten (ziektestadium II/III) kregen over de jaren ook 
steeds meer bestraling. Het aantal patiënten met en zonder diabetes dat werd 
bestraald, werd zelfs ongeveer gelijk (81% van de diabeten en 87% van de niet 
diabeten). Dus, deze studie liet zien dat een steeds groter deel van de patiënten 
met dikkedarmkanker én diabetes chemotherapie en bestraling krijgen. Echter, 
patiënten met diabetes krijgen nog steeds minder vaak chemotherapie dan 
patiënten zonder diabetes. We weten niet of dit betekent dat: 1. De artsen terecht 
minder vaak chemotherapie geven omdat diabeten een hoger risico op 
complicaties van chemotherapie hebben. 2. Zij patiënten onterecht te weinig 
behandelen en daarmee de overlevingskansen van deze patiënten verminderen. 
Invloed geneesmiddelen op overleving van patiënten met dikkedarmkanker
In de afgelopen tien jaar is er steeds meer bewijs gekomen dat de relatie tussen 
diabetes en de kans om te overlijden voor kankerpatiënten afhankelijk is van het 
glucoseverlagend middel dat gebruikt wordt (metformine of insuline). In dit 
proefschrift hebben we bekeken of patiënten met dikkedarmkanker die metformine 
gebruikten na de kankerdiagnose een betere overleving hadden dan degenen 
die sulfonylureumderivaten gebruikten (Hoofdstuk 5). Met andere woorden: wat 
heeft elke extra dag inname van metformine (ten opzichte van sulfonylureum-
derivaten) na dikkedarmkanker voor invloed op de kans om te overleven? In onze 
statistische analyses zagen we dat het gebruik van metformine (elke extra maand 
gebruik) na de diagnose dikkedarmkanker geen invloed had op de kans om te 
overleven. Wel zagen we dat patiënten die metformine gingen gebruiken al een 
59% lager risico hadden om te overlijden vóórdat ze het medicijn hadden gebruikt. 
Dit komt dus niet door het medicijn zelf, maar zeer waarschijnlijk doordat de 
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patiënten die metformine gebruiken over het algemeen gezonder zijn dan 
patiënten die sulfonylureumderivaten krijgen. Studies die het effect van metformine 
op de kans om te overleven voor kankerpatiënten bestuderen, zullen rekening 
moeten houden met patiëntverschillen tussen de geneesmiddelengroepen. Een 
arts schrijft bij de ene patiënt metformine voor en bij de andere sulfonylureum-
derivaten. Heel veel factoren, zoals het gewicht en andere bijkomende ziekten, 
spelen bij de keuze van de arts een rol. Is de patiënt die metformine gaat krijgen 
al ‘gezonder’ voordat deze start met metformine? Gerelateerd hieraan hebben 
wij een ingezonden brief gestuurd naar aanleiding van een recent gepubliceerde 
studie. Deze studie keek naar het effect van metformine op de kans om te overleven 
voor  prostaatkankerpatiënten (Hoofdstuk 6). In de brief aan het tijdschrift legden 
wij uit dat de auteurs van het artikel hun conclusie baseerde op een voordeel van 
metformine wat er al was bij nul dagen gebruik van metformine. Dit kan dus geen 
effect van metformine zijn, maar eerder een gevolg van patiëntverschillen tussen 
de geneesmiddelengroepen.  
Statines (cholesterolverlagers) en aspirine (antistollingsmiddel) zijn twee genees-
middelen(groepen) die vaak worden voorgeschreven aan mensen met diabetes. 
Beide geneesmiddelen hebben mogelijk ook een effect op de kans om te 
overleven voor kankerpatiënten. Wij hebben onderzocht of het gebruik van 
metformine, statines en aspirine na een diagnose dikkedarmkanker (onafhankelijk 
van elkaars gebruik) invloed heeft op de kans om te overleven voor patiënten met 
diabetes (Hoofdstuk 7). De patiënten die wij selecteerden voor de studie hadden 
al diabetes voordat zij de diagnose kanker kregen. In onze statistische analyses 
zagen we dat het gebruik van metformine en aspirine (elke extra maand gebruik) 
na de diagnose dikkedarmkanker geen invloed had op de kans om te overleven. 
Maar, de overleving van patiënten met dikkedarmkanker én diabetes verbeterde 
wel duidelijk met elke extra maand van statine gebruik. Onze bevindingen 
suggereren dus dat statines een gunstig effect hebben op de kans om te overleven 
voor patiënten met dikkedarmkanker. Omdat we het effect van statines hebben 
onderzocht in een observationele studie – gegevens zijn verzameld uit de klinische 
praktijk – worden onze resultaten beïnvloed door de beslissingen die een arts 
maakt. Artsen kunnen statines juist voorschrijven aan de ‘gezondste’ patiënten. 
Maar artsen kunnen de ‘ongezondste’ patiënten ook adviseren te stoppen met 
statines. Hierdoor lijken statines een gunstig effect op de prognose te hebben, 
terwijl het eigenlijk komt doordat alleen de ‘gezondste’ patiënten statines krijgen 
voorgeschreven.  
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Invloed kanker op diabetescontrole en therapietrouw diabeten
De meeste studies die de relatie tussen diabetes, kanker en overleving 
onderzochten, richtten zich op de invloed van diabetes en glucoseverlagende 
middelen op kanker. Het omgekeerde effect, de invloed van kanker en de 
kankerbehandeling op diabetescontrole heeft maar zeer weinig aandacht 
gekregen. In dit proefschrift hebben we de invloed van kanker en de behandeling 
hiervan op HbA1c-waarden (maat voor bloedglucose) onderzocht bij patiënten 
met diabetes die glucoseverlagende middelen gebruikten (Hoofdstuk 8). Het 
HbA1c veranderde rondom de diagnose dikkedarmkanker. De waardes daalden 
in de twee jaar voorafgaande aan de diagnose kanker voor alle patiënten met 
dikkedarmkanker. Ze stegen in de twee jaar na de diagnose kanker in patiënten 
met dikkedarmkanker die niet uitging van de endeldarm (laatste deel dikkedarm). 
De meest duidelijke verlaging in het HbA1c werd gezien in patiënten met kanker 
in het eerste deel van de dikkedarm. Maar ook bij mensen die voor de kanker-
diagnose geneesmiddelen gebruikten voor een bloedarmoede veroorzaakt door 
een ijzertekort. Onze resultaten kunnen betekenen dat de diabetescontrole (de 
bloedglucose) verbetert door kanker. Maar mogelijk ook dat bij patiënten die 
geneesmiddelen voor een bloedarmoede gebruiken, de HbA1c-waarde geen 
goede maat is voor de bloedglucose. 
De aanwezigheid van kanker kan invloed hebben op de therapietrouw. Het trouw 
zijn aan glucoseverlagende middelen is cruciaal om een goede diabetesinstelling 
te bereiken. Daarom is het ook van belang voor de kans om te overleven voor 
een patiënt. In dit proefschrift hebben we de invloed van kanker (alle soorten) op 
het trouw zijn aan glucoseverlagende middelen onderzocht bij diabetespatiënten 
(Hoofdstuk 9). Diabetespatiënten die kanker kregen werden vergeleken met 
diabetespatiënten die geen kanker kregen met eenzelfde duur van diabetes. Om 
de therapietrouw te bepalen hebben we per maand berekend welk deel van die 
maand glucoseverlagende middelen werden gebruikt door de patiënt met 
diabetes. Wanneer de patiënt de helft van de maand glucoseverlagende middelen 
had gebruikt, hadden we dus een waarde van 50%. In de studie veranderde de 
therapietrouw op het moment van een kankerdiagnose. De grootste daling in 
therapietrouw, veroorzaakt door de aanwezigheid van kanker, werd gezien in 
patiënten met long-, slokdarm-, maag-, dikkedarm-, alvleesklier- en leverkanker. 
Bij deze patiënten daalde de therapietrouw met 15%. Met andere woorden: door 
de diagnose kanker gebruikten diabetespatiënten 5 dagen per maand geen 
glucoseverlagende middelen meer, terwijl ze dat eerst wel deden. Het is niet 
duidelijk wat deze 5 dagen zonder glucoseverlagend middel voor invloed hebben 
op de kans om te overleven voor kankerpatiënten. Daarnaast, zal de reden van 
deze daling in therapietrouw verder onderzocht moeten worden. Komt het doordat 
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de patiënt het gevecht tegen kanker belangrijker vindt? Adviseert de arts juist om 
te stoppen met de glucoseverlagende middelen, omdat de bloedglucose 
verbetert?
Concluderende opmerkingen
Het aantal patiënten met diabetes én kanker neemt sterk toe. In de afgelopen 15 
jaar is in Nederland het aantal kankerpatiënten met diabetes zelfs al verdubbeld. 
Daarom is het van groot belang te begrijpen welke factoren bijdragen aan de 
hogere kans op overlijden gezien voor kankerpatiënten met diabetes in vergelijking 
met kankerpatiënten zonder diabetes. Dit proefschrift geeft verdere aanknopings-
punten hoe de relatie tussen diabetes en kanker de kans om te overleven voor 
patiënten beïnvloedt. Zo werd er gezien dat bij patiënten met baarmoederkanker 
de slechtere overleving van diabetespatiënten waarschijnlijk niet werd veroorzaakt 
door een effect van diabetes op de kanker zelf. Waarschijnlijk zullen andere ziekten 
de overleving van deze patiënten beïnvloeden. Artsen zullen moeten worden 
aangemoedigd om bij patiënten met baarmoederkanker én diabetes, aandacht 
te besteden aan de diabetesinstelling om zo diabetescomplicaties te voorkomen. 
Daarnaast laat dit proefschrift zien dat diabetes invloed heeft op het aantal 
patiënten dat voor hun dikkedarmkanker een kankerbehandeling krijgt. Dit zal 
mogelijk de kans op genezing en dus ook de kans om kanker te overleven 
beïnvloeden. Onze en andere studies suggereren momenteel steeds meer dat 
er geen relatie bestaat tussen het gebruik van metformine en de kans om te 
overleven voor patiënten met dikkedarmkanker. Echter, het gebruik van statines 
lijkt de kans om te overleven na de diagnose dikkedarmkanker te verbeteren en 
lijkt dus veelbelovend. Dit zal prioriteit moeten hebben op onderzoeksagenda’s. 
Verder toont dit proefschrift aan dat de bloedglucose bij diabetespatiënten 
waarschijnlijk verbeterde door een diagnose dikkedarmkanker. Maar we zagen 
ook dat het trouw zijn aan glucoseverlagende middelen bij diabeten verslechterde 
rondom de kankerdiagnose. Dit kan betekenen dat de arts op basis van een 
verbeterde bloedglucose adviseert te stoppen met de glucoseverlagende 
middelen. Ook kan het betekenen dat de patiënt het gevecht tegen kanker 
belangrijker vindt dan het adequaat slikken van zijn geneesmiddelen voor de 
behandeling van diabetes. Voor de huidige medische praktijk met patiënten met 
kanker én diabetes, dragen de resultaten van dit proefschrift bij aan de 
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